

(19)



(11)

**EP 1 417 489 B1**

(12)

**EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:  
**17.10.2007 Bulletin 2007/42**

(51) Int Cl.:  
**G01N 33/543 (2006.01)**

(21) Application number: **02753996.4**

(86) International application number:  
**PCT/CA2002/001210**

(22) Date of filing: **02.08.2002**

(87) International publication number:  
**WO 2003/012443 (13.02.2003 Gazette 2003/07)**

(54) **RAPID DIAGNOSTIC DEVICE AND ASSAY**

DIAGNOSTIKTESTVORRICHTUNG UND VERFAHREN

DISPOSITIF DE DIAGNOSTIC RAPIDE ET DOSAGE

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
IE IT LI LU MC NL PT SE SK TR**

(72) Inventor: **CHAN, Hermes, K.W.**  
**Halifax,**  
**Nova Scotia B3S 1H4 (CA)**

(30) Priority: **03.08.2001 US 309477 P**  
**06.06.2002 US 163675**

(74) Representative: **Goddar, Heinz J.**  
**FORRESTER & BOEHMERT**  
**Pettenkoferstrasse 20-22**  
**80336 München (DE)**

(43) Date of publication of application:  
**12.05.2004 Bulletin 2004/20**

(73) Proprietor: **MedMira Inc.**  
**Toronto,**  
**Ontario M9W 5Z9 (CA)**

(56) References cited:  
**EP-A- 0 806 666** **WO-A-01/55723**  
**WO-A-89/11654** **US-A- 4 087 567**  
**US-A- 5 185 264** **US-A- 5 877 028**  
**US-A- 5 879 951**

**EP 1 417 489 B1**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**Description****FIELD OF THE INVENTION**

5 **[0001]** An improved rapid diagnostic device, assay and multifunctional buffer are provided for the detection of a target analyte in a fluid test sample. The assay utilizes a multifunctional buffer reagent and flow-through device comprising a test unit in combination with a detachable post-filter unit. A method for utilizing the flow-through device, a test kit and a formulation for generating the multifunctional buffer are also provided.

**10 BACKGROUND OF THE INVENTION**

**[0002]** Diagnostic assays have become an indispensable aid in medical and research fields for detecting a variety of components in biological fluids and tissue samples such as drugs, hormones, enzymes, proteins, antibodies, and infectious agents. A fundamental principle underlying the operation of a number of these assays is a specific recognition and binding reaction that occurs between two or more members to form a complex that can subsequently be detected. Normally, the members involve a capture reagent (e.g. receptor) that will specifically recognize and bind to a target analyte of interest (e.g. ligand) in a fluid test sample.(e.g. whole blood, plasma, serum, urine, saliva, etc.). Moreover, a visually detectable indicator reagent is included in the reaction which will recognize and bind to any analyte complexed with the capture reagent to produce a signal indicating that a positive reaction has occurred. In particular, immunological assays are designed to function on the basis of antibody recognition and selective binding reaction to antigen and accordingly, have proven extremely valuable over the years in clinical applications for the detection of numerous infectious disease states.

**[0003]** In order to achieve accurate results, however, immunoassays often require precision in performing a series of time-consuming steps, as well as technical knowledge in operating sophisticated laboratory equipment. Accordingly, their use in diagnosing infectious disease has been essentially confined to clinical facilities that have the necessary resources for making such determinations including highly trained technical personnel and laboratories equipped with appropriate diagnostic equipment.

**[0004]** On this basis, as with many technologies, immunodiagnostic testing is evolving towards more simplistic approaches in the rapid identification and diagnosis of infectious disease states. The need for a simplistic qualitative assay for detecting analyte in a biological sample is becoming more desirable since it would offer an appealing possibility for use in less conventional settings having limited resources, e.g. physician's office, or domestic household. Whether in a public health clinic or a rural setting, it is preferable that an assay for detection of a target analyte in a fluid test sample be performed without the aid of complicated instruments and the requisite skills and knowledge of professionally trained personnel.

**[0005]** Another important factor to consider in pursuit of improved diagnostic testing is the lack of, or limited availability of, freezers and refrigeration in many third world countries. On this basis, it has become more desirable to develop assay reagents that will maintain their stability and integrity at room temperature for prolonged periods of time. Presently, some diagnostic devices and methods require the use of several assay reagents which have varying stability depending on the temperature at which they are stored and handled. Some of these reagents are stable at room temperature and may be stored for short periods of time, while others are relatively unstable and begin to deteriorate quickly, thereby adversely affecting the overall sensitivity and reliability of the assay. Thus, most commercially available diagnostic devices require at least one or more of the necessary reagents be kept at low temperatures in order to ensure their stability. Accordingly, a diagnostic device incorporating reagents that can be stored at ambient temperatures and remain stable for long periods of time while retaining all, or most, of its initial activity would have a clear advantage over current state of the art devices. On this basis, a factor worth considering towards simplifying diagnostic testing and thus, making it more practical and widely operational, is to minimize the number of assay reagents (e.g. mixing, washing, diluting solvents, etc.) and integrated steps in the assay protocol.

**[0006]** An immunodiagnostic assay which is simple to use, rapid and reliable would also be advantageous in improving screening and diagnostic services. According to the U.S. Center for Disease Control and Prevention report, rapid diagnostic tests enable healthcare providers to supply within minutes the test results to patients at the time of testing, thus potentially increasing the overall effectiveness of counseling and testing programs. It would also be expected that simplification of diagnostic devices and assays would likely be less costly to manufacture and perform compared to other conventional devices, thus making them economically feasible and more affordable to use in the interim. This is particularly desirable in third world countries where a simple, rapid, sensitive, and economical diagnostic device and assay would be ideal.

**[0007]** Towards this end, numerous analytical devices in an wide assortment of shapes, configurations and formats have been developed for detecting the presence of a target analyte in a fluid test sample, including chromatographic test strips, dipsticks, lateral flow and flow-through systems, to name a few. Many of these devices employ reaction

membranes onto which a capture reagent capable of recognizing and binding to the target analyte is immobilized. In essence, the method of performing the assay typically involves applying a fluid test sample suspected of containing the target analyte, either directly or indirectly by filtration, to the reaction membrane. If the target analyte is present in the sample, it will bind to the capture reagent. Subsequent methods are then employed to determine whether the target

analyte has bound to the capture reagent, thus indicating its presence in the sample.

**[0008]** U.S. Patent No. 4,517,288 (Giegel, *et al.*) discloses methods for conducting ligand-binding assays using inert porous materials. In particular, the patent discloses immobilizing an immunological binding material (e.g. antibody) specific for the ligand of interest (e.g. antigen) within a finite test zone of the porous material and applying the ligand to the test zone which will be captured by the immobilized binding material. Immobilization of the binding material to the porous material may be achieved by any number of conventional methods including adsorption, covalent bonding, use of a coupling agent, etc. An enzyme-labeled indicator reagent, which will also recognize and bind with the ligand, is then applied to the test zone where it will become immobilized in an amount directly proportional to that of ligand present in the zone. A solvent is then applied to the center of the test zone to remove any unbound indicator reagent, thus enabling the determination of a signal to be made, with or without the aid of appropriate analytical instruments.

**[0009]** A more sophisticated version of a specific binding assay is described in U.S. Patents Nos. 4,094,647, 4,235,601 and 4,361,537 (Deutsch, *et al.*) which incorporates a chromatographic test strip capable of transporting a developing liquid by capillary action. The test strip is designed so that it has a first zone for receiving a sample, a second zone impregnated with a first reagent capable of being transported by the developing liquid and a third zone impregnated with a second reagent or the material of the strip. The first reagent is capable of reacting with one of the group consisting of (1) the sample, (2) the sample and the second reagent, or (3) the second reagent in competition with the sample, to form a product in an amount dependent on the characteristic being determined. A sample is contacted with the first zone and the strip is then dipped into the developing liquid to bring about transport of the sample and the first reagent to form the reaction product. The retarding element slows transport of either the product or the first reagent (the moving reagent) to spatially separate the two and the amount of the moving element is then measured at the measurement location.

**[0010]** A variation of the device by Deutsch, *et al.* is described in U.S. Patent No. 4,960,691 (Gordon *et al.*) for the analysis of antigens, antibodies or polynucleotides which also uses a length of a chromatographic material (i.e. test strip), a solvent carrier and mobile reagents. Essentially, the strip has three separate zones comprising a first zone impregnated with a mobile reagent reactive with the analyte of interest, a second zone for receiving a test sample suspected of containing the analyte, and a third zone impregnated with an immobilized reagent which selectively binds to the analyte, thereby rendering the analyte in an immobilized form. Each zone is sequentially located an equidistant from its neighbour along a longitudinal axis of the test strip. The device optionally comprises fourth and fifth zones impregnated with indicator reagents that will provide a means of detecting the presence of the analyte. The method involves depositing the test sample in the second zone, followed by solvent addition to the strip at the end where the first zone is located so that sequential movement and arrival of the analyte and first reagent eventually occurs at the third zone. The site relationship between the second and third zones is such that the analyte is immobilized against solvent transport at the third zone prior to the first reagent reaching the third zone. Any interfering non-analyte sample components which are reactive with the first reagent are cleared from the third zone by solvent transport prior to the arrival of the first reagent to the third zone. Multiple and single pathway devices are also disclosed for accomplishing a variety of multi-step assay procedures.

**[0011]** U.S. Patent No. 4,168,146 (Grubb, *et al.*) discloses the use of test strips for carrying out sandwich-type immunoassays. The strips are formed of bibulous carrier materials to which antibodies have been attached by adsorption, absorption or covalent bonding. Preferred test strip materials include cellulose fibre-containing materials such as filter paper, ion exchange paper and chromatographic paper. Also disclosed are uses of materials such as cellulose thin-layer chromatography discs, cellulose acetate discs, starch and three-dimensional cross-linked materials such as Sephadex (Pharmacia Fine Chemicals, Uppsala Sweden). The immunoassay is performed by wetting the test strip with a measured volume of a test sample suspected of containing the antigen. Any antigen present in the test sample migrates by capillary action along the test strip. However, the extent of migration of the antigen over a fixed time period is determined by the antigen concentration in the test sample because the bound antibodies retard the migration of the antigens for which they are specific. Afterwards, the antigen-containing areas of the diagnostic device are indicated by the addition of labeled antibodies.

**[0012]** An immunodiagnostic flow-through system comprising a series of method steps is disclosed in U.S. Patent No. 4,632,901 (Valkirs, *et al.*). The first step involves taking a fluid test sample suspected of containing a first member of a specific binding pair (e.g. antigen) and pouring it onto a porous material to which a second member of the specific binding pair (e.g. antibody) is immobilized. Influenced by the capillary action properties of an absorbent material, the fluid test sample is drawn downwards in a vertical direction through the porous material and pass the immobilized antibody. Any antigen present in the sample will subsequently be captured by the immobilized antibody. The second step involves passing a separate solution of labeled antibody through the porous material so that the labeled antibody may bind to

the antigen already captured by the immobilized antibody to form a three-membered complex. Any unreacted or unbound labeled antibody is then flushed away from the porous material via a third step, normally referred to as a washing step, using a suitable reagent which may then be followed by an incubation period. Finally, a fourth step involving a separate solution containing a substrate reactive with the label on the antibody of the second solution is added to cause a visible color change indicative of the presence of the antigen of interest. To facilitate accurate performance of this method, the apparatus is designed in such a way as to funnel the sample through to the absorbent material which, by capillary action, draws the sample through the material and into the bottom of the apparatus.

**[0013]** An immunodiagnostic flow-through system described by Liotta in U.S. Patent No. 4,446,232 utilizes a combination of two different reaction zones arranged in three separate layers. The first reaction zone comprises two layers fabricated from porous material wherein the first and second layers are impregnated with soluble enzyme-linked antibody and immobilized antigen, respectively. The third layer, or second reaction zone, contains immobilized indicator reagent that will react with the enzyme linked to the antibody of the first reaction zone to produce a color. If a liquid sample contains the antigen of interest, then after the sample is applied to the first reaction zone, the antigen contained therein will bind with the soluble enzyme-linked antibody and diffuse through to the second reaction zone following a short incubation period. The presence of antigen will be detected when the enzyme reacts with the indicator reagent to produce a color. By contrast, if a liquid sample does not contain any antigen, then the enzyme-linked antibody will migrate to the second layer of the first reaction zone, aided by diffusion of the fluid test sample, where it will bind to immobilized antigen. The binding reaction that occurs will prevent any enzyme-linked antibody from reaching the second reaction zone where it would react with the indicator reagent. Thus, in this particular scenario, no color is observed indicating the lack of antigen in the fluid test sample.

**[0014]** While the methods and devices described above may provide compact and somewhat reliable means for performing immunodiagnostic assays, several problems regarding their use still exist. In particular, one of the disadvantages encountered in determining the presence or absence of a target analyte in the majority of cases is the requirement to perform several addition and washing steps using a range of solvents. The washing steps are essential at various stages of the assay protocol in order to prevent undesired cross-reactions and to remove any excess unbound reagents and substances which may subsequently interfere with the results. Unfortunately, this only complicates the overall procedure and effectively reduces the level of efficiency desired in order to develop an improved and simplified version of an immunodiagnostic assay. Thus, the need to adhere to several addition, washing and incubation steps has largely limited these procedures to clinical settings where skilled personnel and sophisticated equipment are available to carefully monitor and perform the assay with precision and accuracy.

**[0015]** In addition, immunodiagnostic assays that employ chromatographic test strips or dipsticks suffer from a problem regarding sequential treatment with one or more solvents at various stages of the assay procedure. As each solution is added to the device, or as each device immersed into successive solutions, the opportunity for spillage or contact between the solutions and the user are enhanced, thus leading to possible contamination and reduction in the reliability of the test.

**[0016]** Depending on the assay and device used, it is usually necessary that the test sample be diluted with an appropriate reagent prior to application so that it will diffuse more easily throughout the porous material and/or not overwhelm the concentration of the labeled reagent. However, dilution of the test sample not only reduces the speed and ease of performing an assay by including an additional step and reagent, but it can also reduce the sensitivity of an assay due to the correlation of analyte concentration to the detection signal generated.

**[0017]** US 5,879,951, US 5,877,028, WO 01/55723 and EP 0 806 666, describe lateral flow devices.

**[0018]** Depending on the relative mobility of the analyte of interest, the type of reagents and solvent used, and the site relationship between the different reaction zones, adequate time is essential in order to allow for efficient migration of all the various components along the chromatographic solid phase material. Moreover, the lateral flow technique often contributes to a higher incidence of inaccurate results due to the tendency of mobile reagents to accumulate at, rather than clear, the periphery of the reaction zone. As a result, these reagents will often interact at the zone and produce color products that may be easily mistaken for a true positive or negative result.

**[0019]** Various buffers and additives for such immunodiagnostic assays are known, including the buffer compositions and additives disclosed in US 5,185,264, US 4,087,567 and US 5,879,951.

**[0020]** Accordingly, the present invention provides an improved rapid diagnostic device, assay and multifunctional buffer for the detection of a target analyte in a fluid test sample which is efficient, reliable and practical to perform. The simplified 2-step assay utilizes a multifunctional buffer reagent and a dual component flow-through device comprising a test unit in combination with a detachable post-filter unit which are capable of receiving the fluid test sample and multifunctional buffer, respectively.

**[0021]** The multifunctional buffer serves as a combination washing, diluting, wetting and resolubilizing reagent, without sacrificing the sensitivity or specificity of the diagnostic assay. Additionally, the buffer is formulated to preserve and optimize protein stability, as well as minimize, if not eliminate, non-specific interactions that might lead to the generation of a false signal.

## SUMMARY OF THE INVENTION

**[0022]** An object of the present invention is to overcome the disadvantages associated with existing rapid diagnostic assays by providing an improved device, method and multifunctional buffer reagent.

**[0023]** The object of the present invention is achieved by a downward or vertical flow through test device according to claim 1, a method for determining the presence or absence of a target analyte according to claim 51, a method for determining the presence or absence of a target analyte according to claim 53 and a test kit according to claim 55. Preferred embodiments are disclosed in the respective sub-claims.

**[0024]** Using the simplified device and single buffer reagent of the present invention, a qualitative and semi-quantitative assay (1) can be performed and read easily, (2) requires a minimum number of steps, (3) does not require lengthy incubation periods, and (4) is highly sensitive, specific and reliable. Typically, as little as a single drop (50  $\mu$ L) of a fluid test sample is needed to perform the assay. Moreover, the device and assay of the present invention is particularly advantageous in that it is not only convenient and simple to use, but the device and reagents can be stored at room temperature for long periods of time without diminishing the activity or sensitivity of the assay.

**[0025]** The combination of features associated with the present invention relates to the implementation of a flow-through technique in conducting diagnostic assays that are based on specific binding reactions between two or more complementary members. On this basis, the rapid diagnostic device, assay and multifunctional buffer of the present invention have broad applicability in a variety of specific binding pair assay methods that essentially employ a capture reagent which will recognize and bind to a target analyte of interest. For example, the device of this invention can be used in an immunodiagnostic assay for the detection of either antigen or antibody in a fluid test sample and is adaptable for use in a sandwich or competitive detection format.

**[0026]** The kinetics of the reaction between the target analyte and the indicator reagent are extremely rapid and complete because the assay device and procedure operates on the basis of a flow-through format. Moreover, the method of the present invention improves the accuracy of the assay compared to conventional assays since the final step of the assay involves the addition of resolubilized indicator reagent to the target analyte after the analyte has already complexed with the capture reagent. By contrast, most conventional assays require premixing of the indicator reagent with a fluid test sample before addition to the capture reagent. As a result, the overall sensitivity of the assay is reduced due to the likelihood of the indicator reagent coming into contact with contaminants present in the test sample during the initial stage of the assay protocol, instead of only the analyte of interest.

**[0027]** The improved rapid diagnostic device is advantageously used in combination with a multifunctional buffer reagent for the purpose of detecting a target analyte in a fluid test sample based on the principle of a specific binding interaction between two or more complementary members. The device of the invention comprises, as a first component, a test unit capable of receiving a fluid test sample, in combination with a second component, namely a post-filter unit, capable of receiving the multifunctional buffer. The test unit comprises (1) a reaction zone containing immobilized capture reagent that can specifically recognize and bind to the target analyte, (2) an absorbent zone supporting the reaction zone, and optionally, (3) a blood separation zone in lateral fluid communication with the reaction zone. The post-filter unit comprises a label zone permeated with a dried indicator reagent which is resolubilized upon addition of the multifunctional buffer. The reaction zone of the test unit is oriented so that the label zone of the post-filter unit can be brought into fluid communication therewith after the fluid test sample is applied to the test unit.

**[0028]** In the case of an immunodiagnostic assay, for example, in which the analyte of interest is an antigen, an antibody, preferably a monoclonal antibody or an affinity purified polyclonal antibody for the antigen, is bound to the reaction zone as the capture reagent. In a preferred embodiment, the reaction zone is comprised of a porous membrane compatible for immobilization of the capture reagent and has low non-specific binding for the indicator reagent. Any non-specific binding sites on the surface of the porous reaction membrane are inactivated by applying a protein blocking agent. The specificity and affinity of the immobilized capture reagent is such that it efficiently binds and concentrates any analyte contained in the fluid test sample within a defined region as the sample diffuses by capillary action from the reaction membrane to the absorbent zone directly underneath.

**[0029]** The sensitivity of reaction-membrane type immunoassays (i.e. the ability to detect very low levels of target analyte) can be increased if the sample is concentrated through the reaction membrane. Therefore, concentration of analyte on the reaction membrane is achieved by having an absorbent material, defining the absorbent zone, placed directly beneath the reaction membrane that will draw the fluid test sample in, leaving only captured analyte on the upper surface of the reaction membrane. Since the absorbent material is in fluid communication with the reaction membrane, the material is selected on the basis of having physical properties (e.g. pore size, wicking power, etc.) which will effectively induce the flow of fluid through the reaction membrane, adequately hold assay sample and reagent fluids, and provide support for the membrane.

**[0030]** To facilitate the detection of a target analyte in a whole blood sample, an alternate embodiment of the present invention provides a test unit capable of receiving and separating the fluid portion of a whole blood sample from the red blood cells (RBC), while transporting the RBC-free fluid portion of the sample to the reaction zone for the detection of

analyte. This particular feature is useful in preventing any interference during visualization of a colour reaction for the detection of analyte (i.e. the use of "direct" labels which provide a visually detectable signal directly without the aid of instruments) and also avoids the necessity to obtain a preliminary extraction of serum or plasma in settings where proper equipment to perform such a procedure is unavailable.

5 **[0031]** Thus, in the case where the fluid test sample to be analyzed is a whole blood sample, the test unit optionally features a separate blood separation zone in lateral fluid communication with the reaction zone. In general, the blood separation zone functions to selectively retain cellular components (i.e. red blood cells) contained within the whole blood sample and deliver the remaining components of the blood sample, including any analyte, to the reaction zone. A first end of the blood separation zone, located a short lateral distance from the reaction zone, defines a region for receiving the whole blood sample prior to introduction of the analyte at the reaction zone. A second end of the blood separation zone is contiguous with, and thus in direct fluid communication with, the reaction zone thereby promoting the capillary movement of the RBC-free fluid portion of the blood sample from the first end to the reaction zone for direct analysis of the target analyte. Thus, in effect, the blood separation material functions as a lateral flow material for the selective removal of an effective amount of red blood cells from the whole blood sample to prevent interference with the visual detection of the analyte, while allowing other components of the sample to flow with relatively unimpaired movement through the test unit.

10 **[0032]** In a preferred embodiment, the blood separation zone is an elongate or rectangular strip of porous material employing a hydrophobic carrier or backing and having intrinsic properties which enable it to preferentially entrap or retain the red blood cells in the sample within the blood separation zone. The carrier or backing provides support for the blood separation material and reduces seepage of the whole blood sample as the RBC-free fluid portion migrates along the material towards the reaction zone.

15 **[0033]** The second component of the device, namely the post-filter unit, comprises a label zone permeated with a dried indicator reagent. The label zone of the post-filter unit is capable of being placed in transient fluid communication with the reaction zone of the test unit shortly following application of the fluid test sample to the test unit.

20 **[0034]** Impregnating the label zone of the post-filter unit with a permanently detectable indicator reagent eliminates the need to perform separate resolubilization steps involving precise measuring, adding and premixing with a suitable solvent which increases the possibility of user error. In a preferred embodiment, the label zone comprises a filter medium selected on the basis of having a pore size large enough so that when the dried indicator reagent is resolubilized by addition of the multifunctional buffer, it will easily flow through an exposed area of the porous filter medium by the process of diffusion. The shape and dimensions of the post-filter unit are such that it will hold and effectively channel the multifunctional buffer through the porous filter medium when the label zone is placed in transient fluid communication with the reaction zone of the test unit during the assay procedure.

25 **[0035]** According to another important aspect of the invention, methods and devices are provided utilizing "direct" labeled specific binding materials (i.e. colloidal particle labeled materials) which are dried onto a filter medium and hence, are capable of being rapidly resolubilized and transported to the reaction zone in the presence of the multifunctional buffer. Direct labels are well known in the art and highly advantageous for their use in rapid diagnostic systems. Direct labels are capable of producing a visually detectable signal without the aid of instrumentation or the addition of ancillary reagents and are stable when stored in the dry state. Supplying the indicator reagent by way of incorporating it within the filter medium in a dried form provides an inexpensive and convenient means of storing such reagent. The preferred label for carrying out diagnostic assays is colloidal metal particles, more preferably colloidal gold, although other direct labels may be employed which include, but are not limited to, non-metal sols, dye sols, latex particles, carbon sol, and liposome contained colored bodies.

30 **[0036]** According to a further important aspect of the present invention, there is provided an aqueous composition suitable for use as a multifunctional reagent in a diagnostic assay, comprising: (1) a biological buffer to maintain the pH between about 7.0 to 10.0; (2) at least one surfactant to reduce non-specific binding of assay reagents while simultaneously avoiding inhibition of a specific binding interaction; (3) a high molecular weight polymer as a dispersing and suspending reagent having a molecular weight in a range of from about  $2 \times 10^2$  to about  $2 \times 10^6$  D; (4) a pH stabilizer to maintain the pH of the multifunctional buffer between about pH 7.0 to 10.0; (5) an ionic salt to reduce the non-specific binding of antibodies; (6) at least one preservative to reduce bacterial and microbial growth; and (7) a calcium chelator to prevent a whole blood test sample from clotting; wherein the biological buffer, surfactant, high molecular weight polymer, pH stabilizer, ionic salt, preservative and calcium chelator are all at effective concentrations.

35 **[0037]** The improved buffer formulation does not require ancillary additives or the maintenance and inspection by laboratory instruments. More importantly, however, is the multifunctional nature of the buffer reagent which enables it to serve as a combination wash solution, diluent, resolubilization and solvent transport reagent, thereby eliminating the need for several separate solutions and steps to be performed during the assay protocol. The development of a single multifunctional buffer greatly simplifies the assay procedure by reducing the time and manual steps required to perform the assay, thereby minimizing the likelihood for user error. In addition, utilizing the multifunctional buffer in a flow-through format promotes quick release and enhanced mass transfer of the dried indicator reagent from the post-filter unit to the

test unit immediately following resolubilization. Other functional properties exhibited by the multifunctional buffer are that it maintains protein stability, thereby preserving and optimizing the specific binding reaction that occurs between complementary binding members, i.e. capture reagent and target analyte. Moreover, upon resolubilization of the dried indicator reagent, the buffer helps to maximize signal generation in the case of a specific binding reaction and minimize nonspecific binding to the reaction membrane that might otherwise lead to the generation of a false signal.

**[0038]** According to yet a further aspect of the present invention, there is provided a simple 2-step procedure for performing a diagnostic assay comprising (1) depositing a fluid test sample onto the reaction zone of the test unit, or if a whole blood sample, onto a first end of a blood separation zone and shortly thereafter, bringing the test unit and the post-filter unit into operable association therewith such that the label zone of the post-filter unit is in transient fluid communication with the reaction zone of the test unit, and (2) adding the multifunctional buffer to the post-filter unit followed by removal of the post-filter unit to observe the test result. Following addition of the multifunctional buffer to the post-filter unit, the buffer reagent diffuses through the label zone to reconstitute the indicator reagent and transport it to the reaction zone where it will bind with any captured analyte. If analyte is present in the fluid test sample, a detectable signal will appear in the reaction zone which can be visually inspected for color and thus, a determination of the presence or absence of analyte made following removal of the post-filter unit. An important advantage provided by the present invention is that the binding affinity of the capture reagent is capable of immobilizing and optimizing exposure of the analyte in the flowing stream of reconstituted indicator reagent so that it is accumulated in the reaction zone and thus, efficiently separated from the background stream of non-concentrated indicator reagent.

**[0039]** The present invention also provides a diagnostic test kit for use in the detection of a target analyte in a fluid test sample suspected of containing the analyte. Essentially, the kit comprises in a packaged combination: (1) the rapid diagnostic assay device comprising both the test unit and post-filter unit as described above; (2) a multifunctional buffer reagent for reconstitution of the dried indicator reagent; and (3) instructions for performing the diagnostic assay. The test kit preferably includes a suitable container for housing the test unit and the post-filter unit in order to safeguard the solid phase materials and dried indicator reagent from contamination, as well as to provide ease and convenience in handling of the assay device. Optionally, the test kit also includes a means for applying the test sample and multifunctional buffer to the test unit and post-filter unit, respectively (e.g. disposable pipettes).

#### BRIEF DESCRIPTION OF THE DRAWINGS

**[0040]**

Fig. 1A is a diagrammatic illustration of a first embodiment of the flow-through diagnostic device of the present invention comprising the test unit and post-filter unit;

Fig. 1B is a diagrammatic illustration of a second embodiment of the flow-through diagnostic device of the present invention for analyzing a whole blood test sample comprising the test unit and post-filter unit;

Fig. 2A is a diagrammatic illustration of a test sample applied to the reaction zone of the test unit which contains target analyte;

Fig. 2B is a diagrammatic illustration of target analyte complexed with the capture reagent after the test sample has completely diffused through the reaction zone and into the absorbent zone of the test unit;

Fig. 2C is a diagrammatic illustration of the post-filter unit in fluid communication with the reaction zone of the test unit, to which the multifunctional buffer is added;

Fig. 2D is a diagrammatic illustration of resolubilized indicator reagent reacted with complexed capture reagent and analyte following addition of the multifunctional buffer to the post-filter unit;

Fig. 3A is a diagrammatic illustration of a test sample applied to the porous reaction membrane of the test unit which does not contain target analyte;

Fig. 3B is a diagrammatic illustration of uncomplexed capture reagent after the test sample has diffused through the reaction membrane and into the absorbent material of the test unit;

Fig. 3C is a diagrammatic illustration of the post-filter unit in fluid communication with the reaction zone of the test unit, to which the multifunctional buffer is added;

Fig. 3D is a diagrammatic illustration of unreacted indicator reagent following resolubilization by the multifunctional buffer after diffusing through the reaction zone and into the absorbent zone of the test unit;

5 Fig. 4 shows an exploded cross-sectional view of an example of a suitable container which houses the test unit and the post-filter unit;

Fig. 5 shows an enlarged cross-sectional view of the container of Fig. 4 in its assembled form;

10 Fig. 6 is a diagrammatic illustration of a second embodiment of a portion of the test unit comprising a material defining the blood separation zone in fluid communication with the reaction zone; and

Fig. 7A is a diagrammatic illustration of a top plan view of the top member of a 2-reservoir test cartridge for receiving and analyzing a whole blood sample; and

15 Fig. 7B is a diagrammatic illustration of a top plan view of the bottom member of a 2-reservoir test cartridge for receiving and analyzing a whole blood sample.

[0041] While this invention is satisfied by embodiments in many different forms, there will herein be described in detail preferred embodiments of the invention, with the understanding that the present disclosure is to be considered as  
20 exemplary of the principles of the invention and is not intended to limit the invention to the embodiments illustrated and described. The scope of the invention will be measured by the appended claims and their equivalents.

#### DETAILED DESCRIPTION OF THE INVENTION

25 [0042] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. It must also be noted that, as used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. For example, reference to an "antigen" or "antibody" is intended to include a plurality of antigen molecules or antibodies.

30 [0043] Ranges may be expressed herein as from "about" or "approximately" one particular value and/or to "about" or "approximately" another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value forms another embodiment.

35 [0044] As employed throughout the disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

Absorbent Zone - the term "absorbent zone" is intended to include one or more layers of a permeable (e.g. porous or fibrous) material, which layers can be the same or different, and are capable of drawing or wicking fluid by capillary action. The absorbent zone should also be capable of absorbing a substantial volume of fluid that is equivalent to  
40 or greater than the total volume capacity of the material itself, and thus have a high absorbent capacity.

**Analyte (or target analyte)** - the compound or composition of interest to be detected in a biologically derived fluid test sample. Examples of analytes may include drugs, hormones, polypeptides, proteins including immunoglobulins, polysaccharides, nucleic acids, and combinations thereof.

45 **Antibody** - an immunoglobulin, whether natural or partly or wholly synthetically produced. The term also covers any polypeptide or protein having a binding domain which is, or is homologous to, an antibody binding domain. These can be derived from natural sources, or they may be partly or wholly synthetically produced. Examples of antibodies are the immunoglobulin isotypes and their isotypic subclasses; fragments which comprise an antigen binding domain such as Fab, scFv, Fv, dAb, Fd; and diabodies.

50 Antibodies useful in conducting the immunoassays of the present invention include those specifically reactive with various analytes the detection of which in biological fluids is desired. Such antibodies are preferably IgG or IgM antibodies or mixtures thereof, which are essentially free of association with antibodies capable of binding with non-analyte molecules. The antibodies may be polyclonal or monoclonal and are commercially available or may be  
55 obtained by mouse ascites, tissue culture or other techniques known to the art. A typical description of hybridoma procedure for the production of monoclonal antibodies may be found in Wands, J. R., and V. R. Zurawski, Gastroenterology 80:225 (1981); Marshak-Rothstein, A., et al.; J. Immunol. 122:2491 (1979); Oi, V. Y. and L. A. Herzenberg, "Immunoglobulin Producing Hybrid", Mishell B. B. and S. M. Shiigi (eds) Selected Methods in Cellular Immunology,

San Francisco: W.H. Freeman Publishing, 1979; and U.S. Patent No. 4,515,893 issued to Kung, et al. The use of mixtures of monoclonal antibodies of differing antigenic specificities or of monoclonal antibodies and polyclonal antibodies may be desired. It is further contemplated that fragments of antibody molecules may be used as specific binding reagents according to the invention including half antibody molecules and Fab, Fab' or F(ab')<sub>2</sub> fragments known in the art. Regardless of the particular source or type of antibodies, however, it is preferred that they be generally free of impurities. The antibodies may be purified by column chromatographic or other conventional means but are preferably purified according to known affinity purification techniques. Antibodies materials may also be labeled with colloidal particles according to the invention and used in sandwich type assays for the detection of antigen analytes or in competition assays for the detection of antibody analytes.

**Antigen** - antigens and haptens useful in carrying out the immunoassays of the present invention include those materials, whether natural or synthesized, which present antigenic determinants for which the analyte antibodies are specifically reactive when used according to the present invention. Synthesized antigens include those which are constructed according to conventional chemical syntheses as well as those constructed according to recombinant DNA techniques. Antigen materials may also be labeled with colloidal particles according to the invention and used in sandwich type assays for the detection of antibody analytes or in competition assays for the detection of antigen analytes.

**Blood Separation Zone** - The term "blood separation zone" is intended to include a porous and/or fibrous material which is capable of retaining red blood cells (RBC) from a whole blood sample allowing the RBC-free fluid, including any target analyte, to migrate in a lateral flow by way of capillary action.

**Capillary Action** - as used herein, the term "capillary" includes a capillary or other channel or pathway which permits a liquid to traverse a porous, fibrous or absorbent material. The material in capillary communication with the reaction membrane of the test unit is selected on the basis of having intrinsic properties which enable it induce flow of a fluid, either vertically or laterally, without the use of external means.

**Capture Reagent** - any compound or composition capable of recognizing a particular spatial and/or chemical structure of an analyte. In the case of an analyte which is a specific immunoglobulin species, the capture reagent may be the specific protein or epitope recognized by the immunoglobulin. Other types of capture reagents include naturally occurring receptors, antibodies, antigens, enzymes, Fab fragments, lectins, nucleic acids, avidin, protein A, and the like.

**Fluid test sample** - the fluid test sample is assayed to form a detectible reaction product on the reaction membrane of the test unit. In preferred assay embodiments, the fluid test sample is biologically derived (e.g. whole blood, plasma, serum, urine, saliva, etc.) and is suspected to include as the target analyte, typically an antigen, antibody, or hapten capable of being bound by the capture reagent immobilized on the reaction membrane.

**Indicator Reagent** - a conjugate comprised of a specific binding member to the target analyte and a label conjugated to the specific binding member which is capable of being visually detected. Additionally, the indicator reagent can be comprised of a general marker protein, e.g. Protein A, Protein G, or anti-IgG conjugated to a label. For example, in an assay for detecting antibody as a target analyte, a preferred indicator reagent would be protein A labeled with colloidal gold. Other indicator reagents may also include a labeled anti-human antibody directed to the antibody of interest, e.g. goat anti-human IgG labeled with colloidal gold for the detection of human antibody in a fluid test sample.

**Label** - a label may be any molecule bound or conjugated to a specific binding member or general marker protein which can produce a signal. In the subject invention, the label is preferably a "direct" label which is capable of spontaneously producing a detectible signal without the addition of ancillary reagents and will be easily detected by visual means without the aid of instruments. The preferred embodiment of the invention uses colloidal gold particles as the label. Other suitable labels may include other types of colloidal metal particles, minute colored particles, such as dye sols, and coloured latex particles. Many such substances will be well known to those skilled in the art.

**Label Zone** - The term "label zone" is intended to include a porous material which is impregnated with a dried indicator reagent that can be readily resolubilized upon addition of a buffer reagent thereto.

**Reaction Zone** - the term "reaction zone" is intended to include a porous material to which the capture reagent and other molecules employed in the analytical assay are bound as well as additional porous supporting material, if any, that forms the lower surface of the reaction zone.

**Specific Binding Member** - this describes two or more complementary members of a specific binding interaction which have binding affinity for one another. The specific binding members may be naturally derived or synthetically produced. One member of the specific binding interaction has an area on its surface, or a cavity, which specifically binds to and is therefore complementary to a particular spatial and/or chemical structure of the other complementary member. Examples of types of specific binding pairs are antigen-antibody, biotin-avidin/streptavidin, hormone-hormone receptor, receptor-ligand, enzyme-substrate, and the like.

## 1.0 INTRODUCTION

**[0045]** The present invention provides an improved rapid diagnostic device, assay and a multifunctional buffer for the detection of a target analyte in a fluid test sample, such as a body fluid. The rapid diagnostic device is not only simple to use and economical to manufacture, but it is reliable enough to be utilized in sensitive analytical assays without requiring lengthy incubation periods, extra washing steps, or dilution of the sample. Since the assay may be varied according to the target analyte in question, the present invention is useful for a wide variety of biological assays. For instance, a fluid test sample (e.g. serum, plasma, whole blood, saliva, urine, etc.) may be quickly and accurately analyzed for antigen, antibodies, natural or synthetic steroids, hormones, and the like.

**[0046]** The rapid diagnostic device useful in the practice of the invention is a dual component flow-through system comprising a test unit and a post-filter unit capable of receiving the fluid test sample and multifunctional buffer, respectively. The test unit comprises a reaction zone containing immobilized capture reagent that can specifically recognize and bind to the target analyte and an absorbent zone supporting the reaction zone. The reaction zone of the test unit is oriented so that the label zone of the post-filter unit can be brought into transient fluid communication therewith shortly after the fluid test sample is applied to the reaction zone of the test unit. To facilitate the detection of a target analyte in a whole blood sample, an alternate embodiment of the present invention provides a test unit further comprising a blood separation zone in lateral fluid communication with the reaction zone, whereby a first end of the blood separation zone located a short lateral distance from the reaction zone defines a region for receiving the whole blood sample. A second end of the blood separation zone may overlap slightly with the reaction zone so as to ensure direct fluid communication therewith. The post-filter unit comprises a label zone containing a dried indicator reagent and is capable of being placed in transient fluid communication with the reaction zone of the test unit during the assay procedure.

**[0047]** The assay protocol is a simple 2-step procedure involving (1) depositing a fluid test sample onto the reaction zone of the test unit, or if a whole blood sample, onto a first end of the blood separation zone and shortly thereafter, bringing the test unit and the post-filter unit into operable association such that the label zone of the post-filter unit is in transient fluid communication with the reaction zone of the test unit, and (2) adding the multifunctional buffer to the post-filter unit and removing the post-filter unit to observe the test result. The multifunctional buffer passively diffuses through the label zone of the post-filter unit to resolubilize the indicator reagent and transport it to the reaction zone of the test unit where it will bind to the corresponding analyte complexed with the capture reagent. If analyte is present in the fluid test sample, a detectable signal will appear in the reaction zone which can be easily visualized following removal of the post-filter unit from the test unit. An advantage provided by the methodology of the present invention is the enhanced sensitivity and reliability of the test. This is achieved by maximizing the opportunity for thorough capture of the analyte, even at low concentrations. Additionally, the implementation of assay steps which increase the likelihood of contamination of the sample and reagents is eliminated altogether by the assay of the present invention.

## 2.0 SPECIFIC BINDING REACTION

**[0048]** The assay device of the present invention is used to qualitatively and semi-quantitatively detect the presence of a target analyte in a fluid test sample. Analytes suitable for detection in the assay device are essentially members of a specific binding interaction such that one of the members is able to recognize and bind, usually non-covalently, to a complementary, non-identical member so as to form a stable complex that can be easily be detected, either directly or indirectly. The members of the specific binding reaction may be referred to as a target analyte and a capture reagent and may include a wide variety of biologically derived substances that may participate in an immunological reaction, e.g. antigen-antibody, or a non-immunological reaction, e.g. avidin and biotin, cell surface receptor and an effector agent, DNA and RNA, and so forth. For a disclosure of specific binding members see U.S. Patent No. 3,996,345 (Ullman, et al.).

**[0049]** As applied to binding assays, the assay device of the present invention can be designed to detect any number of target analytes, for which there is a specific binding partner. The analyte usually is a peptide, protein, carbohydrate, glycoprotein, steroid, or other organic or inorganic molecule for which a specific binding partner exists in a biological system, or can be synthesized. The binding assay essentially involves the specific binding of the analyte (i.e. the first specific binding member) to a capture reagent (i.e. the second specific binding member) immobilized on a solid phase material and additionally, an indicator reagent (comprising a label attached to an ancillary second specific binding member or a general marker protein). The immobilization of the capture reagent to the solid phase material forms a "capture

situs" and thus, facilitates the separation or removal of the target analyte from other components of the test sample. The label, which enables the indicator reagent to produce a detectable signal signifying the presence of analyte in the fluid test sample, is achieved through direct or indirect binding of the binding member of the indicator reagent. Generally, the ancillary second specific binding member binds to the target analyte at a site which does not interfere with the specific binding interaction between the target analyte and the capture reagent. Exemplary, but not exclusive of the present invention, is the specific binding interaction that occurs as a result of antibody-antigen interactions.

**[0050]** It will be appreciated by those skilled in the art that while the rapid diagnostic assay device described herein is anticipated to be primarily employed in assaying either antigens or antibodies through the formation of an immune complex, that in fact, its applicability is considerably broader, and is not restricted to these molecules. At a minimum, the device merely requires that a first member that recognize and bind with a second member of a specific binding reaction. The first member can be conveniently termed a target analyte and the second member a capture reagent. While antigen and antibody are preferred embodiments of a target analyte and capture reagent, serving respective or alternative roles, the device can be used with a variety of capture reagent and analyte molecules. For example, hormone receptor molecules are a type of capture reagent molecule and can be attached to the reaction zone of the test unit and used to assay for the corresponding hormone analyte. Alternatively, a hormone could be bound to the reaction zone and used to assay for hormone receptors (Hermanson, G.T. (1996) Bioconjugate Techniques, Academic Press).

**[0051]** The system is also adaptable to the detection of DNA sequences. For example, a fluid test sample suspected of containing a DNA sequence as target analyte is deposited on the reaction zone and binds to a known complimentary DNA sequence immobilized as capture reagent on the reaction zone. Then, a labeled DNA probe is transported by way of the multifunctional buffer to the reaction zone. If hybridization occurs, the labeled DNA probe will be retained in a visually detectable form on the surface of the reaction zone. This system is described in Polsky-Cynkin, R., et al., Clin. Chem. 31/9, 1438 (1985).

**[0052]** Thus, it will be readily apparent to those skilled in the art that there are many such combinations of capture reagent-target analyte pairs that may be suitably employable in the present diagnostic device and method.

### 3.0 ASSAY DEVICE AND METHODOLOGY

#### 3.1 SANDWICH TECHNIQUE

**[0053]** A preferred embodiment of the present invention employs a direct binding (sandwich) assay format. The format is based on the principle of a specific binding interaction that will occur between a target analyte comprising the first specific binding member, a capture reagent comprising a second specific binding member that is immobilized to a solid phase material, and a dried indicator reagent comprising an ancillary second specific binding member, or a general marker protein. The aforementioned members form a three-membered complex when the contents of a fluid test sample containing the target analyte are reacted with immobilized capture reagent, followed by the addition of the indicator reagent. In general, the diagnostic assay thus depends upon the ability of a second specific binding member to specifically recognize and bind to the first specific binding member. Depending upon the type of target analyte to be detected, an indicator reagent comprising an ancillary second specific binding member labeled with a visually detectable moiety is employed to determine the existence of such binding. The amount of indicator reagent detected and measured after the reaction can be correlated to the amount of analyte present in the test sample. For example, in the sandwich immunoassay format, a test sample containing an antigen, i.e. the target analyte, is contacted with a primary antibody which is immobilized on a solid phase material, i.e. the capture reagent. The solid phase material is subsequently treated with the indicator reagent, namely a secondary antibody that has been labeled with a visually detectable moiety. The secondary antibody then becomes bound to the corresponding antigen immobilized by the primary antibody immobilized to the solid phase material and any color change is then visually detected which is indicative of antigen present in the test sample.

**[0054]** Thus, in its simplest embodiment, Figure 1A provides a diagrammatic illustration of the assay device **1** of the present invention which comprises two separate components, a test unit **2** and a post-filter unit **3**. The test unit **2** is comprised of a reaction zone **5** having its lower surface supported by an absorbent zone **4**. The reaction zone **5** receives the fluid test sample **9** directly and provides clear visualization of a test result due to the presence of immobilized capture reagent **6** contained therein which is capable of recognizing and binding the target analyte of interest through a specific binding interaction, in a preferred embodiment, the reaction zone **5** is comprised of a porous membrane compatible for immobilization of the capture reagent **6** and has low non-specific binding for the indicator reagent **8**. The absorbent zone **4** is preferably made from permeable material possessing intrinsic properties that enable it to draw fluid in by capillary action, adequately hold reagent and sample fluids, and additionally provide support for the reaction zone **5**. The post-filter unit **3** comprises a label zone **7** permeated with a dried indicator reagent **8**. The dried indicator reagent **8** comprises a label and a specific binding member which will also recognize and bind to the analyte of interest, but at a site which does not interfere with the specific binding interaction between the target analyte and the capture reagent. The label zone **7** preferably comprises a filter medium selected on the basis of having a pore size large enough so that when the

dried indicator reagent **8** is resolubilized by addition of the multifunctional buffer **12**, it will easily flow through an exposed area of the label zone **7** by the process of diffusion. The shape and dimensions of the post-filter unit **3** are such that it will hold and effectively channel the multifunctional buffer through the label zone **7** when placed in transient fluid communication with the reaction zone **5** of the test unit **2** during the final step of the assay procedure.

5 **[0055]** Figure 1B provides a diagrammatic illustration of the assay device **1** of a second embodiment of the present invention which comprises two separate components, a test unit **2** and a post-filter unit **3**, wherein the test unit **2** additionally comprises a blood separation zone **100** capable of receiving and separating the fluid portion of a whole blood sample **9'** from the red blood cells (RBC), while transporting a RBC-free fluid portion, including any analyte, to the reaction zone **5** for direct analysis. The preferred material for the blood separation zone **100** is selected on the basis of having intrinsic properties which enable it to preferentially entrap or retain the red blood cells in the sample **9'** as the fluid portion migrates in a lateral direction towards the reaction zone **5**.

10 **[0056]** Figure 2 is a diagrammatic illustration showing the method of the invention using the device of Figure 1A. In this particular instance, Figure 2A shows a fluid test sample **9** containing the target analyte **10**, as well as other non-essential components **11**, which is applied to the reaction zone **5** of the test unit **2**. As the fluid test sample **9** diffuses through the reaction zone **5** and into the absorbent zone **4** underneath, the free analyte **10** comes into contact with available sites of attachment on the capture reagent **6** and forms a complex, while unbound non-essential component **11** continues to be drawn into the absorbent zone **4** below (Figure 2B). As shown in Figure 2C, the label zone **7** of the post-filter unit **3** is subsequently brought into fluid communication with the reaction zone **5** of the test unit **2** prior to the addition of the multifunctional buffer **12**. Immediately following resolubilization of the dried indicator reagent **8** by the buffer **12**, the indicator reagent **8** is transported to the reaction zone **5** of the test unit **2**, where it will bind with any analyte **10** that has complexed with the capture reagent **6**. The binding reaction of the indicator reagent **8** with the analyte **10** produces a visually detectable signal thereby indicating a positive result that is easily observed following removal of the post-filter unit **3**, as per Figure 2D.

15 **[0057]** Figure 3A is a diagrammatic illustration showing the method of the invention using the device of Figure 1A when a fluid test sample **9** devoid of target analyte is applied to the reaction zone **5** of the test unit **2**. As the fluid test sample **9** diffuses through the reaction zone **5** and into the absorbent zone **4** underneath, the non-essential components **11** completely bypass the capture reagent **6**, leaving the sites of attachment unoccupied (Figure 3B). As shown in Figure 3C, the label zone **7** of the post-filter unit **3** is subsequently brought into fluid communication with the reaction zone **5** of the test unit **2** prior to the addition of the multifunctional buffer **12**. Immediately following resolubilization of the dried indicator reagent **8** by the buffer **12**, the indicator reagent **8** is transported to the test unit **2**, where it diffuses through the reaction zone **5**, pass the capture reagent **6** and into the absorbent zone **4** below due to the absence of any target analyte complexed with capture reagent **6**. Following removal of the post-filter unit **3**, a color signal will not be detected thereby indicating a negative result due to the absence of binding between the indicator reagent **8** and complexed analyte.

20 **[0058]** To facilitate the detection of a target analyte in a whole blood sample, an alternate embodiment of the present invention provides a test unit having a blood separation zone capable of receiving and separating the fluid portion of a whole blood sample from the red blood cells (RBC), while transporting the RBC-free fluid portion, including any analyte, to the reaction zone for direct analysis. As shown in Figure **6**, the blood separation zone **100** is preferably an elongate strip of porous material which is selected on the basis of having intrinsic properties which enable it to preferentially entrap or retain the red blood cells in the sample **9'** as the fluid portion migrates in a lateral direction towards the reaction zone **5**. Although the shape and dimensions are not critical, preferably the blood separation zone **100** is a rectangular form having dimensions suitable for allowing efficient removal of a substantial amount of red blood cells from the whole blood sample **9'** prior to the RBC-free fluid portion of the sample **9'** arriving at the reaction zone **5**. Thus, in effect, the blood separation material functions as a lateral flow material for the selective removal of an effective amount of red blood cells from the whole blood sample **9'** so as to avoid interference with the visual detection of the analyte, while allowing other components of the sample, including any analyte, to flow with relatively unimpaired movement to the reaction zone **5**. Preferably, a hydrophobic carrier **103** is affixed to the lower surface of the blood separation zone **100** to provide support and reduce seepage of the fluid phase while the RBC-free fluid portion of the whole blood sample migrates towards the reaction zone **5**. The carrier **103** is preferably similar in shape and size to the blood separation zone **100**.

25 **[0059]** A first end **101** of the blood separation zone **100**, located a short lateral distance from the reaction zone **5**, defines a region for receiving the whole blood sample **9'** prior to introduction of the analyte at the reaction zone **5**. A second end **102** of the blood separation zone **100** is contiguous with and may overlap slightly with the reaction zone **5**, so as to be in direct fluid communication with the reaction zone **5**, thereby promoting the capillary movement of the RBC-free fluid portion of the blood sample **9'** from the first end of the blood separation zone **100** to the reaction zone **5**. The blood separation zone **100** and the reaction zone **5** must contact one another in order to ensure optimal transfer of the sample from one zone to the other. Therefore, it is preferably that the blood separation zone **100** and the reaction zone **5** overlap with one another slightly as opposed to being abutted to one another.

30 **[0060]** Thus, the two-step assay protocol optionally employs a simultaneous separation of red blood cells from a whole blood sample **9'** in order to permit testing for a desired analyte without the requirement for additional steps. For example,

in the case where a whole blood sample **9'** contains analyte, the sample **9'** is simply applied to the first end of the blood separation zone **100** of the test unit, rather than the reaction zone **5**. As the RBC-free fluid portion of the blood sample **9'** migrates in a lateral direction to arrive at the reaction zone **5**, the free analyte eventually comes into contact with available sites of attachment on the capture reagent and forms a complex. Thus, similar to the method steps shown in Figure 2, unbound non-essential components are drawn into the absorbent zone located beneath the reaction zone. The label zone of the post-filter unit is subsequently brought into fluid communication with the reaction zone of the test unit prior to the addition of the multifunctional buffer. Immediately following resolubilization of the dried indicator reagent by the buffer, the indicator reagent is transported to the reaction zone of the test unit, where it will bind with any target analyte that has complexed with the capture reagent. The binding reaction of the indicator reagent with the target analyte produces a visually detectable signal thereby indicating a positive result that is easily observed following removal of the post-filter unit.

### 3.2 COMPETITIVE TECHNIQUE

**[0061]** Those skilled in the art can deduce the application of the present invention in competitive, as well as noncompetitive (e.g. sandwich), assays for target analyte of suitable interest. In the competitive format, it is an ancillary first specific binding member of the indicator reagent (as opposed to an ancillary second specific binding member in the case of the "sandwich" technique) which is capable of binding to the second specific binding member, i.e. the capture reagent. In other words, ancillary first specific binding member of the indicator reagent competes with the target analyte, i.e. first specific binding member, for binding to sites of attachment of the capture reagent. The ancillary first specific binding member will comprise, for example, an analogue or other authentic sample of the target analyte which has comparable binding affinity with the first binding member. When the fluid test sample is deposited on the reaction zone, any target analyte, if present, will bind to available sites of attachment of the capture reagent, i.e. the second binding member, and thus potentially block the ancillary first binding member of the indicator reagent from binding to the capture reagent following its addition. If the fluid test sample happens to contain the target analyte, the absence of a color signal will indicate a positive result due to the inability of the indicator reagent to bind to the capture reagent. Alternatively, if the test sample does not contain any target analyte, the presence of a color signal will indicate a negative result due to the ability of the indicator reagent to bind to unoccupied sites of attachment of the capture reagent.

### 4.0 TEST UNIT

**[0062]** As described above, the diagnostic device of the present invention comprises, as a first component, a test unit having a reaction zone containing immobilized capture reagent that can specifically recognize and bind to the target analyte, an absorbent zone supporting the reaction zone, and optionally, a blood separation zone in lateral fluid communication with the reaction zone. The reaction zone of the test unit is oriented so that the label zone of the post-filter unit can be brought into transient fluid communication therewith shortly after the fluid test sample is applied to the test unit.

### 4.1 REACTION ZONE

**[0063]** The term "reaction zone" is intended to include the porous material to which the capture reagent and other molecules employed in the analytical assay are bound as well as additional porous supporting material, if any, that forms the lower surface of the reaction zone.

**[0064]** The selection of the material for the reaction zone is not critical to the invention. The materials used to fabricate the device of the present invention are well known in the art. Porous materials, such as those described in U.S. Patents Nos. 4,670,381, 4,632,901, 4,666,863, 4,459,361, 4,517,288, and 4,552,839, may be composed singly or in combination of glass fibers, cellulose acetates, nylon, or various synthetic or natural materials.

**[0065]** The preferred material of the reaction zone is a membrane which has a pore size permitting separation and filtration of other non-essential components from the fluid test sample being assayed. The flow of the aqueous reagents is controlled through diffusion and the membrane should have low nonspecific binding for the indicator reagent before or after treatment with reagents such as proteins, detergents, or salts. There are many porous membrane, films, or papers available commercially which have controlled hydrophobicity and are suitable for the practice of the invention. The reaction membrane can be any shape and thickness but usually is flat and thin. The absorption, diffusion or filtration of the liquid phase of the reactants from the solid phase particles in the separation step of the assay can be facilitated by the addition of a fibrous or hydrophilic material (absorbent pad) in contact with the underside of the reaction membrane. The size of the area exposed to the solid phase particles can be controlled by using a hydrophobic material such as plastic, plastic laminate, or other similar substance that is placed in contact with the reaction membrane and seals the reaction zone such that only a surface area no greater than about 150 mm<sup>2</sup> is exposed to the particulate solid phase.

**[0066]** The porosity of the membrane has a large influence on the flow rate of the liquid and sensitivity of the assay.

The larger the pore size of the membrane, the faster the flow rate for a given liquid. As the flow rate increases, the interaction time available between the target molecule in the sample and the receptor immobilized on the reaction membrane decreases, thus decreasing assay sensitivity. Additionally, larger pore sizes provide less surface area for immobilizing the receptor molecule, which is another parameter attributable to decreased assay sensitivity. For most assays, the porosity of the membrane is preferably in the range of about 0.1 to about 12.0 microns, and more preferably ranging from about 0.2 to 0.8 microns.

**[0067]** The wicking power of the membrane may also affect assay sensitivity and depends on the thickness and nature of the membrane material. Wicking power can be measured as the migration of a standard solution through a certain distance per unit time. Often times, selecting a membrane having a relatively low wicking power can increase assay sensitivity. Thus, in addition to porosity, the overall thickness of the reaction membrane may affect assay sensitivity and therefore, must also be considered.

**[0068]** The thickness of the reaction membrane, which is the distance between the upper and lower surfaces of the reaction membrane, can vary depending upon the flow characteristics needed for a given diagnostic assay. Typically, the thickness will range from about 0.05 mm to about 3.0 mm, and more commonly from about 0.1 to about 1.0 mm. With some immunoassays in particular, it has been found that when the thickness of the reaction membrane is greater than about 0.1 mm, and preferably in the range of about 0.2 mm to about 1.0 mm, higher sensitivity can be achieved. Moreover, it is believed that prior art devices which have relatively thin reaction membranes, such as nitrocellulose membranes less than 0.1 mm thick and which are not paper-backed, tend to allow the sample to flow sideways across the reaction membrane rather than downwards through the middle of the reaction membrane. On the other hand, a thicker reaction membrane may allow more capture reagent to be available for binding to the target analyte, thereby providing a further increase in assay sensitivity. Thus, the thickness of the membrane should be selected so that an adequate amount of binding reagent can be immobilized to capture the sample component. However, if the membrane thickness is too large, it may cause undue delay of the passage of the fluid test sample through the membrane.

**[0069]** Another factor to be considered is that the material of the reaction membrane be selected on the basis that it is compatible for immobilization of the capture reagent. The reaction membrane may be any suitable porous material capable of immobilizing the capture reagent employed in the diagnostic assay so long as the performance of the assay is not adversely affected. Suitable materials include nitrocellulose (supported or unsupported), glass fiber, polyester, cellulose nitrate, polyester, polycarbon, nylon, and other natural and synthetic materials which can be coupled directly or indirectly to the selected capture reagent. Usually the membrane will comprise negative charges that allow the capture reagent molecule to bind. Certain membrane materials which are charged include cellulose nitrate which has partial negative charges contributed by the nitro groups.

**[0070]** In some cases commercial filters are available that have immobilized to their internal and/or external surfaces a reactant for the attachment of biological molecules, such as antibodies or antigens, to the surfaces. Examples of various filters include cellulosic filters (filter papers), polyamide membranes (e.g. numerous variations of polyamide membranes are manufactured by the Pall Corporation), and various other microporous membranes, such as those available commercially from Amicon, Geleman, and Schleicher & Schuell. For example, the following membranes are available from Pall Corporation: Biodyne<sup>®</sup>, a N66 polyamide microporous membrane (U.S. Patent No. 4,340,479 issued to Pall); Carboxydyne<sup>®</sup>, a hydrophilic, microporous, skinless nylon 66 membrane with control surface properties characterized by carboxyl functional groups at its surfaces; and immunodyne<sup>™</sup>, a modified Carboxydyne<sup>®</sup> membrane prepared by treating a Carboxydyne<sup>®</sup> membrane with trichloro-s-triazine. Other microporous membranes, prepared by the Millipore Corporation, are described in U.S. Patents Nos. 4,066,512 and 4,246,339.

**[0071]** Other materials may be pre-treated to provide a charged membrane. For example, polyester can be derivatized with carboxyl or amino groups to provide either a negatively or positively charged membrane. Nylon can be treated with acid to break peptide bonds to provide positive charges (from the amine groups) and negative charges (from the carboxyl groups).

**[0072]** A preferred material for utilization as a reaction membrane is a nitrocellulose membrane backed with porous paper similar to filter paper, or other types of nitrocellulose membranes with similar characteristics. A representative example is commercially available under the trade name BAC-T-KOTE by Schleicher and Schuell. This material is substantially more durable than nitrocellulose alone and can be employed without any other support component while allowing for easier handling and device assembly. Additionally, it has been found that analytical devices employing paper-backed nitrocellulose for the reaction zone have enhanced sensitivity in certain immunoassays.

**[0073]** Other commercially available materials are from EY Laboratories Inc. (San Mateo, Calif.; Cat. Nos. PBNC15-1, PBNC15-10, PBNC15M-1, and PBNC15M-10).

#### 4.2 IMMOBILIZATION OF THE CAPTURE REAGENT

**[0074]** In a typical system, the capture reagent is immobilized on the porous membrane of the reaction zone which will specifically recognize and bind to any target analyte present in the fluid test sample being assayed. Such reagent,

typically an immunological protein such as an antibody or antigen, can be immobilized directly or indirectly onto such materials, such as nitrocellulose, by either absorption, adsorption, or covalent bonding. When a fluid test sample suspected of containing the target analyte of the specific binding interaction is applied to the reaction zone containing the immobilized capture reagent, it becomes non-diffusively bound to the reaction zone. Thus, by appropriate application of a fluid test sample suspected of containing the target analyte of interest, a high concentration of the target analyte can be obtained in a well defined region within the center of the reaction zone. In appropriate cases, the capture reagent may be coated on the upper surface of the reaction zone or be a particulate which is entrapped within the matrix of the porous material of the reaction zone. Therefore, as used herein, the term "immobilized" is intended to embrace any means for fixing the capture reagent to the porous material.

**[0075]** A first step of the present method is to immobilize the capture reagent within a finite zone of the reaction zone. Immobilization can be accomplished by methods such as adsorption, absorption, evaporative deposition from a volatile solvent solution, covalent bonding between the capture reagent and the reaction membrane, or immunological immobilization. Covalent bonding may, for example, involve bonding the capture reagent to the reaction zone through a coupling agent, such as a cyanogen halide, e.g. cyanogen bromide or by the use of gluteraldehyde, as described by Grubb, et al. in U.S. Patent No. 4,186,146. Immunological immobilization to the reaction membrane may be by absorption, or by covalent linkage, directly, or through a linker of sorts well-known to those skilled in the art. Suitable methods of carrying out these procedures are given, for example, by Iman and Hornby in *Biochemical Journal* (Volume 129; Page 255; Campbell, Hornby, and Morris In *Biochem. Biophys. Acta* (1975), Volume 384; Page 307; and Mattisson and Nilsson in *F.E.B.S. Letters*, (1977) Volume 104, Page 78. See also, for example, U.S. Patents Nos. 4,376,110 and 4,452,901. In addition, chemically pretreated materials suitable for coupling antibodies can be purchased commercially.

**[0076]** Immunological immobilization is preferred for the practice of the present invention. For example, if a sandwich immunoassay is employed in the present device using antibody as the capture reagent, then the reaction membrane is impregnated with antibody by way of absorption using a dispenser/printer technique (BioDot, California, USA). This involves applying one or more distinct antibodies to the membrane by spraying them directly onto a reaction membrane. The above technique is most readily achieved using a commercial printing device termed a BIOJET QUANTI 3000, and provides a stream of the immunological protein under a variety of conditions, and at varying stream widths. Using this technique, it is possible to rapidly deposit a series of lines, or other discrete patterns on the reaction membrane, each containing an antibody with different antigenic specificities for binding one or more antigens. Thus, the number of antigens that can be assayed is a function of the number of different antibodies that can be applied in distinct patterns.

**[0077]** Depending on the detection limits the user wishes to impose on the diagnostic assay, the capture reagent can be deposited singly or in various combinations in the reaction zone in a variety of configurations to produce different detection or measurement formats. For example, a panel of two or more different specific binding members selected as the capture reagent for the diagnostic assay may be applied to different regions of the same reaction membrane so that the presence of multiple analytes in a single fluid test sample may be simultaneously analyzed, e.g. for the detection of HIV and HCV. Preferably, the capture reagent is deposited in a discrete test zone having an area substantially smaller than that of the entire surface area of the porous material used in the reaction zone. Various patterns that are convenient for the distribution of the capture reagent may include, but are not limited to, numerals, letters, dots, lines and symbols, or the like, which display the detectable signal upon completion of the assay. It is preferred that the pattern of the discrete test zone be in the form of a single line to enhance the visibility of the test result.

#### 4.3 CAPTURE REAGENT

**[0078]** Since the present apparatus is designed to be used in a method for detecting a target analyte in a fluid test sample, a capture reagent must be provided which will recognize and be capable of specifically binding to the target analyte. One of ordinary skill in the art will appreciate that the term "specific binding" refers to the interaction that will occur between two or more complementary non-identical components to form a complex. Examples of such binding pairs include antigens and antibodies, hormones (and other intracellular messengers) and cell receptors, sugars and lectins. Either member of the specific binding pair can be immobilized to the reaction zone with the other member being the analyte being detected in the test sample. Exemplary, but not exclusive of the present invention, is the specific binding interaction that occurs as a result of antibody-antigen interactions. However, it should be realized that the use of terms such as antigen and antibody are not mutually exclusive since antibodies can act as antigens for other antibodies.

**[0079]** Because of the relative ease with which specific antibodies can now be prepared against antigens, preferred embodiments of the invention may or can use monoclonal antibodies attached to the reaction membrane to detect the presence of their specific antigen in a fluid test sample. The monoclonal antibodies can belong to any of the classes or subclasses of antibodies, including IgA, IgD, IgE, IgG (subclasses 1-4, if human; 1, 2a, 2b, 3, if murine), or IgM. Actively binding fragments of antibodies can also be employed, such as Fab, Fv, F(ab')<sub>2</sub>, or the like. The preparation of monoclonal antibodies is well known in the art which is accomplished by fusing spleen cells from a host sensitized to the antigen with myeloma cells in accordance with known techniques or by transforming the spleen cells with an appropriate trans-

forming vector to immortalize the cells. The cells can be cultured in a selective medium, cloned, and screened to select monoclonal antibodies that bind the designated antigens. Numerous references can be found on the preparation of monoclonal and polyclonal antibodies (e.g. Kohler and Milstein, (1975) Nature (London) 256, 495-497; Kennet, R., (1980) in Monoclonal Antibodies (Kennet et al., Eds. pp. 365-367, Plenum Press, NY).

#### 4.4 CONTROL ZONE

**[0080]** In addition to the capture reagent, a defined area of the exposed reaction zone may also contain a control molecule. In this regard, color development at the test site may be compared with the color of one or more standards controls to determine whether the reagents are stable and the test is performing properly. In general, when testing for the presence of target analyte, the diagnostic device will have a built-in control of an antibody directed to human immunoglobulin G (IgG), IgM, IgE, or IgA. Thus when a fluid test sample is added to the diagnostic device, immunoglobulin will bind to the control region regardless of whether or not target analyte happens to be present in the sample. For example, a suitable control may be established by using Protein A which is disclosed in U.S. Patent No. 5,541,059 (Chu). Other suitable controls are well known in the art.

#### 4.5 BLOCKING THE REACTION ZONE

**[0081]** As noted above, the capture reagent, and the optional use of controls, are typically applied only to defined regions of the exposed surface of the reaction zone. The capture reagent will often be applied to a region within the center of the reaction zone such that the perimeter of the exposed surface of the reaction zone will not have any capture reagent bound thereto. On the other hand, in some situations, it may be appropriate to cover the entire exposed surface of the reaction zone with the capture reagent. If, however, capture reagent is immobilized onto a limited region of the exposed surface of the reaction zone, the porous material or membrane from which the zone is made can be treated with a blocking composition that prevents the target analyte and other components of the sample from non-specifically binding to the reaction zone. For assays where non-specific binding is not problematic, a blocking step will be unnecessary. Also, the use of a good quality paper-backed nitrocellulose may make a blocking step unnecessary in some assays. However, if a blocking step is needed, common blocking solutions comprising bovine serum albumin (BSA) or other proteins which do not interfere with, or cross-react with, reagent materials of the assay can be used. BSA is usually used in amounts from about 1 to 10%.

**[0082]** The blocking treatment typically occurs after the analytical device has already been assembled and the capture reagent is immobilized to the reaction zone. A sufficient amount of blocking composition which will cover the exposed surface of the reaction zone is applied. After the blocking composition has dried, the analytical device is ready for use.

#### 4.6 ABSORBENT ZONE

**[0083]** The sensitivity of reaction-membrane type immunoassays (i.e. the ability to detect very low levels of target substance) can be increased if the sample is concentrated through the reaction zone. With some devices, concentration of the sample through a reaction zone is achieved by having an absorbent material, or pad, beneath the reaction zone that draws the sample, which is added to the surface of the reaction zone, through to the absorbent material below. The absorbent zone can be generated from any material capable of wicking fluid by way of capillary action, such as cotton or paper. Membrane-based immunoassays that utilize various absorbent materials to concentrate sample are exemplified in U.S. Patents Nos. 5,185,127, 5,006,464, 4,818,677, 4,632,901, and 3,888,629.

**[0084]** An absorbent material is situated underneath the lower surface of the reaction zone so as to be in direct fluid communication with the reaction zone. Thus, the upper surface of the absorbent material is immediately adjacent to the lower surface of the reaction zone. Fluid communication contact involving direct physical contact of the absorbent material with the reaction zone may optionally include the separation of a portion of the absorbent material from the reaction zone by an intervening spacer layer which has an opening therein. Accordingly, the spacer layer still permits direct contact between the reaction zone and the absorbent zone thereby enabling the assay reagents to flow uniformly from the upper surface down to the lower surface of the assay apparatus. Although not critical to the performance of the apparatus, the spacer layer also serves to hold the porous membrane of the reaction zone. The spacer layer may be made of any rigid or semi-rigid material that does not bind or interact with assay reagents used in conjunction with the invention. Exemplary of materials for the spacer layer are fiberglass, paper, hydrophilic polypropylene, or cellulose. The thickness of the spacer layer will generally be in the range of about 0.1 mm to 1 mm. In embodiments of the invention where ease of manufacture and reduced costs are desired, the upper surface of the absorbent material is typically placed immediately adjacent the lower surface of the reaction zone.

**[0085]** The selection of material for the absorbent zone is not critical and a variety of fibrous filter materials can be used, including one or more layers of the same or different materials, providing that the material selected is compatible

with the target analyte and the assay reagents. Any conventionally employed absorbent material that is capable of drawing or wicking fluid through a porous membrane, such as for example, by capillary action, can be used in the present invention. The absorbent material should be capable of absorbing a volume of fluid test sample that is equivalent or greater than the total volume capacity of the material itself. Useful known materials include cellulose acetate fibers, polyester, polyolefin or other such materials. The absorbent material provides a means to collect the sample by providing uniform "suction" to deliver the sample from the well, through the reaction zone, and down into the absorbent material. Thus, the absorbent body also acts as a reservoir to hold the sample, and various reagents that are used when the assay is performed. Accordingly, when used in assays where relatively large volumes of fluid are used, the absorbent material should have high absorbent capacity so as to prevent or minimize the possibility of back-flow of sample and reagents from the absorbent body back into the reaction membrane.

**[0086]** As with the reaction zone material, the wicking power of the absorbent material can be an important parameter. Wicking time is defined in terms of the time required for water to travel a defined distance through the absorbent material and is related to the thickness and porosity of the material. Wicking power can vary greatly from one material to the next and therefore, the properties of the analytical device and flow rate of sample and reagents can be modified by varying the absorbent material used.

#### 4.7 BLOOD SEPARATION ZONE

**[0087]** To facilitate the detection of a target analyte in a whole blood sample, an alternate embodiment of the present invention provides a test unit capable of receiving and separating the fluid portion of a whole blood sample from the red blood cells (RBC) featuring a blood separation zone in lateral fluid communication with the reaction zone. The blood separation zone functions to selectively retain cellular components (i.e. red blood cells) contained within the whole blood sample and deliver the remaining components of the RBC-free fluid portion of the blood sample, including any analyte, to the reaction zone for eventual analysis. This particular feature is useful in preventing any interference during visualization of a color reaction for the detection of analyte and avoids the necessity of obtaining a preliminary extraction of serum or plasma in settings where proper equipment to perform such a procedure is unavailable.

**[0088]** Various methods for the separation of blood cells from the fluid portion of blood are described using separation coatings, erythrocyte aggregating and agglutinating agents, materials having asymmetric pore sizes, polymer-containing matrixes, and multilayer systems, to name a few, e.g. U.S. Pat. No. 3,768,978 to Grubb et al., U.S. Pat. No. 3,902,964 to Greenspan, U.S. Pat. No. 4,477,575 to Vogel et al., U.S. Pat. No. 4,594,372 to Zuk, U.S. Pat. No. 4,753,776 to Hillman et al., U.S. Pat. No. 4,816,224 to Vogel et al., U.S. Pat. No. 4,933,092 to Aunet et al., U.S. Pat. No. 5,055,195 to Trasch et al., U.S. Pat. No. 5,064,541 to Jeng et al., U.S. Pat. No. 5,076,925 to Roesink et al., U.S. Pat. No. 5,118,428 to Sand et al., U.S. Pat. No. 5,118,472 to Tanaka et al., U.S. Pat. No. 5,130,258 to Makino et al., U.S. Pat. No. 5,135,719 to Hillman et al., U.S. Pat. No. 5,209,904 to Forney et al., U.S. Pat. No. 5,212,060 to Maddox et al., U.S. Pat. No. 5,240,862 to Koenhen et al., U.S. Pat. No. 5,262,067 to Wilk et al., U.S. Pat. No. 5,306,623 to Kiser et al., U.S. Pat. No. 5,364,533 to Ogura et al., and U.S. Pat. No. 5,397,479 to Kass et al.

**[0089]** In a preferred embodiment, the blood separation zone is an elongate or rectangular strip of porous material having intrinsic physical properties which enable it to preferentially and sufficiently entrap or retain the red blood cells in the sample within the blood separation zone. A first end of the blood separation zone, located a short lateral distance from the reaction zone, defines a region for receiving the whole blood sample during the first step of the assay protocol, and prior to introduction of the target analyte at the reaction zone. A second end of the blood separation zone, in direct fluid communication with the reaction zone, helps to promote the movement of the RBC-free fluid portion of the blood sample from the first end of the blood separation zone to the reaction zone for eventual analysis. The blood separation zone and the reaction zone must contact one another in order to ensure optimal transfer of the sample from one zone to the other. Accordingly, the materials selected for the blood separation zone and the reaction zone may overlap slightly with one another in order to ensure adequate migration of the RBC-free portion of the whole blood sample.

**[0090]** A variety of materials can be used for the blood separation zone such as glass fiber, glass fiber/cellulose mixtures, cellulose, or other proprietary materials, including synthetic materials, e.g., nylon. Preferably, a permeable glass fiber matrix is employed as the blood separation material to facilitate the separation of red blood cells from whole blood. A variety of grades of different thicknesses and absorbencies of glass fiber materials are commercially available to facilitate blood separation and include, for example, GF-24, GF-25, and #33, available from Schleicher & Schuell (Keene, N.H., USA); G143, G144, and G167, available from Ahlstrom (Mount Holly Springs, Pa., USA); GFQA30VA, GF/P 30, GF/DE 30, GF/SE 30, GF/CM30VA, GF/CM 30, F 075-14, F487-09, GF DVA, GFVA 20, and GD-2, available from Whatman (Fairfield, N.J., USA).

**[0091]** Useful glass fiber/cellulose mixture materials include F255-07 90 glass/10 cellulose, F255-09 70 glass/30 cellulose, F255-11 50 glass/50 cellulose, and F255-12 50 glass/50 cellulose, available from Whatman.

**[0092]** Useful cellulose materials include 598, available from Schleicher & Schuell. Miscellaneous or other materials falling outside the above categories can also be used, including HemaSep V and Leukosorb; which article of manufacture

according to the subject invention available from Pall BioSupport (Port Washington, N.Y., USA).

**[0093]** One useful nylon material is Nylon 6.6 Transfer Membrane, which is commercially available under the tradename Biodyne B (Pall Specialty Materials, Port Washington, N.Y.). In addition, the material known as "PlasmaSep", available from Whatman, can be used.

**[0094]** Although the shape and dimensions of the blood separation zone are not critical, preferably it has a narrow rectangular form and dimensions suitable for allowing efficient removal of a substantial amount of red blood cells from the whole blood sample during migration of the fluid portion of the sample from the first end to the second end of the zone. Thus, in effect, while a narrow rectangular shape is preferred to channel fluid portion of the blood sample to the reaction zone, the dimensions may vary depending on the intrinsic properties (e.g. absorbency, migration rate, etc.) of the material selected for the blood separation zone. In a preferred embodiment, the blood separation zone is made using the glass fiber material F487-09, available from Whatman, having dimensions between approximately 4 to 7 mm in width, between approximately 10 and 15 mm in length, and between approximately 0.2 mm and 1.0 mm in thickness. More preferably, the blood separation material is about 7 mm in width by about 10 mm in length and about 0.5 mm in thickness. These dimensions are optimized to be capable of receiving and separating the total volume of a whole blood sample, e.g. two drops of blood.

**[0095]** The blood separation material preferably has a rigid or semi-rigid carrier or backing affixed to its lower surface to provide support and reduce seepage of the RBC-free fluid portion of the whole blood sample while it migrates towards the reaction zone. Suitable materials for use as a carrier or backing include, for example, hydrophobic materials such as polycarbonate, polyethylene, Mylar, polypropylene, vinyl, cellophane and polystyrene, etc. as well as water-proofed or fluid-resistant cardboard or similar materials. The carrier or backing may be affixed either directly or indirectly to the blood separation material by means of a fluid-resistant adhesive.

**[0096]** Suitable adhesives are well-known in the art. The carrier may be of any shape and of almost any size which may conveniently be handled. However, the carrier is preferably similar in shape and size to the blood separation material. Thus, the carrier is preferably formed as an elongate or rectangular strip having a length and width similar to or the same as the blood separation material.

## 5.0 POST-FILTER UNIT

**[0097]** As discussed above, the diagnostic device of the present invention comprises, as a second member, a post-filter unit comprising a label zone permeated with a dried indicator reagent.

**[0098]** The selection of the material for the label zone is not critical and can be any suitably absorbent, porous or capillary possessing material through which the multifunctional buffer and resolubilized indicator reagent may be transported by wicking action. The criteria of selection is that the material allow for the resolubilization and mixing of the dried indicator reagent upon addition of the multifunction buffer, as well as initiate the transfer of the buffer and freshly dissolved indicator reagent to the reaction zone of the test unit.

**[0099]** Natural, synthetic, or naturally occurring materials that are synthetically modified, can be used as a filter medium including, but not limited to cellulose materials such as paper, cellulose, and cellulose derivatives such as cellulose acetate and nitrocellulose, fiberglass, cloth, films of polyvinyl chloride, and the like. Although a preferred filter medium is nitrocellulose, the material should be chosen for its ability to release the indicator reagent upon reconstituting with the multifunctional buffer. Moreover, the fluid flow through the filter medium should be laminar as opposed to turbulent flow characteristics which adequately allows for initial mixing of the buffer with the indicator reagent.

## 5.1 INDICATOR REAGENT

**[0100]** The use of indicator reagents to detect the presence of a target analyte in a test sample is well known in the art. Depending on the type of diagnostic assay employed, the label employed in the indicator reagent is conjugated to a specific binding member or general marker protein (e.g. Protein A, Protein G, anti-IgG) that will directly, or indirectly, bind to the target analyte. Formation of an indicator reagent between a specific binding member and a label may be any of the conventional types including metal complex labels, radioactive labels, enzyme labels, fluorescent labels, radioactive labels, chemiluminescent labels, and the like.

**[0101]** An important consideration in the design of a rapid diagnostic device is that the label chosen in the generation of the indicator reagent should give rise to a readily detectable signal, e.g. a strongly-coloured area easily detectable by the eye. Thus, an important preferred embodiment of the invention is the use of "direct labels", attached to one of the specific binding members. Direct labels are well known in the art and highly advantageous for their use in rapid diagnostic systems. Examples of direct labels include, but are not limited to metal sols, non-metal sols, dye sols, latex particles, carbon sol, and liposome contained colored bodies. Some of their advantages are that they can be used to produce a visually detectable signal without the need to add further reagents, are readily visible to the naked eye without the aid of instrumentation, and can be readily used in a diagnostic device since they are stable when stored in the dry

state. With respect to the latter, their stability and immediate release on contact with a buffer reagent can be accomplished by the use of soluble glazes. In view of the above comments, indirect labels, such as enzymes, e.g. alkaline phosphatase and horseradish peroxidase, are less preferred because they usually require the addition of one or more substrates before a visible signal can be detected.

5 **[0102]** Non-metal sols, such as those of selenium, tellurium and sulfur may be produced according to the methods described in U.S. Patent No. 4,954,452 (Yost, et al). Dye sol particles may be produced as described by Gribnau et al., in U.S. Patent No. 4,373,932 and May et al., WO 88/08534, dyed latex as described by May, supra, Snyder, EP-A 0 280 559 and 0 281 327, and dyes encapsulated in liposomes by Campbell et al., U.S. Patent No. 4,703,017. The use of polymerized dye materials in colloidal form for specific binding assays is also described by in U.S. Patent No. 4,166,105  
10 by Hirschreid which relates to labeled specific binding reagents reactive with specific antigens prepared by linking fluorescent dye molecules to analyte specific antibodies through polymers comprising reactive functional groups. Also of interest is U.S. Patent No. 4,313,734 by Leuvering relating to metal sols; Leuvering, et al., "Sol Particle Immunoassay (SPIA)", Abstract, Journal of Immunoassay, 1(1), pp. 77-91 (1980); Leuvering Dissertation (1984), Sol Particle Immunoassay (SPIA): The Use of Antibody Coated Particles as Labeled Antibodies in Various Types of Immunoassay; Uda et al., Anal. Biochem. 218 (1994), 259-264, DE-OS 41 32 133, page 3, lines 16-18, for applications as markers and Tang et al., Nature 356 (1992), 152-154; Eisenbraun et al., DNA and Cell Biology 12 (1993), 791-797. Furthermore it is also known that non-metallic colloidal particles such as carbon particles (van Amerongen, Anabiotic '92 (1993), 193-199) can also be used. Moeremans, et al., EPO Application No. 158,746 discloses the use of colloidal metal particles as labels in sandwich blot overlay assays. At present colloidal gold particles are used most frequently.

20 **[0103]** Among the direct labels, metallic sols are preferred, more preferably gold sol particles such as those described by Leuvering in U.S. Patent No. 4,313,734. Leuvering discloses the use of metal sol particles as labels for *in vitro* determination of immunological components in an aqueous test medium. Specifically disclosed are immunoassay test kits for the detection of antigens or antibodies employing one or more labeled components obtained by coupling the component to particles of an aqueous sol dispersion of a metal, metal compound or polymer nuclei coated with a metal  
25 or metal compound having a particle size of at least 5 nm.

**[0104]** The metal sol particles to be used in accordance with the present invention may be prepared by methods which are well known in the prior art. For instance, the preparation of gold sol particles is disclosed in an article by G. Frens, Nature, 241, 20-22 (1973). Additionally, the metal sol particles may be metal or metal compounds or polymer nuclei coated with metals or metal compounds, all as described in the Leuvering patent mentioned above. In this regard, the metal sol particles may be of platinum, gold, silver or copper or any number of metal compounds which exhibit characteristic colors.  
30

## 5.2 COLLOIDAL GOLD PARTICLES

35 **[0105]** Colloidal particles which are suitable as labels according to the invention include those which may be conjugated to specific binding members or general marker proteins without interfering with the activity of such reagents or with other reagents or analytes.

**[0106]** Colloidal metal particles are particularly suitable as labels according to the present invention and include those particles which are comprised of metals or metal compounds selected from the group consisting of the metals platinum, gold, silver and copper and the metal compounds, silver iodide, silver bromide, copper hydroxide, iron oxide, iron hydroxide or hydrous oxide, aluminum hydroxide, or hydrous oxide, chromium hydroxide or hydrous hydroxide, lead sulfide, mercury sulphide, barium sulphate and titanium dioxide. Preferred colloidal metal particles include those made up of gold.  
40

**[0107]** Colloidal gold particle markers are simple to use in comparison to other conventional markers. For example, they do not require instruments necessary for detection of other markers such as radioactive isotopes and unlike enzymes, they do not require the additional step of adding a substrate.  
45

**[0108]** Colloidal gold particles may be produced according to methods generally known in the art. Of interest to the present invention are those references relating to the use of dispersions of colloidal particles in immunological assay procedures. Specifically, Frens, Nature, 241, 20-23 (1973) discloses methods for the production of gold sol particles of varying sizes through the reduction of gold chloride with aqueous sodium citrate. The colors of the visually detectable signal from the metal particle label is dependent upon the identity and particle size of the metal particle which may be controlled by varying the concentration of the reactants. For example, colloidal gold particles produce colors ranging from orange to red to violet depending upon the particle size of the sol.  
50

**[0109]** The colloidal gold reagent is selected for its unusual properties including the ability to intensify color to the naked eye when concentrated on solid surfaces, to minimally bind nonspecifically to solid surfaces, to be prepared in relatively uniform particle sizes, and to be easily lyophilized and resolubilized. Colloidal gold particles can be prepared in a number of ways through the reduction of tetrachloroauric acid which produces a variety of particle sizes ranging from 5 nm to 100 nm. The preferred particle sizes are from 15 to 20 nm. The colloidal gold particles can have an intermediary binder absorbed to its surface prior to the addition of the binding substance, but direct attachment is  
55

satisfactory. Absorbing the selected binding substance is achieved by carefully controlling concentrations, ionic strength and pH of the reaction mixture. The choice of method of producing the colloidal gold raw material or the method of attaching the binding substance are well known to those skilled. In the art. After the labeling with colloidal gold is complete, the reagent is differentially centrifuged or filtered to control particle size. Particle sizing by gel filtration methods are also well known. The colloidal gold labeled reagent can be used as a colloidal suspension or as a lyophilized reagent with or without the presence of the aforesaid solid phase particles as an indicator reagent.

**[0110]** The resulting coated and stabilized colloidal metal particles may then be conjugated with various proteins. Any protein which may be subjected to freeze-drying or other forms of drying such as by incubator, air-drying and spray drying may be applied in the present invention. Exemplary of protein for use in the present invention includes, but is not limited to, polyclonal or monoclonal antibodies, antigen, lectin, protein A, protein G, bacterial, and the like. In those instance where an immunodiagnostic assay is a sandwich format employing an antibody as the capture reagent for the detection of an antigen as the target analyte, the binding member of the indicator reagent is usually a second antibody having specificity for antigen bound to the first antibody, but which binds to the antigen at a site apart from where the first antibody is bound. On the other hand, the binding member of the indicator reagent is usually an analogue, or other authentic example, of the antigen which can bind to the capture reagent at the same site where the target analyte binds in the case of a competitive format.

**[0111]** For details and engineering principles involved in the synthesis of colored particle conjugates see Horisberger, Evaluation of Colloidal Gold as a Cytochromic Marker for Transmission and Scanning Electron Microscopy, Biol. Cellulaire, 36, 253-258 (1979); Leuving et al, Sol Particle Immunoassay, J. Immunoassay 1 (1), 77-91 (1980), and Frens, Controlled Nucleation for the Regulation of the Particle Size in Monodisperse Gold Suspensions, Nature, Physical Science, 241, pp. 20-22 (1973). Surek, et al., Biochem, and Biophys. Res. Comm., 121, 284-289 (1984) discloses the use of protein A labeled colloidal gold particles for the detection of specific antigens immobilized on nitrocellulose membranes.

### 5.3 DRYING PROCESS - SUGAR/GLAZING TREATMENT

**[0112]** According to one important aspect of the invention, the label zone of the post-filter unit essentially comprises the indicator reagent impregnated and dried within the thickness of a porous material which can then be resolubilized by addition of the multifunctional buffer. Thus, by incorporating one of the assay reagents within the device of the present invention, makes possible the reduction in the number of steps required in the assay protocol by eliminating the addition and/or prior mixing of an indicator reagent.

**[0113]** In order to assist the free mobility of the indicator reagent when the label zone of the post-filter unit is moistened with the multifunctional buffer, the post-filter unit is pre-treated with a glazing material in the region to which the indicator reagent is applied. Glazing can be achieved, for example, by depositing an aqueous sugar or cellulose solution, e.g. of sucrose or lactose, on the relevant region of the post-filter unit, while avoiding the remainder of the filter unit, and air drying. The indicator reagent can then be applied to the glazed portion.

**[0114]** The glazing process involving the use of one or more sugars (e.g. glucose, lactose, trehalose and sucrose) is highly advantageous when employing the dried indicator reagent of the present invention in that the sugar serves (1) as a protein stabilizer, (2) to improve the long term stability of the dried indicator reagent, and (3) acts as a rapid releasing agent. According to a preferred embodiment of the invention, sucrose was determined to be the best sugar compared to others in the performance of the assay because of (1) its solubility, (2) short period of drying, (3) the overall sensitivity of the assay result, (4) its use as a preservative, and (5) it is economical to use.

### 6.0 BUFFER REAGENT

**[0115]** Conventional diagnostic assays usually necessitate the use of two or more fluid reagents in order to perform various steps of the assay protocol including, for example, resolubilizing a dried indicator reagent, diluting a fluid test sample, blocking the membrane surface where the assay reaction takes place, facilitating transport of critical reagents and/or washing unbound reactants from the reaction zone. Since each of these steps involves the mixing or preparation of different reactants, different formulations of liquid reagents are likely required due to differing pH, ionic strength, additives, type and strength of buffer, temperature, etc. For example, the resolubilization process usually requires the use of a physiological buffer such as buffered saline or double distilled water, the blocking process uses a liquid reagent formulated with any number of animal serum albumins, gelatin or non-fat milk, and the washing and/or diluting process involves the use of a phosphate buffered saline containing different amounts of surfactant or detergent at neutral pH to remove any non-specific binding reactants. Moreover, in order to ensure that the user performs each step of the assay correctly using the appropriate liquid reagent, the reagents themselves must be clearly labeled and readily distinguished from one another, so as to avoid any possible confusion and user error.

**[0116]** An important aspect of the present invention overcomes the various problems described above associated

with the use of several assay reagents by providing a multifunctional buffer for single utilization in the 2-step assay procedure. The multifunctional buffer is formulated to serve as a combination resolubilization reagent of the dried indicator reagent, transport facilitating reagent of resolubilized indicator reagent from the label zone of the post-filter unit to reaction zone of the test unit, and washing reagent to remove unbound reactants from the reaction zone. In order to simplify the number of reagents and steps required to perform the assay, the multifunctional buffer has been specially formulated to be used in conjunction with the dried indicator reagent. It is therefore, particularly advantageous to utilize the multifunctional buffer and dried indicator reagent as a combined system since the multifunctional buffer allows optimal sensitivity and higher specificity to be achieved during performance of the assay, while additionally avoiding aggregation and inactivation of the dried indicator reagent in solution.

**[0117]** As will be apparent to one skilled in the art, the composition of the multifunctional buffer may vary in accordance with the requirements of the specific assay such as the particular capture reagent and indicator reagent employed to determine the presence of a target analyte in a test sample, as well as the nature of the analyte itself. In general, the multifunctional buffer will contain compounds that have primary functions in the assay with respect to their properties in serving as a diluting, washing and resolubilizing agent. However, since the reaction zone of the present invention is already pretreated with conventional blocking agents following immobilization of the capture reagent, the buffer formulation eliminates the need to include a non-specific blocking agent. A method of using the multifunctional buffer as provided by the present invention essentially involves dropwise addition of the buffer to the post-filter unit in the final step of the 2-step assay to resolubilize the dried indicator reagent. A kit containing the multifunctional buffer as a component is also provided.

**[0118]** Accordingly, the present invention provides an improved buffer which serves as a multifunctional reagent without sacrificing either the sensitivity or specificity of the assay comprising: (1) a biological buffer to maintain the pH between about 7.0 to 10.0; (2) at least one surfactant to reduce non-specific binding of assay reagents while simultaneously avoiding inhibition of a specific binding interaction; (3) a high molecular weight polymer as a dispersing and suspending reagent having a molecular weight in a range of from about  $2 \times 10^2$  to about  $2 \times 10^6$  D; (4) a pH stabilizer to maintain the pH of the multifunctional buffer between about pH 7.0 to 10.0; (5) an ionic salt to reduce the non-specific binding of antibodies; (6) at least one preservative to reduce bacterial and microbial growth; and (7) a calcium chelator to prevent a whole blood test sample from clotting; wherein the biological buffer, surfactant, high molecular weight polymer, pH stabilizer, ionic salt, preservative and calcium chelator are all at effective concentrations.

**[0119]** The improved multifunctional buffer composition of the invention can include a conventional buffer such as a phosphate buffer, MES (morpholino-ethanesulfonic acid) buffers, BIS-TRIS buffers, citrate buffers, TRIS-HCl buffers and borate buffers, at an effective concentration which can range from about 5 to 100 mM, preferably in the range of from about 5 to 30 mM, and most preferably about 5 mM. The preferred buffer is a phosphate buffer, preferably comprising sodium phosphate, monobasic and sodium phosphate, dibasic, at concentrations such that the effective pH of the buffer is achieved. The pH of the buffer of the present invention can range from a pH of about 7.0 to a pH of about 10.0.

**[0120]** The biological detergents (surfactants) used in the present invention can include non-ionic surfactants, anionic surfactants, zwitterionic surfactants and cationic surfactants. The Non-ionic detergents useful in the invention include polyoxyethylene sorbitan monolaurate (Tween<sup>®</sup>20), polyoxyethylene sorbitan monooleate (Tween<sup>®</sup>80), polyoxyethylene ethers (Triton<sup>®</sup>, Brij<sup>®</sup>) and octylphenel ethylene oxide (Nonidet<sup>®</sup>). Preferably, non-ionic detergents are used. The most preferred non-ionic detergent is Triton<sup>®</sup>X-100. Non-ionic detergent acts as a dispersing agent to reduce the non-specific binding of antibodies/antigens to the reaction membrane which may occur as a result of target analyte adhering to the solid phase due to a non-specific reaction, thereby increasing the background of the assay. Although biological detergents reduce the event of such binding caused by nonpolar or hydrophobic interactions, non-ionic detergents are preferred for their ability to reduce non-specific binding while avoiding the inhibition of specific binding. Effective concentrations of the biological detergent range from about 0.01 to about 0.50% (w/v), preferably range from about 0.05 to about 0.10% (w/v), and most preferably the concentration is about 0.07% (w/v).

**[0121]** Ionic salts provide a source of cations and anions which helps to reduce the frequency of non-specific binding of antibodies, other than analyte antibodies, caused by ionic interactions. Salts that are useful in the formulation of the multifunctional buffer reagent are NaCl and KCl, most preferably NaCl. Effective concentrations of sodium chloride range from about 0 to about 300 mM, preferably range from about 50 to about 200 mM.

**[0122]** The high molecular weight polymer functions as a dispersing and suspending reagent while additionally preserving the binding capacity of antibodies. Examples of high molecular weight polymers which may be used in the buffer are polyvinylpyrrolidone (PVP), dextrans, polyethylene glycol (PEG), and polyvinyl alcohol, to name a few. The preferred high molecular weight polymer for use in generating the buffer is PVP; most preferably PVP-40, at an effective concentration. Effective concentrations of PVP in the buffer of the invention range from about 0.1 to about 3.0% (w/v), preferably range from about 0.5 to about 2.5%, and most preferably the concentration is about 1.4%. The high molecular weight polymer selected for use in the invention can include PVP having molecular weights of from about 10 kD to about 1500 kD, dextrans with molecular weights ranging from about 10 kD to about 2000 kD, polyethylene glycols (PEG) having molecular weights in the range of from about 200 D to about 10,000 D, and polyvinyl alcohol having a molecular weight

of about 10,000 D to about 100,000 D. Other examples of high molecular weight polymer also include polybrene (hexadimethrine bromide), methylcellulose, gum acacia, protamine sulfate, merquat, celquat and magnafloc, provided at an effective concentration.

5 [0123] It is preferable to include a calcium chelating agent, such as ethylenediaminetetraacetic acid (EDTA), or salts thereof, in the multifunctional buffer composition, to reduce or prevent the possible clotting of a finger-pricked whole blood test sample through the blood coagulation process. Calcium chelating agents, other than EDTA, such as citrate, citrate salts, and ethylenebis(oxyethylenenitrilo)tetraacetic acid may similarly be used. Bopolymers (i.e. non-chelating agents) such as heparin and sulfated chitosan, which will inactivate specific clotting factors within the blood coagulation process can also be used. EDTA is included in the buffer composition at an effective concentration ranging from about 10 5 mM to 100 mM, more preferably at about 10 mM to about 50 mM, and most preferably about 20 mM.

[0124] The pH stabilizer functions to maintain the pH of the buffer within a range of about pH 7.0 to 10.0. An exemplary pH stabilizer includes trizma hydrochloride, although other known stabilizers may also be useful in this composition. The effective concentration of trizma hydrochloride is preferably from about 20 to 30 mM.

## 15 7.0 HOUSING

[0125] In general, the assay composite comprising the test unit and the post-filter unit can be housed in a suitable container to form an analytical apparatus. Preferably, the container should safeguard the solid phase materials and dried indicator reagent from contamination and to provide ease and convenience in handling of the assay device. Moreover, 20 the container should be teak-proof thereby ensuring containment of fluids and their safe disposal after use.

[0126] The apparatus 13 illustrated in Figures 4 and 5 provides a representative example of the type of container that can be included in a test kit which incorporates the flow-through device of the present invention. The apparatus 13 comprises two detachable components, namely the test cartridge 14 and the post-filter cap 15, which are vertically and spatially distinct to one another when placed in transient fluid communication during the assay protocol. The housing is 25 capable of maintaining the layers of the test unit under compression so as to provide continuous and uniform contact therebetween and so that liquid will flow uniformly through the apparatus 13. The housing will be made of an inert material conveniently being any of a variety of disposable commercial plastics which may be molded, for example, polyethylene, polypropylene, styrene, ABS, polyacrylate, polystyrene, or the like.

[0127] Although the two components of the apparatus 13 have the particular configuration and dimensions depicted therein, any other appropriate design or modifications may be employed so long as the components are still capable of 30 being transiently connected to one another in a single movement during the assay protocol. The means of connecting the two components is not critical so long as so that they are properly aligned to effect optimal fluid communication with one another upon interconnection of the post-filter cap 15 with the test cartridge 14. For example, according to the design shown in Figures 4 and 5, the post-filter cap 15 may be frictionally fitted to the reservoir 22 of the test cartridge 14. 35 Although not illustrated therein, the post-filter cap 15 may be optionally hinged to the test cartridge 14 to avoid possible lost or misplacement of the two components. On the other hand, the two components could be slidably and reversibly disposed to one another in a single horizontal movement providing the post-filter unit is engaged in proper alignment above the test unit. In this particular instance, proper alignment of the two components may be achieved through the use of guide rails, or projections designed to align with recesses formed in the device or housing, additionally acting as 40 an interconnection means for the two components.

[0128] The precise dimensions of the housing are not essential to the function of the assay apparatus, but in general, the apparatus will be of a size convenient for transport, manipulation, and assembly. The housing will generally have a length in the range of about 2 to 5 cm, preferably 3.5 cm. The width will be in the range of about 1 to 3 cm, preferably 2.5 cm. The height of the housing will be in the range of about 0.5 to 5 cm, preferably 1.3 cm.

45 [0129] Figure 4 provides an exploded view of the apparatus 13 comprising the test unit 2 and the post-filter unit 3, while Figure 5 provides an enlarged vertical cross-sectional view of the fully assembled apparatus 13. The apparatus 13 of the present invention comprises two separate components in its fully assembled form, namely the test cartridge 14, which contains the test unit 2, and the post-filter cap 15, which contains the post-filter unit 3. The test cartridge 14 and the post-filter cap 15 are designed to be connected to one another briefly during the assay protocol. The apparatus 50 13 is intended to be simple in design and construction, and can be manufactured using readily available materials.

[0130] As shown in Figure 4, the test cartridge 14 of the apparatus 13 houses the test unit 2 which comprises both a top member 16 and a bottom member 17. The outer perimeter of the bottom member 17 has a slightly indented ridge 18 which allows it to be fitted and interconnected with the rim 19 bordering the top member 16 to form the assembled test cartridge 14. It will be appreciated by those skilled in the art that while the test cartridge 14 shown in Figures 4 and 5 has a rectangular shape, it is not limited to this particular configuration so long as it can be adapted to hold the absorbent material, or pad 20, in direct contact with the reaction membrane 21. 55

[0131] Contained within the top member 16 of the test cartridge 14 is a reservoir 22 which is in direct alignment with the exposed reaction membrane 21 of the test unit 2. The reservoir 22 (a) provides access to the reaction zone for

introducing the fluid test sample, (b) provides operable attachment of the post-filter cap **15** for introduction of the multi-functional buffer reagent, and (c) permits viewing of the test result on the reaction membrane **21** following removal of the post-filter cap **15**, i.e. detect the color, or fluorescence, or other signal, in the indicator zone(s). As depicted in the drawing, the upper surface surrounding the reservoir **22** is slightly curved and extended downwards so as to form a cup-like receptacle terminating at a portion of the reaction membrane **21**. In this way, the amount of test sample introduced into the reservoir **22** cannot bypass any components of the apparatus **13**. The configuration of the inner wall **23** and the dimensions of the reservoir **22** are selected so that the reservoir **22** can connect to and be in operable association with the post-filter cap **15** during the assay protocol. Preferably, both the reservoir **22** and the post-filter cap **15** have a funnel shape configuration. Thus, when the reservoir **22** and the post-filter cap **15** are in the operating position and the multi-functional buffer is applied to the filter cap **15**, this configuration will permit a suitable amount of the buffer to contact and pass through a small amount of surface area of the reaction membrane **21**. Thus, by selectively matching the size of reservoir **22** with the post-filter cap **15**, the operation of the apparatus **13** can be simplified so that, for example, the multifunctional buffer **12** can be delivered to the reservoir **22** in a single step of the assay procedure.

**[0132]** According to the embodiment shown in Figures 4 and 5, the post-filter cap **15** is detachably affixed to the reservoir **22** of the test cartridge **14** by means of a friction fit between the inner wall **23** of the reservoir **22** and the external wall **33'** of the filter cap **15**. Such other means for detachably affixing the post-filter cap **15** to the test cartridge **14** can be used. In addition, the height of the external wall **33'** of the post-filter cap **15** is slightly less than the height of the inner wall **23** of the reservoir **22** so that when the filter cap **15** is affixed to the reservoir **22**, the base **24** of the filter cap **15** terminates immediately above, but not touching, the reaction membrane **21**. The dimensions of both the reservoir **22** and the post-filter cap **15** can be varied without affecting the performance of the apparatus **13**, although the following approximate dimensions have been determined as satisfactory: reservoir **22** - 1.5 cm top and bottom diameters and 0.6 cm deep; post-filter cap **15** - 0.9 cm bottom diameter, 1.1 cm top diameter, and 0.5 cm deep.

**[0133]** As described above, the test unit of the present invention comprises a reaction membrane **21** and an absorbent pad **20**, whereby the lower surface of the reaction membrane **21** is supported by the upper surface of the absorbent pad **20**. The reaction membrane **21**, which contains capture reagent capable of binding target analyte, essentially defines the reaction zone in which various specific binding reactions take place during the assay. As previously described, the reaction membrane **21** can be fabricated from a number of biologically inert, porous materials.

**[0134]** Positioned directly underneath the lower surface of the reaction membrane **21**, and in fluid communication therewith, is an absorbent pad **20** defining the absorbent zone. In embodiments of the invention where ease of manufacture and reduced costs are desired, the entire upper surface of the absorbent pad **20** is typically immediately adjacent the lower surface of the reaction membrane **21**. The test unit may optionally include a separating means between the reaction membrane **21** and the absorbent pad **20** which will generally be incapable of binding the target analyte of interest. According to the embodiment shown in Figure 4, the separating means in the form of a spacer layer **25** isolates a portion of the reaction membrane **21** from the absorbent pad **20**. Although not critical to the performance of the apparatus **13**, the spacer layer **25** serves to secure the reaction membrane **21** in place and permit assay reagents to flow uniformly from the upper surface down to the lower surface of the assay apparatus **13**.

**[0135]** The spacer layer **25** has an opening **26** defined by a rim **27** which has perimeter dimensions and a shape similar to the reaction membrane **21** thereby enabling the upper and lower surfaces of the reaction membrane **21** to be accessible when the membrane **21** and the spacer layer **25** are sealed together to form a press-fit piece. Referring to Figure 4, which depicts one embodiment of the apparatus **13**, a portion of the reaction membrane's **21** upper surface is fully exposed so that when the diagnostic assay is performed, the fluid test sample and the assay reagents can be added directly to the reaction membrane **21**. The reaction membrane **21** is sized to completely cover the opening **26**. Preferably the reaction membrane **21** will be the same shape as the opening **26**, but sized slightly larger than the opening **26** so that it can be sealed to the lower surface of the spacer layer **25** at the periphery of the opening **26**. However, the shape of the reaction membrane **21** and the shape of the opening **26** can differ and are not limited to the configuration shown in Figure 4. Thus, in combination, the rim **27** surrounding the opening **26** and the exposed upper surface of the reaction membrane **21** essentially define a test region. Moreover, after the test cartridge **14** of the apparatus **13** is assembled, the absorbent pad **20** is still capable of contacting the lower surface of reaction membrane **21** located directly beneath the reaction membrane **21**. The dimensions of the spacer layer **25** and the absorbent pad **20** are chosen to fit cooperatively within the base of the test cartridge **14**, thereby ensuring that the absorbent pad **20** is in proper alignment and fluid communication with the lower surface of reaction membrane **21**. Generally, the surface area of the upper surface of the absorbent pad **20** will usually be greater than that of the reaction membrane **21**, but similar to that of the spacer layer **25**.

**[0136]** The absorbent pad **20** is selected to have a capillary pore size so as to induce flow of the fluid test sample through the reaction membrane **21** without the use of external means. Thus, conveniently, the absorbent pad **20** serves to both promote and direct the flow of reagents through the reaction membrane **21**. The absorbent pad **20** is of sufficient size and composition so that it is capable of absorbing excess sample, indicator reagent and buffer. The material from which the absorbent pad **20** is fabricated may be any permeable wettable material that is substantially inert to the assay reagents employed in the performance of an assay. The absorbent pad **20** will have essentially the same perimeter

dimensions and shape as the spacer layer **25** which holds the reaction membrane **21**. The precise thickness of the absorbent pad **20** is not essential to the function of the present invention, generally ranging from about 2 to 10 mm.

**[0137]** The second component of the apparatus is the funnel-shaped post-filter cap **15** which readily accommodates a suitable amount of the multifunctional buffer needed to perform the assay in a single application. The post-filter cap **15** comprises the post-filter unit **3** and inner **28** and outer **29** sleeves being open-ended at both the top and bottom. The bottom opening **30,30'** of sleeves **28** and **29** is sized to achieve the flow rate desired for the assay in question. The opening of the sleeves can conveniently have a diameter in the range of 12.6 to 15.2 mm. Preferably the opening **30,30'** diameter is 9.5 mm.

**[0138]** In the assembled form, the post-filter cap **15** comprises a funnel **31** having at its top outwardly extending flanges **32, 32'** and depending sidewalls **33,33'**. The depending sidewalls **33** of the outer sleeve **29** terminate at base **24**. The opening **30'** at the base **24** allows a stream of fluid traveling through the funnel **31** to flow into the test cartridge **14**. The post-filter unit **3** of the present invention is securely held in the base **24** of post-filter cap **15** by the inner **28** and outer sleeves **29** of the post-filter cap **15**. An inner collar **34**, integrally formed at the base **24** of the outer sleeve **29**, is capable of supporting the post-filter unit **3** so that when the inner sleeve **28** is frictionally fitted inside the outer sleeve **29**, the post-filter unit **3** will be held permanently in place.

**[0139]** The post-filter unit **3** comprises a filter medium impregnated with dried indicator reagent which defines the label zone. The dried indicator reagent is resolubilized and transported by the multifunctional buffer to the reaction membrane **21** following addition of the buffer to the post-filter cap **15**. The selection of the filter medium for the post-filter unit **3** is not critical to the invention and can be any suitably absorbent, porous or capillary possessing material through which the multifunctional buffer and resolubilized indicator reagent may be transported by wicking action. The criteria of selection is that the material allow for the resolubilization and mixing of the dried indicator reagent upon addition of the multifunctional buffer, as well as initiate the transfer of the buffer and freshly dissolved indicator reagent to the reaction membrane **21** of the test unit **2**.

**[0140]** For convenience of manipulation in using the apparatus **13**, a handle **35** is secured to the extending flange **32** of the post-filter cap **15** so that when the filter cap **15** is affixed to the reservoir **22**, it extends slightly beyond the boundary of the reservoir **22** for ease of removal of the post-filter cap **15** from the test cartridge **14**.

**[0141]** A representative example of a modified version of the test cartridge of the invention incorporating a blood separation zone in lateral fluid communication with the reaction zone for the detection of analyte in a whole blood sample is illustrated in Figures 7A and 7B.

**[0142]** As shown in Figure 7A, the test cartridge is provided with a top member **16** constructed and adapted to fit snugly with a bottom member **17**. In this particular embodiment, the top member **16** of the test cartridge defines a first opening or internal recess therethrough in the form of a reservoir **22**. The reservoir **22** serves to (a) provide operable attachment of the post-filter cap for introduction of the multifunctional buffer reagent, and (b) permit viewing of the test result on the membrane following removal of the post-filter cap, i.e. detect the color or fluorescence, or other signal, in the indicator zone(s). Thus, the configuration and dimensions of the reservoir **22** are selected on the basis that it can be operably connected to the post-filter cap to enable transient fluid communication between the label zone of the post-filter unit and the reaction zone of the test unit.

**[0143]** Spaced a short lateral distance from the reservoir **22**, the top member defines a second opening therethrough in the form of a reservoir **104** which may, as shown, have beveled sides, or may be in any shape or size or configuration of convenience which will sufficiently direct and provide access to the first end of the blood separation zone upon application of a whole blood sample. After introducing a whole blood sample to the reservoir **104** and allowing for a short incubation time to enable sufficient separation and migration of the RBC-free fluid along the blood separation zone to the reaction zone, the post-filter cap is operably attached to the reservoir **22** to enable completion of the 2-step assay protocol so that a final determination for the presence of target analyte can be made.

**[0144]** As shown in Figure 7B, the bottom member **17** of the test cartridge provides a first base structure **105** having a plurality of supporting walls which serve as a solid enclosure for the absorbent pad and thus, is configured to receive and hold the absorbent pad securely in place. Additionally provided is a second base structure **106** having a plurality of protruding columns of the same height which serves as an elevated support for the blood separation zone. The position of the second base structure **106** in relation to the first base structure **105**, as well as its configuration, are such that when the blood separation zone is positioned within the bottom member **17**, the blood separation zone is contiguous with and in direct planar horizontal alignment with the reaction zone. Although the base structure **106** depicted therein has a plurality of supporting columns and/or walls which serve to support the perimeter and centre of the blood separation zone, any number of configurations or strategies are possible as long as the blood separation zone is securely and correctly positioned in relation to the reaction zone when the test cartridge is fully assembled.

## 8.0 METHODOLOGY

**[0145]** In operation, the apparatus of the present invention broadly is used to determine the presence of target analyte

in a fluid test sample, employing at least one capture reagent to form a detectible product on the reaction membrane as an indication that the analyte is present in the sample. The assay device and apparatus is particularly applicable to an immunoassay wherein the sample component is one component of an immunological pair including antigens, antibodies, or haptens. The immunological pair includes two components which immunologically bind to each other. Specific immunological pairs include antigens and their antibodies (monoclonal antibodies or affinity purified polyclonal antibodies, including fragments thereof), or biologically functional haptens and their antibodies. While monoclonal antibodies have known advantages over polyclonal antibodies, either type of immunological reagents can be used in accordance with the present invention. Thus, for simplicity of representation, the assay and device of the present invention will be described with respect to immunoassays using the antigen-antibody immunological pair. The fluid test sample is biologically derived, e.g. urine or serum, and the capture reagent and indicator reagent can comprise an antibody or antigen, depending on the analyte of interest and whether the sandwich or competitive technique is employed.

**[0146]** The immunoassays that use the analytical apparatus of the present invention can be very simple and fast, and can be qualitative or semi-quantitative. The analytical apparatus can be adapted for use in many different types of assays. For example, the target analyte can be a hormone, antibody, antigen, protein, etc. A non-inclusive list of possible target analytes is provided in U.S. Patent No. 5,006,464 (Chu, et al.). The immunoassay format, will depend on the target analyte sought to be detected. Again, these are already known in the art. It will be appreciated by those skilled in the art that in order to maximize sensitivity for the detection of a particular target analyte, various components of the analytical device and/or assay procedure can be modified, such as the porosity, thickness and type of material used for the reaction membrane. The analytical device used in the assays essentially requires no sample manipulation and the entire assay protocol can be performed in less than 1 minute.

**[0147]** The assay device of the invention is contemplated to be used in any flow-through immunoassay procedure including competitive and preferably sandwich assays. As mentioned above, the reaction membrane is coated with a capture reagent, generally a specific antibody, or fragment thereof. Alternatively, if the target analyte is an antibody, the capture reagent may be a specific antigen. In either case, after capture reagent is applied to the membrane, it is preferred to fill any unoccupied binding sites with an inert protein to prevent nonspecific binding of any other assay reagent, such as the indicator reagent, to the membrane. In the present disclosure, the term "inert protein" means a protein which is immunologically unreactive toward any other component of the assay and which does not substantially bind nonspecifically to other proteins in the assay medium, with the understanding that the inert protein may well be immunologically reactive toward other materials which are not part of the assay of the invention. Representative non-limiting examples of suitable inert proteins are albumin and casein.

**[0148]** Referring first to a sandwich assay for the detection of antigen, the capture reagent will be a first antibody specific for the predetermined antigen and the indicator reagent will comprise a second antibody also specific for the predetermined antigen. The first antibody, preferably a monoclonal antibody or an affinity purified polyclonal antibody, is bound to the reaction membrane as the capture reagent. The first antibody is selected for its ability to recognize and bind to a specific epitopic site on the antigen of interest. The second antibody forming part of the indicator reagent will be selected on the basis that it will recognize and bind to an alternative epitopic site on the antigen of interest and thus, not interfere with the binding interaction of the first antibody with the antigen. One of skill in the art will also appreciate that the sandwich assay may also be performed by reversing the roles of the antigen and antibody. For example, the immobilized member of the immunological pair may be the antigen for the detection of an antibody of interest in the test sample utilizing a labeled anti-human antibody or Protein A as the indicator reagent.

**[0149]** Referring to Figures 4, 5 and 7, and using a fluid test sample other than whole blood, the method of the invention is carried out by directly depositing a volume of the fluid test sample onto the upper surface of the reaction membrane **21** by introduction through the opening in the reservoir **22**. The amount of fluid test sample and multifunctional buffer reagent added to the assay apparatus **13** via the reservoir **22** may vary with different embodiments of the subject invention. In general, for a given specific embodiment, a predetermined and undiluted quantity of test sample will be added, while the multifunctional buffer reagent will normally be added in excess. A predetermined volume of sample is preferably added dropwise, using a standard sterilized pipette, to the centre of the reservoir **22** so that uniform contact between the sample and the immobilized capture reagent is maintained. In a preferred embodiment of the invention, only a single drop of the fluid test sample is required to be added to the reservoir. As the fluid test sample is induced to flow through the absorbent pad **20** by capillary action, any free antigen that may be present in the test sample comes into contact with the antibody immobilized to the surface of the reaction membrane **21**. The free antigen thus becomes immobilized by the antibody while the fluid test sample diffuses into the absorbent pad **20** underneath. The post-filter cap **15** is subsequently connected and brought into operable association with the reservoir **22** of the test cartridge **14**. A predetermined volume of multifunctional buffer may be measured by a marker in the reservoir **22**, or preferably added dropwise, using a second standard sterilized pipette. The dropwise addition of the buffer reagent to the centre of the post filter-cap **15** should encourage uniform contact and saturation of the post-filter unit **3** so that the dried indicator reagent will be fully resolubilized. Furthermore, the volume of buffer reagent should be sufficient to separate any unbound indicator reagent from the reaction membrane **21** after the specific binding interactions have occurred. As the stream of

buffer reagent contacts and subsequently diffuses through the reaction membrane **21**, unbound reactants are separated from the bound reactants. According to a preferred embodiment of the present invention a range of 10 to 15 drops of buffer can be added to the post-filter cap **15**. Upon addition of the multifunctional buffer and following resolubilization of the dried indicator reagent comprising labeled antibody, the labeled antibody is transported to the reaction membrane **21** by the buffer, where it will bind with any antigen that is bound by the immobilized antibody. Due to the volume and chemical properties of the multifunctional buffer, a separate washing step is not required in order to remove unbound labeled antibody. The presence of labeled antibody on the reaction membrane **21** is then determined as an indication of the presence of the target antigen in the sample. The binding reaction of the labeled antibody with the antigen produces a visually detectable signal indicative of a positive result that is easily observed directly following removal of the post-filter cap **15**.

**[0150]** The present invention is also applicable to the competitive binding technique for example, described in U.S. Patent No. 4,366,241 (Tom, et al.). In such system for the detection of antigen in a fluid test sample, the corresponding member of the immunological pair, namely the antibody, is immobilized on the reaction membrane **21** surface. However, the binding member of the indicator reagent will be an authentic sample of the target antigen which has a comparable binding affinity for the antibody immobilized to the reaction membrane **21**. After the fluid test sample is deposited on the reaction membrane **21**, the presence of antigen, if any, and the ancillary antigen of the indicator reagent compete for sites of attachment to the antibody. Since the immobilized antibody is in limited supply, a competition is set up between the antigen in the sample and the labeled antigen. If there is no antigen present in the test sample, labeled antigen aggregates on the reaction membrane **21**. Thus, the presence of color signifies a negative result due to the absence of detectable levels of antigen in the sample. If antigen is present, no color develops due to a reduction in the amount of labeled antigen bound by the immobilized antibody having binding sites already occupied by the target antigen, thus indicating a positive result. Accordingly, the signal emitted from the label is inversely proportional to the amount of antigen in the sample. Moreover, as with the sandwich assay, the competitive binding assay may be performed by reversing the roles of the antigen and antibody. For example, the immobilized member of the immunological pair may be the antigen for the detection of an antibody of interest in the test sample which competes with labeled antibody.

**[0151]** As a further consideration, this system could be expanded to include the simultaneous detection of two or more analytes of interest in a fluid test sample by using a corresponding number of immobilized immunological reagents on the reaction zone. As an example, a first antibody may be selected that is reactive with a particular subunit of a number of different antigens. If a second antibody is specific for a subunit of one antigen only, such second antibody can be used as the immobilized antibody and a single labeled first antibody can be used as the universal labeled antibody for antigen of interest. On the other hand, two different types of immobilized antibody may be employed if it is expected that antigen capable of being recognized by its appropriate binding partner is likely to present in a fluid test sample, e.g. anti-HCV antibody and anti-HIV antibody found in a co-infected patient sample.

**[0152]** In the case of analyzing a whole blood sample, the method of the invention is essentially identical to that described above with the exception that a volume of the sample is directly deposited into the reservoir **104** which allows access to and direct contact with the first end of the blood separation zone through the opening defined therein (refer also to Figure 7A). The amount of the whole blood sample applied to the reservoir **104** and the amount of multifunctional buffer reagent added to the reservoir **22** may vary with different embodiments of the subject invention. In general, for a given specific embodiment, a predetermined and undiluted quantity of test sample will be added, while the multifunctional buffer reagent will normally be added in excess. A predetermined volume of the sample is preferably added dropwise, using a standard sterilized pipette, to the centre of the reservoir **104** so that uniform contact between the sample and the blood separation zone is ensured.

**[0153]** In a preferred embodiment of the invention, only two drops of the whole blood sample are required to be added to the reservoir **104**. Following a short incubation period, the RBC-free portion of the whole blood sample, including any analyte, migrates in a lateral direction along the blood separation zone until it arrives at the reaction membrane **21**. As the RBC-free fluid test sample is induced to flow through the absorbent pad **20** by capillary action, any free antigen that may be present in the test sample comes into contact with the antibody immobilized to the surface of the reaction membrane **21**. The free antigen thus becomes bound by the antibody while the fluid test sample, along with non-essential components, diffuses into the absorbent pad **20** underneath. The post-filter cap **15** is subsequently connected and brought into operable association with the reservoir **22** of the test cartridge **14**. A predetermined volume of multifunctional buffer may be measured by a marker in the reservoir **22**, or preferably added dropwise, using a second standard sterilized pipette. The dropwise addition of the buffer reagent to the centre of the post filter-cap **15** should encourage uniform contact and saturation of the post-filter unit **3** so that the dried indicator reagent will be fully resolubilized. Furthermore, the volume of buffer reagent should be sufficient to separate any unbound indicator reagent from the reaction membrane **21** after the specific binding interactions have occurred. As the stream of buffer reagent contacts and subsequently diffuses through the reaction membrane **21**, unbound reactants are separated from the bound reactants. According to a preferred embodiment of the present invention a range of 10 to 15 drops of buffer can be added to the post-filter cap **15**. Upon addition of the multifunctional buffer and following resolubilization of the dried indicator reagent comprising

labeled antibody, the labeled antibody is transported to the reaction membrane **21** by the buffer, where it will complex with any antigen that is bound by the immobilized antibody. Due to the volume and chemical properties of the multifunctional buffer, a separate washing step is not required in order to remove unbound labeled antibody. The presence of labeled antibody on the reaction membrane **21** is then determined as an indication of the presence of the target antigen in the sample. The binding reaction of the labeled antibody with the antigen produces a visually detectable signal indicative of a positive result that is easily observed following removal of the post-filter cap **15**.

## 9.0 TEST KIT

**[0154]** According to the invention, kits may be produced which include the rapid assay device, the multifunctional buffer, as well as instructions describing the assay protocol for determining the presence of a target analyte in a fluid test sample. The diagnostic device of the present invention, which incorporates the test unit and post-filter unit, will typically be packaged in the form of a diagnostic kit for use in the detection of the target analyte of interest. The kit will normally include the flow-through assay device, preferably housed in a suitable container, the multifunctional buffer, disposable plastic pipettes and instructions describing the method for carrying out the assay protocol. Depending on the type of assay performed, i.e. sandwich or competitive, and the target analyte to be determined in the fluid test sample, the instructions will also include the relative amounts of test sample and multifunctional buffer to be added to the test unit and post-filter unit, respectively. In addition, the time periods required involving the sequential addition of the sample and buffer, as well as that the time required for the generation of a result will be included.

**[0155]** The preferred kit of the present invention uses the flow-through diagnostic device as described and shown in Figures 1 to 3. Preferably, the flow-through diagnostic device is housed within a suitable container that can be included in the test kit comprising two detachable components, each component separately containing the test unit and the post-filter unit, which are arranged in a vertically and spatially distinct format. In particular, the design of the container should allow the test unit and post-filter unit to be operably connected to one another so that the reaction zone and the label zone can be placed in transient fluid communication with one another during the assay protocol in a single movement. The container housing the test unit should be capable of maintaining the layers of the test unit under compression so as to provide continuous and uniform contact therebetween so that liquid will flow uniformly through the apparatus. Figures 4, 5 and 7 provides a representative example of the type of container that can be included in a test kit which incorporates the flow-through device of the present invention.

**[0156]** The invention will be further understood from the following non-limiting examples. The following examples are provided to describe in detail some of the representative, presently preferred methods and materials of the invention. These examples are provided for purposes of illustration of the inventive concepts, and are not intended to limit the scope of the invention as defined by the appended claims.

## 10.0 EXAMPLES

**[0157]** The foregoing is a general description of the apparatus, method and reagents of the invention. A sandwich-type reaction may be performed for the detection of *Helicobacter pylori*. Thus, by way of an example provided below, the capture reagent is a solution of *Helicobacter pylori* which is applied to the reaction membrane of the test unit. Although dye sols, gold sols or coloured latex particles may be linked to Protein A to form the indicator reagent, the preferred visual label utilized in the example assay will be colloidal gold particles. Using an apparatus comprising the test unit and post-filter unit, such as the one illustrated in Figures 4 and 5, and by performing the 2-step rapid assay of the present invention, a determination of antibody against *Helicobacter pylori* in a serum test sample can be made in less than three minutes.

### 10.1 PREPARATION OF THE DIAGNOSTIC ASSAY APPARATUS

**[0158]** The apparatus **13**, illustrated in Figures 4 and 5 comprising a test cartridge **14** and post-filter cap **15**, represents a suitable container to house the test unit **2** and post-filter unit **3** of the present invention.

#### A. Test Cartridge

**[0159]** The test cartridge, which houses the test unit of the rapid test device, is made of clean technical grade white polypropylene plastic and has a top **16** and bottom **17** component. Both are made in synchronized **16** cavity mold, precisely engineered to allow a snugly fitting tight seal when the two components are pressed together. The components are supplied as individual casings by Top View International Limited, Hong Kong, and are assembled at the manufacturing plant of MedMira Laboratories, Halifax, Canada. These components meet the following criteria:

## EP 1 417 489 B1

- Appearance - a clear, white smooth texture of the plastic.
- A snug fit to produce a leak-proof housing to ensure safe containment of all applied liquids.
- Consistency of dimensions to specifications of 2.5 cm width, 3.5 cm length, and 1.3 cm height.
- Consistency of dimensions of the reservoir **22** opening of 1.6 cm in diameter and a formed cylinder depth of 0.5 cm.
- Consistency in the location of the reservoir **22** in the top component of the test cartridge **14**.

### B. Reaction Zone

**[0160]** The material used for the reaction zone is a membrane **21** such as nitrocellulose having an average pore size of 0.45 microns (Whatman, England) and cut to 12 mm x 12 mm. The membrane **21** is 0.2 mm thick paper-backed nitrocellulose and specially treated for enhanced protein binding. Certified specifications given by the manufacturer (Whatman, England) include a binding capacity of 80-90 mg protein/cm<sup>2</sup>, a water flow rate of 6 mL/min/cm<sup>2</sup> and a bubble point of 3.5 bar. The reaction membrane **21** is prepared having two immunoreactive test sites, namely a test zone and a control zone, each zone produced in the shape of a distinct vertical line. The control line and the test line are positioned perpendicular to, but not touching, one another to provide a clear differentiation between the two. The test zone of the membrane is prepared by applying a solution of *Helicobacter pylori* in phosphate buffer (pH 7 to 9.5) using a printer device (BioJet Quanti 3000 dispenser). The control zone is similarly prepared by applying a mixture of a specially calibrated antigen preparation that binds to all classes of IgG antibodies ordinarily present in a biological fluid test sample regardless of *Helicobacter pylori* IgG antibody status, and thus serves as a control zone. After the membrane is dried at room temperature for 10 minutes, it is treated with a solution of 1 % bovine serum albumin in 0.1 M sodium phosphate buffer and allowed to completely dry at ambient temperature for approximately 24 hours.

### C. Optional Spacer Layer

**[0161]** A spacer layer **25** supporting the reaction membrane **21** may be produced by securing the outer perimeter of the upper surface of the reaction membrane **21** to the lower surface of the spacer layer **25** such that the upper surface of the reaction membrane **21** is exposed through an opening of the spacer layer **25**. The upper surface of the reaction membrane **21** is sealed to the lower surface of the spacer layer with a fluid-resistant adhesive so as to form an impermeable seal between the rim **27** of the spacer layer **25**, defining the opening **26**, and the unexposed upper surface of the reaction membrane **21**. This arrangement helps to promote the flow of fluids in a downward, as opposed to lateral, direction through the reaction membrane **21** and into the absorbent pad **20** below. The spacer layer **25** may be purchased with water-soluble adhesive already adhered to the lower surface, or the adhesive may be applied during the manufacturing process. The spacer layer **25** is a polystyrene material insert with a brown paperback double-sided tape (Halifax Folding Company, Nova Scotia, Canada). The reaction membrane **21** is secured to the spacer layer **25** by the double-sided tape. The assembled spacer layer **25** is approximately 29.0mm x 20.5mm in area and 1.0 mm in thickness and is positioned on the upper surface of the absorbent pad **20** which sits in the base of the test cartridge **14** as shown in Figures 4 and 5.

### D. Absorbent Zone

**[0162]** The absorbent zone comprises a pad **20** placed directly beneath the reaction membrane **21** and securely inside the bottom member **17** of the test cartridge **14**. The pad **20** is composed of thickened compressed cellulose acetate with a porosity of 40 mL/min (Filtrona, Richmond Inc., Richmond, VA). It is made of synthetic fibers without the use of resins or adhesives and provides an excellent level of aqueous fluid compatibility. Void space is specified at 80 to 85% and absorption of liquids at 6 times the dry unit weight and up to 90% of the total void volume. It is resistant to pH in the range of 2.5 to 9.5. The pad **20** is die cut to a specification of 2.2 cm width, 3.2 cm length and 0.5 cm height. The pad **20** fits securely into the bottom member **17** of the test cartridge **14** so as to create a compressed composite of the reaction membrane **21** with the absorbent pad **20** to ensure a continuum of fluid communication between the porous materials for enhanced hydrodynamics and complete absorption when test samples are applied to the reaction membrane **21**.

### E. Post-Filter Cap

**[0163]** The post-filter cap **15**, which houses the post-filter unit **3** of the rapid test apparatus **13**, is comprised of an outer funnel sleeve **29** having an internal collar **34** at its base, an inner funnel sleeve **28** having a handle **35** extending therefrom, and the post-filter unit **3**. The funnel sleeves **28,29** and the handle **35** are molded from a plastic material. One preferred plastic material is polystyrene resin (Fouzhou Chimoplus Chemical Company Ltd., China). The outer **29** and inner **28** funnel sleeves are cylindrical in shape with an outside diameter of 15.0 mm and 12.5 mm, respectively and

## EP 1 417 489 B1

the assembled cap **15** fits snugly into the reservoir **22** of the test cartridge **14**. The post-filter cap **15** is designed to be connected to the reservoir **22** of the test cartridge **14** following post-application of the test sample to the reservoir **22**, and removed shortly after the multifunctional buffer has been added and diffused through the post-filter unit **3** of the filter cap **15**. In the assembled form, the volume capacity of the post-filter cap **15** is about 0.5 mL.

**[0164]** The label zone of the post-filter unit **3** is comprised of one filter layer permeated with indicator reagent that will be in direct fluid communication with the reaction zone of the test unit **2** to improve the subsequent reactivity between the antibodies of the colloidal gold conjugate and the antigen-coated reaction membrane **21**. The filter is comprised of glass micro fiber with OVA binder (Whatman, GF/AVA) which is white and has a basis weight of 48 g/m<sup>2</sup>, a thickness of 0.303 mm, a flow rate of 150 s/1.5 cm, dry tensile of 640 g/1.5 cm, wet tensile of 324 g/1.5 cm and a porosity of 3 sec/100 mL/in<sup>2</sup>. Once assembled, the freeze-dried colloidal gold conjugate is reconstituted with a solution comprising 0.1-0.15 mL of PBS buffer (0.6-0.7mM potassium chloride, 0.03M sodium chloride, 2-2.1mM di-sodium hydrogen ortho-phosphate anhydrous, 0.3-0.4 mM potassium phosphate mono) containing 10% sugar. The colloidal gold conjugate solution is dispensed (0.1 to 0.15 mL) onto each filter and then dried at a temperature of 37 to 40°C. The filter layer is die cut according to the following specifications: thickness, 790 to 830 microns; porosity, 1.6 to 2.0 s/100mL/in<sup>2</sup>; tensile strength 14.5N/55mm; flow rate, 67 s/7.5cm; absorbancy, 76.4%; pore size, 4.3 microns; wicking, 1.00 min:sec; and diameter, 0.42 mm.

### 10.2 INSPECTION ON PROTEIN A (PA)

#### Formulation

**[0165]** Sodium Chloride  
10% in DDI water

#### BSA

**[0166]** 1% BSA in DDI water pH 5.00 to 9.00 (optimum 6.00).

#### Colloidal gold

**[0167]** Prepared up to the pH step.

#### Stock-solution of the Labeling Material

**[0168]** Original concentration diluted in DDI to a final concentration of 0.1 - 2 mg/mL (optimum 0.1 mg/mL)

#### Procedure

##### **[0169]**

- Prepare a 9 serial dilution Protein A (PA).
- To the PA, dilution add the colloidal gold already pH adjusted in a 1:10 ratio (e.g. to 0.1 mL of PA dilution add 1 mL of colloidal gold).
- Incubate for 10 minutes.
- To each dilution tubes add 8-10 % of sodium chloride to a final concentration of 1% (optimum 0.9%).
- Incubate for 5 minutes.
- To each tube again add 0.07 - 0.1% of bovine serum albumin to a final concentration of 0.1 % (optimum 0.08%).
- Read the absorbance at 520 nm.
- The correct concentration of protein is the minimal amount that will inhibit flocculation.

Conc. (µg)	Absorbance 1	Absorbance 2	Average
0	0,313	0,314	0,314
2	0,524	0,524	0,524
3	0,533	0,532	0,533

## EP 1 417 489 B1

(continued)

Conc. ( $\mu\text{g}$ )	Absorbance 1	Absorbance 2	Average
4	0,533	0,533	0,533
5	0,540	0,540	0,540
6	0,575	0,571	0,573
7	0,580	0,580	0,580
8	0,576	0,583	0,580
9	0,576	0,576	576

5

10

15

**[0170]** Hughes D.A & J. E. Beesley (1998) Preparation of Colloidal Gold Probes in (ed) J.D. Pound. Methods in Molecular Biology vol 80: Immunochemical Protocols, 2nd edition. Humana Press Inc., Totowa, NJ.

### 10.3 PREPARATION OF COLLOIDAL GOLD CONJUGATE

#### Materials

20

#### **[0171]**

25

Sodium Citrate	0.3 mM in DDI water
BSA	1 % BSA in DDI water, pH 5.00 to 9.00
PEG	1 % polyethylene glycol (MW 15,000 to 20,000) in DDI water, pH to 6.00
Phosphate Buffer	mix 0.04M (in DI water) of $\text{NaH}_2\text{PO}_4$ into 0.07M (in water) $\text{KH}_2\text{PO}_4$ in a 1:4.4 ratio; pH to 6.00
Protein A in Hepes Buffer	Protein A in Hepes buffer (0.025M Hepes and 0.25mM Thimerosal pH 7.00 in DDI water) to give a final concentration on 1 mg/mL.
Borate buffer	0.05M of sodium borate in DDI water pH 8.50

30

#### Resuspending Buffer

35

**[0172]** 8mM di-sodium hydrogen orthophosphate anhydrous  
1 % bovine serum albumin  
3mM sodium azide  
0.02% polyethylene glycol  
0.14 - 0.16M sodium chloride  
1.5mM potassium dihydrogen orthophosphate  
2.7mM potassium chloride  
4.3mM tri-sodium orthophosphate

40

**[0173]** Mix the above ingredients in 1000 mL of DDI water, pH 7.30 to 7.50.

45

#### Procedure

#### **[0174]**

50

- Add 1% of tetrachloroauric acid to water for a final concentration of 0.01 %.
- Let solution reach a hard boiling point.
- Add 15 mL of 0.3mM sodium citrate on a reflux for 30 minutes.
- Remove the flask and allow the contents to cool to around 40°C or lower.
- Add 60mL of phosphate buffer (mix 0.04M (in DI water) of  $\text{NaH}_2\text{PO}_4$  into 0.07M (in water)  $\text{KH}_2\text{PO}_4$  in a 1:4.4 ratio; pH to 6.00) or 50mM of borate buffer (pH 8.50); adjust pH of the colloidal gold to 6.00 - 9.00 (optimal is 6.00), if the pH is too low, add drops of 2mM  $\text{K}_2\text{CO}_3$ .
- A portion of the solution is removed to perform an aggregation test to know the concentration of the ligand to add to the gold solution.
- Add Protein A with a final concentration of 5-9 ug/mL +5% (optimum 6 + 0.3 = 6.3 ug/mL)

55

$$\frac{[\text{Final PA} + 5\%] (\text{mg/L}) \times \text{total volume in flask(L)}}{[\text{Initial PA}] (\text{mg/mL})}$$

i.e. Total volume = 500mL CG and dH2O + 15mL sodium citrate + 60mL phosphate

buffer – 3mL test for pH = 572mL = 0.572L

$$\frac{(6 + 0.3)\text{mg/L} \times 0.572\text{L}}{1\text{mg/mL}} = 3.60\text{mL Protein A to be added}$$

- The solution is allowed to proceed for 15-30 minutes (optimum 20 minutes).
- The absorption of the ligand is stop by adding 10% bovine serum albumin pH 5.00 to 9.00 final concentration of 0.1 % stir for 5-15 minutes (optimum 10 minutes).
- The labeled colloidal gold was centrifuged at a speed of 46,500g (20,000rpm) at a temperature of 4-5 C for 50 to 80 minutes.

#### Aspiration and Re-suspension

**[0175]** Aspirate the supernatant with the help of a vacuum flask, taking care not to disturb the pellet. Resuspend in re-suspending buffer (or PBS-BSA) to a final optical density of 1.180 to 4.500 (optimum 2.000) at 520 nm.

#### Lyophilization Process

**[0176]** After the appropriate optical density reach, the solution was filled in 0.6 mL aliquots into a 3 mL glass vials. Slotted stoppers (1-mm in diameter) were inserted halfway into the vials and transferred into the lyophilizer shelves. A temperature of -40 C was maintained for about 5 hours. The primary drying was carried out at a vacuum of less than 100 mTorr with a shelf temperature of -30 C for about 3 hours and a condenser temperature of less than -80 C. Followed is a shelf temperature of -10 C for about 5 hours then a shelf temperature of 0 C, vacuum of 0 mTorr for about 2 hours. A secondary drying is carry on at + 20 C for about 4 hours. At the end of the process, the vials were seal under vacuum with the slotted stoppers. The product was then removed from the shelves and a functional test was performed to assure the quality of the product. Samples were kept for later reference.

### 10.4 STABILIZATION OF COLLOIDAL GOLD CONJUGATE

#### Procedure

#### **[0177]**

- Prepare 1%, 2%, 5% and 10% sucrose in PBS solution, pH 7.0-7.5.
- Reconstitute freeze-dried colloidal gold conjugate with a) 5 drops (150µL) b) 10 drops (350 µL) and c) 15 drops (650 µL) with each percentage of sucrose.
- Apply 5 drops (150 µL) of each reconstitution to the filter medium.
- Let it air dry completely.

## EP 1 417 489 B1

Specimen	Result			
	1%	2%	5%	10%
Control line	2+	2+	2+	3+
Positive control	1 +	1+	1+	2+/3+
Negative control	neg	neg	neg	neg

### 10.5 PREPARATION OF THE POST-FILTER UNIT

**[0178]** One of the goals in diagnostic testing is to develop a test device that requires few manipulative steps. Therefore, by associating the indicator reagent with the filter medium of the post-filter unit **3**, it is possible to eliminate extra steps in which the reagents are added separately to the diagnostic device during the assay protocol.

#### Materials

##### **[0179]**

- Colloidal gold conjugate, Prepared and previously freeze-dried as described above.
- Sugar, e.g. trehalose, lactose, sucrose, glucose, maltose, mannose, fructose, etc.

#### Procedure

##### **[0180]**

- Reconstitute the freeze-dried colloidal gold with 0.1 - 0.15 mL of PBS buffer (0.6 - 0.7mM potassium chloride, 0.03M Sodium chloride, 2 - 2.1 mM di-sodium hydrogen orthophosphate anhydrous, 0.3 - 0.4 mM potassium phosphate mono) containing 10% sucrose.
- Dispense 0.1 to 0.15 mL of colloidal gold solution onto each filter.
- Let the filter dry completely at 37 - 40 C.

### 10.6 PREPARATION OF THE MULTIFUNCTIONAL BUFFER

#### Formulation

**[0181]** 0.01 - 0.1M EDTA  
0.02M Sodium azide  
0.05 - 0.1M Sodium chloride  
6mM di-sodium hydrogen orthophosphate anhydrous  
0.1- 0.25mM Thimerosal  
0.05 - 0.1 % Triton<sup>®</sup>X-100  
0.02 - 0.03M Trizma hydrochloride  
0.2 - 0.3% Tween-20  
0.5 - 2.5% PVP-40

#### Procedure

##### **[0182]**

- Add all ingredients together (0.01 - 0.1M EDTA, 0.02M sodium azide, 0.05 - 0.1M sodium chloride, 6mM di-sodium hydrogen orthophosphate anhydrous, 0.1- 0.25mM Thimerosal, 0.05 - 0.1% Triton<sup>®</sup>X-100, 0.02 - 0.03M Trizma hydrochloride, 0.2 - 0.3% Tween-20, 0.5 - 2.5% PVP-40).
- Fill up with DDI water.
- Adjust the pH to 7.00 to 10.00.

10.6 ASSAY PROTOCOLSerum or Plasma Sample

5 **[0183]** Using a clean pipette, 1 drop of a serum or plasma sample was added to the centre of the reaction membrane and the sample allowed to absorb completely through the membrane and into the absorbent material pad. The post-filter cap was connected to the reservoir of the test cartridge so that the post-filter unit was in fluid communication with the test unit. Ten to fifteen drops of the multifunctional buffer were subsequently added to the funnel of the post-filter cap. After a brief incubation, about 1 minute, during which time the resolubilized colloidal gold conjugate was drawn  
10 through the post filter unit, the post-filter cap was removed from the test cartridge. A distinct colored line(s), one vertical control line and one test line, developed in the centre of the reaction membrane indicating the presence of *Helicobacter pylori* in the test sample. The results of the assay were revealed in about three (3) minutes.

INDUSTRIAL APPLICABILITY

15 **[0184]** The rapid diagnostic device, assay and multifunctional buffer as well as the method, test kit and formulation for generating the multifunctional buffer taught herein generally provide improved diagnostic means for the detection of a target analyte in a fluid sample.

20

**Claims**

1. A downward or vertical flow through test device (1) for determining the presence or absence of a target analyte (10)  
in a fluid test sample (9), comprising:

25

- a test unit (2) comprising a reaction zone (5) in vertical communication with an absorbent zone (4), wherein the reaction zone (5) contains immobilized capture reagent (6) capable of binding with a target analyte (10) of interest to form a two-membered complex of a specific binding interaction and the absorbent zone comprises an absorbent material positioned underneath the reaction zone for facilitating downward or vertical fluid flow  
30 through the reaction zone; and

- a removable post-filter unit (3) comprising a label zone (7) containing a dried indicator reagent (8), wherein the indicator reagent (8) is capable of binding to a member of the specific binding interaction to produce a visually detectable signal following resolubilization thereof by buffer reagent (12); and

35

**characterized in that** the post-filter unit (3) is proximally disposed to the test unit (2) subsequent to formation of the two-membered complex such that the reaction zone (5) of the test unit (2) and the label zone (7) of the post-filter unit (3) allow direct downward or vertical flow of resolubilized indicator reagent (8) from the label zone (7) to the reaction zone (5) following application of buffer reagent (12) to the label zone (7).

40

2. The device (1) according to claim 1, **characterized in that** the specific binding interaction is an antibody-antigen interaction.

45

3. The device (1) according to claim 1, **characterized in that** the indicator reagent (8) is capable of binding to a target analyte (10) at a site which does not interfere with the specific binding interaction between the target analyte (10) and the capture reagent (6).

50

4. The device (1) according to claim 1, **characterized in that** the indicator reagent (8) is capable of binding to the capture reagent (6) at a site which interferes with the specific binding interaction between the target analyte (10) and the capture reagent (6).

55

5. The device (1) according to claim 2, **characterized in that** the target analyte (10) is an antigen and the capture reagent (6) is a monoclonal antibody or an affinity purified polyclonal antibody for the antigen.

6. The device (1) according to claim 1, **characterized in that** the reaction zone (5) is comprised of a material which has a pore size permitting separation and filtration of unbound components from the fluid test sample (9) and a thickness which permits an adequate amount of capture reagent (6) to be immobilized thereto.

7. The device (1) according to claim 6, **characterized in that** the material has a pore size ranging from 0.1 to 12.0

microns.

8. The device (1) according to claim 7, **characterized in that** the material has a pore size ranging from 0.2 to 0.8 microns.
- 5 9. The device (1) according to claim 6, **characterized in that** the thickness of the material ranges from 0.05 mm to to 3.0 mm.
10. The device (1) according to claim 9, **characterized in that** the thickness of the material ranges from 0.1 to 1.0 mm.
- 10 11. The device (1) according to claim 6, wherein the material is a nitrocellulose membrane.
12. The device (1) according to claim 1, **characterized in that** the reaction zone (5) contains two or more different capture reagents (6) immobilized thereto in discernable and separate areas so that multiple target analytes (10) in a single fluid test sample (9) can be analyzed simultaneously.
- 15 13. The device (1) according to claim 1, **characterized in that** the reaction zone (5) further comprises an immobilized control reagent in a discernable and separate area from the capture reagent (6).
- 20 14. The device (1) according to claim 1, **characterized in that** the absorbent zone (4) is separated from the reaction zone (5) by an intervening spacer layer (25) having one or more openings defined therein to permit fluid communication between the reaction zone (5) and the absorbent zone (4).
- 25 15. The device (1) according to claim 14, **characterized in that** the spacer layer (25) is a rigid or semi-rigid fluid-resistant material.
- 30 16. The device (1) according to claim 1, **characterized in that** the absorbent zone (4) comprises one or more layers of a material which is capable of wicking fluid by capillary action and absorbing a substantial volume of fluid.
- 30 17. The device (1) according to claim 16, **characterized in that** two or more layers comprise identical or different materials.
- 35 18. The device (1) according to claim 16, **characterized in that** the material is cellulose acetate.
- 35 19. The device (1) according to claim 1, **characterized in that** the label zone (7) comprises a filter material having a pore size capable of allowing dried indicator reagent (8) to be effectively resolubilized by buffer reagent and transferred to the reaction zone (5) by laminar fluid flow.
- 40 20. The device (1) according to claim 19, **characterized in that** the filter material is glass fiber material.
- 40 21. The device (1) according to claim 1, **characterized in that** the indicator reagent (8) comprises a direct label.
- 45 22. The device (1) according to claim 21, **characterized in that** the direct label is colloidal gold.
- 45 23. The device (1) according to claim 1, **characterized in that** said test unit (2) and said post-filter unit (3) are contained in a suitable housing.
- 50 24. The device (1) according to any one of claims 1 to 23, **characterized in that** said test unit (2) is adapted to determine the presence or absence of a target analyte (10) in a whole blood test sample (9N) and further comprises a lateral flow blood separation zone (100) in lateral communication with the reaction zone (5) wherein the blood separation zone (100) has a first end (101) defining a region for receiving a whole blood test sample (9N), and a second end (102) in direct communication with the reaction zone (5).
- 55 25. The device (1) according to claim 24, **characterized in that** the blood separation zone (100) comprises a material capable of selectively retaining an effective amount of red blood cells (RBC) from the whole blood test sample (9N) to generate a substantially RBC-free fluid portion which can flow with unimpaired movement from the first end (101) of the blood separation zone (100) to the reaction zone (5).
26. The device (1) according to claim 25, **characterized in that** the material is a glass fiber matrix.

## EP 1 417 489 B1

27. The device (1) according to claim 25, **characterized in that** the material comprises a hydrophobic carrier capable of reducing seepage of the whole blood test sample (9N) and the RBC-free fluid portion as it migrates along the blood separation zone (100).
- 5 28. The device (1) according to claim 24, **characterized in that** the test unit (2) and the post-filter unit (3) are housed in a suitable container.
- 10 29. The device (1) according to any one of claims 1 to 28, **characterized in that** said buffer reagent (12) is a multifunctional buffer comprising: a biological buffer to maintain the pH between 7.0 to 10.0; at least one surfactant to reduce non-specific binding of assay reagents while simultaneously avoiding inhibition of a specific binding interaction; a high molecular weight polymer as a dispersing and suspending reagent having a molecular weight in a range of from  $2 \times 10^2$  to  $2 \times 10^6$  D; a pH stabilizer to maintain the pH of the multifunctional buffer within a range of pH 7.0 to 10.0; an ionic salt to reduce non-specific binding of antibodies; at least one preservative to reduce bacterial and microbial growth; and a calcium chelator to prevent a whole blood test sample from clotting; wherein the biological buffer, the surfactant, the high molecular weight polymer, the pH stabilizer, the ionic salt, the preservative and the calcium chelator are all in effective concentrations.
- 15 30. The device (1) according to claim 29, **characterized in that** the concentration of the biological buffer ranges from 5 to 100 mM.
- 20 31. The device (1) according to claim 30, **characterized in that** the concentration of the biological buffer ranges from 5 to 30 mM.
- 25 32. The device (1) according to claim 31, **characterized in that** the concentration of the biological buffer is 5 mM.
- 30 33. The device (1) according to any one of claims 29 to 32, **characterized in that** the biological buffer is a phosphate buffer.
- 35 34. The device (1) according to claim 29, **characterized in that** the concentration of the surfactant ranges from 0.01 to 0.50% (w/v).
- 40 35. The device (1) according to claim 34, **characterized in that** the concentration of the surfactant ranges from 0.05 to 0.10% (w/v).
- 45 36. The device (1) according to claim 35, **characterized in that** the concentration of the surfactant is 0.07% (w/v).
37. The device (1) according to any one of claims 29 and 34 to 36, **characterized in that** the surfactant is Triton<sup>7</sup>X-100.
- 40 38. The device (1) according to claim 29, **characterized in that** the concentration of ionic salt is from 0 to 300 mM.
- 45 39. The device (1) according to claim 38, **characterized in that** the concentration of ionic salt is from 50 to 200 mM.
- 50 40. The device (1) according to any one of claims 29, 38 and 39, **characterized in that** the ionic salt is sodium chloride.
- 55 41. The device (1) according to claim 29, **characterized in that** the polymer is polyvinylpyrrolidone having a molecular weight range from 10 kD to about 1500 kD.
42. The device (1) according to claim 41, **characterized in that** the concentration of polyvinylpyrrolidone polymer is 0.1 to 3.0% (w/v).
- 50 43. The device (1) according to claim 42, **characterized in that** the concentration of polyvinylpyrrolidone polymer is 0.5 to 2.5% (w/v).
- 55 44. The device (1) according to claim 43, **characterized in that** the concentration of polyvinylpyrrolidone polymer is 1.4% (w/v).
45. The device (1) according to claim 29, **characterized in that** the calcium chelator is EDTA.

46. The device (1) according to claim 45, **characterized in that** the concentration of EDTA is from 5.0 to 100.0 mM.

47. The device (1) according to claim 46, **characterized in that** the concentration of EDTA is from 10.0 to 50.0 mM.

5 48. The device (1) according to claim 47, **characterized in that** the concentration of EDTA is 20.0 mM.

49. The device (1) according to claim 29, **characterized in that** the pH stabilizer is tris buffer.

10 50. The device (1) according to claim 49, **characterized in that** the concentration of the pH stabilizer is from 20 to 30 mM.

51. A method for determining the presence or absence of a target analyte (10) in a fluid test sample (9), comprising the steps of:

- 15
- depositing the fluid test sample (9) onto the reaction zone (5) of the test unit (2) of the downward or vertical flow through test device (1) defined in any one of claims 1 to 23;
  - allowing the fluid test sample (9) to flow through the reaction zone (5) into the absorbent zone (4);
  - fitting the post filter unit (3) to the test unit (2) such that the label zone (7) of the post-filter unit (3) and the reaction zone (5) of the test unit (2) are proximally disposed so as to allow direct downward or vertical fluid flow from the label zone (7) to the reaction zone (5);
  - 20 - applying buffer reagent (12) to the post-filter unit (3) to reconstitute the dried indicator reagent (8);
  - allowing the reconstituted indicator reagent to flow through the reaction zone (5) and into the absorbent zone (4), with any unbound reactants being washed from the reaction zone (5) into the absorbent zone (4); and
  - removing the post-filter unit (3) to observe a test result depicted by a presence or absence of a visually detectable signal on the reaction zone (5).
- 25

52. The method according to claim 51, **characterized in that** the buffer reagent (12) is a multifunctional buffer comprising: a biological buffer to maintain the pH between 7.0 to 10.0; at least one surfactant to reduce non-specific binding of assay reagents while simultaneously avoiding inhibition of a specific binding interaction; a high molecular weight polymer as a dispersing and suspending reagent having a molecular weight in a range of from  $2 \times 10^2$  to  $2 \times 10^6$  D; a pH stabilizer to maintain the pH of the multifunctional buffer within a range of pH 7.0 to 10.0; an ionic salt to reduce non-specific binding of antibodies; at least one preservative to reduce bacterial and microbial growth; and a calcium chelator to prevent a whole blood test sample from clotting; wherein the biological buffer, the surfactant, the high molecular weight polymer, the pH stabilizer, the ionic salt, the preservative and the calcium chelator are all in effective concentrations.

30

35

53. A method for determining the presence or absence of a target analyte (10) in a whole blood test sample (9N), comprising the steps of:

- 40
- depositing the whole blood test sample (9N) onto the first end (101) of the blood separation zone (100) of the device (1) defined in any one of claims 24 to 28;
  - allowing the whole blood test sample (9') to flow laterally along the blood separation zone (100) with red blood cell-free sample reaching the reaction zone (5);
  - allowing the red blood cell-free sample to flow vertically or downwardly through the reaction zone (5) into the absorbent zone (4);
  - 45 - fitting the post filter unit (3) to the test unit (2) such that the label zone (7) of the post-filter unit (3) and the reaction zone (5) of the test unit (2) are proximally disposed so as to allow direct downward or vertical fluid flow from the label zone (7) to the reaction zone (5);
  - applying buffer reagent (12) to the post-filter unit (3) to reconstitute the dried indicator reagent (8);
  - allowing the reconstituted indicator reagent to flow through the reaction zone (5) into the absorbent zone (4), with any unbound reactants being washed from the reaction zone (5) into the absorbent zone (4); and
  - 50 - removing the post-filter unit (3) to observe a test result depicted by a presence or absence of a visually detectable signal on the reaction zone.

54. The method according to claim 53, **characterized in that** the buffer reagent (12) is a multifunctional buffer comprising: a biological buffer to maintain the pH between 7.0 to 10.0; at least one surfactant to reduce non-specific binding of assay reagents while simultaneously avoiding inhibition of a specific binding interaction; a high molecular weight polymer as a dispersing and suspending reagent having a molecular weight in a range of from  $2 \times 10^2$  to  $2 \times 10^6$  D; a pH stabilizer to maintain the pH of the multifunctional buffer within a range of pH 7.0 to 10.0; an ionic salt to reduce

55

non-specific binding of antibodies; at least one preservative to reduce bacterial and microbial growth; and a calcium chelator to prevent a whole blood test sample from clotting; wherein the biological buffer, the surfactant, the high molecular weight polymer, the pH stabilizer, the ionic salt, the preservative and the calcium chelator are all in effective concentrations.

5  
**55.** A test kit for use in the detection of a target analyte (10) in a fluid test sample (9) or a whole blood test sample (9N) suspected of containing the analyte (10), **characterized by:**

10  
 - a device (1) as defined in any one of claims 1 to 28; and  
 - buffer reagent (12) to reconstitute the dried indicator reagent (8) and wash any unbound reactants from the reaction zone (5).

15  
**56.** The test kit according to claim 55, **characterized in that** the buffer reagent (12) is a multifunctional buffer comprising: a biological buffer to maintain the pH between 7.0 to 10.0; at least one surfactant to reduce non-specific binding of assay reagents while simultaneously avoiding inhibition of a specific binding interaction; a high molecular weight polymer as a dispersing and suspending reagent having a molecular weight in a range of from  $2 \times 10^2$  to  $2 \times 10^6$  D; a pH stabilizer to maintain the pH of the multifunctional buffer within a range of pH 7.0 to 10.0; an ionic salt to reduce non-specific binding of antibodies; at least one preservative to reduce bacterial and microbial growth; and a calcium chelator to prevent a whole blood test sample (9N) from clotting; wherein the biological buffer, the surfactant, the high molecular weight polymer, the pH stabilizer, the ionic salt, the preservative and the calcium chelator are all in effective concentrations.

20  
**57.** The test kit according to claim 55, further comprising:  
 25  
 - instructions for performing the diagnostic assay; and  
 - a pair of pipettes for separately applying the test sample (9) and the buffer reagent (12) to the test unit (2) and the post-filter unit (3), respectively.

30  
**58.** The test kit according to claim 55, **characterized in that** the test unit (2) and the post-filter unit (3) are housed in a suitable container.

### Patentansprüche

35  
**1.** Abwärts- oder Vertikaldurchflußtestvorrichtung (1) zum Bestimmen der Gegenwart oder Abwesenheit eines Zielanalyts (10) in einer Fluidtestprobe (9), welche umfaßt:

40  
 - eine Testeinheit (2) umfassend eine Reaktionszone (5) in vertikaler Verbindung mit einer Absorbenszone (4), wobei die Reaktionszone (5) immobilisiertes Einfangreagens (6) enthält, das in der Lage ist zur Bindung mit einem interessierenden Zielanalyten (10), um einen zweigliedrigen Komplex einer spezifischen Bindungswechselwirkung zu bilden, und wobei die Absorbenszone ein Absorbensmaterial umfaßt, das unterhalb der Reaktionszone positioniert ist, um Abwärts- oder Vertikalfeldfluß durch die Reaktionszone zu ermöglichen; und  
 45  
 - eine entfernbare Nachfiltereinheit (3) umfassend eine Markierungszone (7), die ein getrocknetes Indikatorreagens (8) enthält, wobei das Indikatorreagens (8) in der Lage ist, an ein Element der spezifischen Bindungswechselwirkung zu binden, um ein visuell detektierbares Signal folgend einer Wiederauflösung desselben durch ein Pufferreagens (12) zu erzeugen; und

50  
**dadurch gekennzeichnet, daß** die Nachfiltereinheit (3) proximal an der Testeinheit (2) nachfolgend der Bildung des zweigliedrigen Komplexes angeordnet wird, so daß die Reaktionszone (5) der Testeinheit (2) und die Markierungszone (7) der Nachfiltereinheit (3) direkten Abwärts- oder Vertikalfeldfluß des wieder aufgelösten Indikatorreagens (8) von der Markierungszone (7) zur Reaktionszone (5) folgend einer Aufbringung des Pufferreagens (12) auf die Markierungszone (7) ermöglichen.

55  
**2.** Vorrichtung (1) nach Anspruch 1, **dadurch gekennzeichnet, daß** die spezifische Bindungswechselwirkung eine Antikörper-Antigen-Wechselwirkung ist.

**3.** Vorrichtung (1) nach Anspruch 1, **dadurch gekennzeichnet, daß** das Indikatorreagens (8) in der Lage ist, an einen Zielanalyten (10) an einer Stelle zu binden, welche nicht die spezifische Bindungswechselwirkung zwischen dem

Zielanalyten (10) und dem Einfangreagens (6) beeinträchtigt.

4. Vorrichtung (1) nach Anspruch 1, **dadurch gekennzeichnet, daß** das Indikatorreagens (8) in der Lage ist, an das Einfangreagens (6) an einer Stelle zu binden, welche die spezifische Bindungswechselwirkung zwischen dem Zielanalyten (10) und dem Einfangreagens (6) beeinträchtigt.
5. Vorrichtung (1) nach Anspruch 2, **dadurch gekennzeichnet, daß** der Zielanalyt (10) ein Antigen ist und das Einfangreagens (6) ein monoklonaler Antikörper oder ein affinitätsgereinigter (affinity purified) polyklonaler Antikörper für das Antigen ist.
6. Vorrichtung (1) nach Anspruch 1, **dadurch gekennzeichnet, daß** die Reaktionszone (5) ein Material umfaßt, das eine Porengröße aufweist, die eine Trennung und Filtration von nicht-gebundenen Komponenten aus der Fluidtestprobe (9) erlaubt, und eine Dicke, welche erlaubt, daß eine adäquate Menge des Einfangreagens (6) daran immobilisiert wird.
7. Vorrichtung (1) nach Anspruch 6, **dadurch gekennzeichnet, daß** das Material einen Porengrößenbereich von 0,1 bis 12,0 Mikrometer aufweist.
8. Vorrichtung (1) nach Anspruch 7, **dadurch gekennzeichnet, daß** das Material einen Porengrößenbereich von 0,2 bis 0,8 Mikrometer aufweist.
9. Vorrichtung (1) nach Anspruch 6, **dadurch gekennzeichnet, daß** die Dicke des Materials in einem Bereich von 0,05 mm bis 3,0 mm liegt.
10. Vorrichtung (1) nach Anspruch 9, **dadurch gekennzeichnet, daß** die Dicke des Materials in einem Bereich von 0,1 bis 1,0 mm liegt.
11. Vorrichtung (1) nach Anspruch 6, wobei das Material eine Nitrocellulosemembran ist.
12. Vorrichtung (1) nach Anspruch 1, **dadurch gekennzeichnet, daß** die Reaktionszone (5) zwei oder mehr unterschiedliche Einfangreagentien (6) enthält, die daran in erkennbaren und getrennten Bereichen immobilisiert sind, so daß mehrere Zielanalyten (10) in einer einzigen Fluidtestprobe (9) gleichzeitig analysiert werden können.
13. Vorrichtung (1) nach Anspruch 1, **dadurch gekennzeichnet, daß** die Reaktionszone (5) ferner ein immobilisiertes Kontrollreagens in einem erkennbaren und getrennten Bereich von dem Einfangreagens (6) umfaßt.
14. Vorrichtung (1) nach Anspruch 1, **dadurch gekennzeichnet, daß** die Absorbenszone (4) von der Reaktionszone (5) durch eine dazwischenkommende Abstandsschicht (25) mit einer oder mehreren darin definierten Öffnungen getrennt ist, um eine Fluidkommunikation zwischen der Reaktionszone (5) und der Absorbenszone (4) zu erlauben.
15. Vorrichtung (1) nach Anspruch 14, **dadurch gekennzeichnet, daß** die Abstandsschicht (25) ein starres oder halbstarres, Fluid-resistentes Material ist.
16. Vorrichtung (1) nach Anspruch 1, **dadurch gekennzeichnet, daß** die Absorbenszone (4) eine oder mehrere Schichten eines Materials umfaßt, das in der Lage ist, Fluid durch Kapillarwirkung aufzunehmen und ein beträchtliches Volumen an Fluid zu absorbieren.
17. Vorrichtung (1) nach Anspruch 16, **dadurch gekennzeichnet, daß** zwei oder mehr Schichten identische oder unterschiedliche Materialien umfassen.
18. Vorrichtung (1) nach Anspruch 16, **dadurch gekennzeichnet, daß** das Material Celluloseacetat ist.
19. Vorrichtung (1) nach Anspruch 1, **dadurch gekennzeichnet, daß** die Markierungszone (7) ein Filtermaterial mit einer Porengröße umfaßt, das in der Lage ist, es getrocknetem Indikatorreagens (8) zu erlauben, effektiv durch Pufferreagens wieder aufgelöst und zur Reaktionszone (5) durch laminaren Fluidfluß überführt zu werden.
20. Vorrichtung (1) nach Anspruch 19, **dadurch gekennzeichnet, daß** das Filtermaterial Glasfasermaterial ist.

## EP 1 417 489 B1

21. Vorrichtung (1) nach Anspruch 1, **dadurch gekennzeichnet, daß** das Indikatorreagens (8) eine Direktmarkierung umfaßt.
- 5 22. Vorrichtung (1) nach Anspruch 21, **dadurch gekennzeichnet, daß** die Direktmarkierung kolloidales Gold ist.
23. Vorrichtung (1) nach Anspruch 1, **dadurch gekennzeichnet, daß** die Testeinheit (2) und die Nachfiltereinheit (3) in einem geeigneten Gehäuse aufgenommen sind.
- 10 24. Vorrichtung (1) nach einem der Ansprüche 1 bis 23, **dadurch gekennzeichnet, daß** die Testeinheit (2) angepaßt ist, um die Gegenwart oder Abwesenheit eines Zielanalyts (10) in einer Vollbluttestprobe (9N) zu bestimmen, und die weiter eine seitliche Blutflußtrennzone (100) in seitlicher Kommunikation mit der Reaktionszone (5) umfaßt, wobei die Bluttrennzone (100) ein erstes Ende (101), das einen Bereich zur Aufnahme einer Vollbluttestprobe (9N) definiert, und ein zweites Ende (102) in direkter Kommunikation mit der Reaktionszone (5) aufweist.
- 15 25. Vorrichtung (1) nach Anspruch 24, **dadurch gekennzeichnet, daß** die Bluttrennzone (100) ein Material umfaßt, das in der Lage ist zum selektiven Halten einer effektiven Menge von roten Blutzellen (RBC) aus der Vollbluttestprobe (9N), um einen im wesentlichen RBC-freien Fluidteil zu erzeugen, der mit unbeeinträchtigter Bewegung vom ersten Ende (101) der Bluttrennzone (100) zur Reaktionszone (105) fließen kann.
- 20 26. Vorrichtung (1) nach Anspruch 25, **dadurch gekennzeichnet, daß** das Material eine Glasfasermatrix ist.
27. Vorrichtung (1) nach Anspruch 25, **dadurch gekennzeichnet, daß** das Material einen hydrophoben Träger umfaßt, der in der Lage ist, ein Versickern der Vollbluttestprobe (9N) und des RBC-freien Fluidteils zu reduzieren, wenn sie bzw. er entlang der Bluttrennzone (100) migriert.
- 25 28. Vorrichtung (1) nach Anspruch 24, **dadurch gekennzeichnet, daß** die Testeinheit (2) und die Nachfiltereinheit (3) in einem geeigneten Behälter aufgenommen sind.
- 30 29. Vorrichtung (1) nach einem der Ansprüche 1 bis 28, **dadurch gekennzeichnet, daß** das Pufferreagens (12) ein multifunktionseller Puffer ist, welcher umfaßt: einen biologischen Puffer, um den pH-Wert zwischen 7,0 und 10,0 zu halten; wenigstens ein oberflächenaktives Mittel, um eine nicht-spezifische Bindung von Untersuchungsreagentien zu reduzieren, während gleichzeitig eine Inhibierung einer spezifischen Bindungswechselwirkung vermieden wird; ein Polymer mit hohem Molekulargewicht als Dispersions- und Suspensionsreagens mit einem Molekulargewicht in einem Bereich von  $2 \times 10^2$  bis  $2 \times 10^6$  D; einen pH-Stabilisator, um den pH-Wert des multifunktionsellen Puffers innerhalb eines Bereichs von pH 7,0 bis 10,0 zu halten; ein ionisches Salz, um nicht-spezifische Bindung von Antikörpern zu reduzieren; wenigstens ein Konservierungsmittel, um bakterielles und mikrobielles Wachstum zu reduzieren; und einen Calciumchelator, um eine Vollbluttestprobe von einem Verklumpen abzuhalten; wobei der biologische Puffer, das oberflächenaktive Mittel, das Polymer mit hohem Molekulargewicht, der pH-Stabilisator, das ionische Salz, das Konservierungsmittel und der Calciumchelator alle in effektiven Konzentrationen vorliegen.
- 35 40 30. Vorrichtung (1) nach Anspruch 29, **dadurch gekennzeichnet, daß** die Konzentration des biologischen Puffers im Bereich von 5 bis 100 mM liegt.
- 45 31. Vorrichtung (1) nach Anspruch 30, **dadurch gekennzeichnet, daß** die Konzentration des biologischen Puffers im Bereich von 5 bis 30 mM liegt.
32. Vorrichtung (1) nach Anspruch 31, **dadurch gekennzeichnet, daß** die Konzentration des biologischen Puffers 5 mM ist.
- 50 33. Vorrichtung (1) nach einem der Ansprüche 29 bis 32, **dadurch gekennzeichnet, daß** der biologische Puffer ein Phosphatpuffer ist.
34. Vorrichtung (1) nach Anspruch 29, **dadurch gekennzeichnet, daß** die Konzentration des oberflächenaktiven Mittels im Bereich von 0,01 bis 0,50% (w/v) liegt.
- 55 35. Vorrichtung (1) nach Anspruch 34, **dadurch gekennzeichnet, daß** die Konzentration des oberflächenaktiven Mittels im Bereich von 0,05 bis 0,10% (w/v) liegt.

## EP 1 417 489 B1

36. Vorrichtung (1) nach Anspruch 35, **dadurch gekennzeichnet, daß** die Konzentration des oberflächenaktiven Mittels 0,07% (w/v) ist.
- 5 37. Vorrichtung (1) nach einem der Ansprüche 29 und 34 bis 36, **dadurch gekennzeichnet, daß** das oberflächenaktive Mittel Triton<sup>7</sup>X-100 ist.
38. Vorrichtung (1) nach Anspruch 29, **dadurch gekennzeichnet, daß** die Konzentration des ionischen Salzes 0 bis 300 mM ist.
- 10 39. Vorrichtung (1) nach Anspruch 38, **dadurch gekennzeichnet, daß** die Konzentration des ionischen Salzes 50 bis 200 mM ist.
40. Vorrichtung (1) nach einem der Ansprüche 29, 38 und 39, **dadurch gekennzeichnet, daß** das ionische Salz Natriumchlorid ist.
- 15 41. Vorrichtung (1) nach Anspruch 29, **dadurch gekennzeichnet, daß** das Polymer Polyvinylpyrrolidon mit einem Molekulargewichtsbereich von 10 kD bis 1500 kD ist.
- 20 42. Vorrichtung (1) nach Anspruch 41, **dadurch gekennzeichnet, daß** die Konzentration des Polyvinylpyrrolidonpolymers 0,1 bis 3,0% (w/v) ist.
43. Vorrichtung (1) nach Anspruch 42, **dadurch gekennzeichnet, daß** die Konzentration des Polyvinylpyrrolidonpolymers 0,5 bis 2,5% (w/v) ist.
- 25 44. Vorrichtung (1) nach Anspruch 43, **dadurch gekennzeichnet, daß** die Konzentration des Polyvinylpyrrolidonpolymers 1,4% (w/v) ist.
45. Vorrichtung (1) nach Anspruch 29, **dadurch gekennzeichnet, daß** der Calciumchelator EDTA ist.
- 30 46. Vorrichtung (1) nach Anspruch 45, **dadurch gekennzeichnet, daß** die Konzentration des EDTA 5,0 bis 100,0 mM ist.
47. Vorrichtung (1) nach Anspruch 46, **dadurch gekennzeichnet, daß** die Konzentration des EDTA 10,0 bis 50,0 mM ist.
- 35 48. Vorrichtung (1) nach Anspruch 47, **dadurch gekennzeichnet, daß** die Konzentration des EDTA 20,0 mM ist.
49. Vorrichtung (1) nach Anspruch 29, **dadurch gekennzeichnet, daß** der pH-Stabilisator tris-Puffer ist.
50. Vorrichtung (1) nach Anspruch 49, **dadurch gekennzeichnet, daß** die Konzentration des pH-Stabilisators 20 bis 30 mM ist.
- 40 51. Verfahren zum Bestimmen der Gegenwart oder Abwesenheit eines Zielanalyts (10) in einer Fluidtestprobe (9), welches die Schritte umfaßt:
- 45 - Abscheiden der Fluidtestprobe (9) auf der Reaktionszone (5) der Testeinheit (2) der Abwärts- oder Vertikaldurchflußtestvorrichtung (1), die in irgendeinem der Ansprüche 1 bis 23 definiert ist;
- Ermöglichen, daß die Fluidtestprobe (9) durch die Reaktionszone (5) in die Absorbenszone (4) fließt;
- Anbringen der Nachfiltereinheit (3) an der Testeinheit (2), so daß die Markierungszone (7) der Nachfiltereinheit (3) und die Reaktionszone (5) der Testeinheit (2) proximal angeordnet sind, um einen direkten Abwärts- oder Vertikalfluidfluß von der Markierungszone (7) zur Reaktionszone (5) zu ermöglichen;
- 50 - Beaufschlagen eines Pufferreagens (12) auf die Nachfiltereinheit (3), um das getrocknete Indikatorreagens (8) zu rekonstituieren;
- Ermöglichen, daß das rekonstituierte Indikatorreagens durch die Reaktionszone (5) und in die Absorbenszone (4) fließt, ohne daß irgendwelche ungebundenen Reaktanten von der Reaktionszone (5) in die Absorbenszone (4) gewaschen werden; und
- 55 - Entfernen der Nachfiltereinheit (3), um ein Testergebnis zu beobachten, das durch eine Gegenwart oder Abwesenheit eines visuell detektierbaren Signals an der Reaktionszone (5) beschrieben wird.
52. Verfahren nach Anspruch 51, **dadurch gekennzeichnet, daß** das Pufferreagens (12) ein multifunktionaler Puffer

ist, welcher umfaßt: einen biologischen Puffer, um den pH-Wert zwischen 7,0 und 10,0 zu halten; wenigstens ein oberflächenaktives Mittel, um nicht-spezifische Bindung von Untersuchungsreagentien zu reduzieren, während gleichzeitig eine Inhibierung einer spezifischen Bindungswechselwirkung vermieden wird; ein Polymer mit hohem Molekulargewicht als ein Dispersions- oder Suspensionsreagens mit einem Molekulargewicht in einem Bereich von  $2 \times 10^2$  bis  $2 \times 10^6$  D; einen pH-Stabilisator, um den pH-Wert des multifunktionellen Puffers innerhalb eines Bereiches von pH 7,0 bis 10,0 zu halten; ein ionisches Salz, um nicht-spezifische Bindung der Antikörper zu reduzieren; wenigstens ein Konservierungsmittel, um bakterielles und mikrobielles Wachstum zu reduzieren; und einen Calciumchelator, um eine Vollbluttestprobe von einem Verklumpen abzuhalten; wobei der biologische Puffer, das oberflächenaktive Mittel, das Polymer mit hohem Molekulargewicht, der pH-Stabilisator, das ionische Salz, das Konservierungsmittel und der Calciumchelator alle in effektiven Konzentrationen vorliegen.

53. Verfahren zum Bestimmen der Gegenwart oder Abwesenheit eines Zielanalyts (10) in einer Vollbluttestprobe (9N), welches die Schritte umfaßt:

- Abscheiden der Vollbluttestprobe (9N) auf dem ersten Ende (101) der Bluttrennzone (100) der Vorrichtung (1), wie sie in einem der Ansprüche 24 bis 28 definiert ist;
- Ermöglichen, daß die Vollbluttestprobe (9') seitlich entlang der Bluttrennzone (100) fließt, wobei eine an roten Blutzellen freie Probe die Reaktionszone (5) erreicht;
- Ermöglichen, daß die an roten Blutzellen freie Probe vertikal oder abwärts gerichtet durch die Reaktionszone (5) in die Absorbenszone (4) fließt;
- Anbringen der Nachfiltereinheit (3) an der Testeinheit (2), so daß die Markierungszone (7) der Nachfiltereinheit (3) und die Reaktionszone (5) der Testeinheit (2) proximal zueinander angeordnet sind, um einen direkten Abwärts- oder Vertikalfluidfluß von der Markierungszone (7) zur Reaktionszone (5) zu erlauben;
- Beaufschlagen von Pufferreagens (12) auf die Nachfiltereinheit (3), um das getrocknete Indikatorreagens (8) zu rekonstituieren;
- Ermöglichen, daß das rekonstituierte Indikatorreagens durch die Reaktionszone (5) in die Absorbenszone (4) fließt, ohne daß irgendwelche ungebundenen Reaktanten aus der Reaktionszone (5) in die Absorbenszone (4) gewaschen werden; und
- Entfernen der Nachfiltereinheit (3), um ein Testergebnis zu beobachten, das durch eine Gegenwart oder Abwesenheit eines visuell detektierbaren Signals an der Reaktionszone beschrieben wird.

54. Verfahren nach Anspruch 53, **dadurch gekennzeichnet, daß** das Pufferreagens (12) ein multifunktionaler Puffer ist, welcher umfaßt: einen biologischen Puffer, um den pH-Wert zwischen 7,0 und 10,0 zu halten; wenigstens ein oberflächenaktives Mittel, um nicht-spezifische Bindung von Untersuchungsreagentien zu reduzieren, während gleichzeitig eine Inhibierung einer spezifischen Bindungswechselwirkung vermieden wird; ein Polymer mit hohem Molekulargewicht als ein Dispersions- und Suspensionsreagens mit einem Molekulargewicht in einem Bereich von  $2 \times 10^2$  bis  $2 \times 10^6$  D; einen pH-Stabilisator, um den pH-Wert des multifunktionellen Puffers innerhalb eines Bereiches von pH 7,0 bis 10,0 zu halten; ein ionisches Salz, um nicht-spezifische Bindung von Antikörpern zu reduzieren; wenigstens ein Konservierungsmittel, um bakterielles und mikrobielles Wachstum zu reduzieren; und einen Calciumchelator, um eine Vollbluttestprobe von einem Verklumpen abzuhalten; wobei der biologische Puffer, das oberflächenaktive Mittel, das Polymer mit hohem Molekulargewicht, der pH-Stabilisator, das ionische Salz, das Konservierungsmittel und der Calciumchelator alle in effektiven Konzentrationen vorliegen.

55. Testkit zur Verwendung in der Detektion eines Zielanalyts (10) in einer Fluidtestprobe (9) oder einer Vollbluttestprobe (9N), die unter dem Verdacht steht, das Analyt (10) zu enthalten, **gekennzeichnet durch**:

- eine Vorrichtung (1), wie sie in irgendeinem der Ansprüche 1 bis 28 definiert ist; und
- ein Pufferreagens (12), um das getrocknete Indikatorreagens (8) zu rekonstituieren und jegliche nicht-gebundenen Reaktanten aus der Reaktionszone (5) zu waschen.

56. Testkit nach Anspruch 55, **dadurch gekennzeichnet, daß** das Pufferreagens (12) ein multifunktionaler Puffer ist, welcher umfaßt: einen biologischen Puffer, um den pH-Wert zwischen 7,0 und 10,0 zu halten; wenigstens ein oberflächenaktives Mittel, um nicht-spezifische Bindung von Untersuchungsreagentien zu reduzieren, während gleichzeitig eine Inhibierung einer spezifischen Bindungswechselwirkung vermieden wird; ein Polymer mit hohem Molekulargewicht als ein Dispersions- und Suspensionsreagens mit einem Molekulargewicht in einem Bereich von  $2 \times 10^2$  bis  $2 \times 10^6$  D; einen pH-Stabilisator, um den pH-Wert des multifunktionellen Puffers innerhalb eines Bereiches von pH 7,0 bis 10,0 zu halten; ein ionisches Salz, um nicht-spezifische Bindung von Antikörpern zu reduzieren; wenigstens ein Konservierungsmittel, um bakterielles und mikrobielles Wachstum zu reduzieren; und einen Calci-

## EP 1 417 489 B1

umchelator, um eine Vollbluttestprobe (9N) von einem Verklumpen abzuhalten; wobei der biologische Puffer, das oberflächenaktive Mittel, das Polymer mit hohem Molekulargewicht, der pH-Stabilisator, das ionische Salz, das Konservierungsmittel und der Calciumchelator alle in effektiven Konzentrationen vorliegen.

5 57. Testkit nach Anspruch 55, weiter umfassend:

- Instruktionen zum Durchführen der diagnostischen Untersuchung; und
- ein Paar von Pipetten zum getrennten Beaufschlagen der Testprobe (9) und des Pufferreagens (12) zur Testeinheit (2) bzw. Nachfiltereinheit (3).

10 58. Testkit nach Anspruch 55, **dadurch gekennzeichnet, daß** die Testeinheit (2) und die Nachfiltereinheit (3) in einem geeigneten Behälter aufgenommen sind.

### 15 Revendications

1. Un flux descendant ou vertical à travers le dispositif de test (1) pour la détermination de la présence ou de l'absence d'un analyte cible (10) dans un échantillon de test du liquide (9), comprenant :

20 - une unité de test (2) comprenant une zone de réaction (5) en communication verticale avec une zone absorbante (4), selon laquelle la zone de réaction (5) contient un réactif de capture (6) capable de se lier avec un analyte cible (10) présentant un intérêt pour former un complexe à deux membres d'une réaction de liaison spécifique et la zone absorbante comprenant un matériel absorbant positionné en-dessous de la zone de réaction pour faciliter l'écoulement descendant ou vertical du liquide à travers la zone de réaction ; et

25 - une unité de post-filtrage amovible (3) comprenant une zone affectée à l'étiquette (7) comprenant un réactif indicateur (8), selon laquelle le réactif indicateur (8) est capable de se lier à un membre d'une interaction de liaison spécifique pour produire un signal visuellement détectable suite à la résolubilisation de celui-ci par un réactif tampon (12) ; et

30 **caractérisé en ce que** l'unité de post-filtrage (3) est disposée proximale à l'unité de test (2) suite à la formation du complexe à deux membres de telle sorte que la zone de réaction (5) de l'unité de test (2) et la zone affectée à l'étiquette (7) de l'unité de post-filtrage (3) dirige l'écoulement descendant ou vertical du réactif de l'indicateur résolubilisé (8) de la zone affectée à l'étiquette (7) vers la zone de réaction (5) suite à l'application du réactif de tamponnage (12) à la zone affectée à l'étiquette (7).

35 2. Dispositif (1) selon la revendication 1, **caractérisé en ce que** l'interaction de liaison est une interaction anticorps-antigène.

40 3. Dispositif (1) selon la revendication 1, **caractérisé en ce que** le réactif indicateur (8) est capable de se lier à un analyte cible (10) à un site qui n'interfère pas avec l'interaction de liaison spécifique entre l'analyte cible (10) et le réactif de capture (6).

45 4. Dispositif (1) selon la revendication 1, **caractérisé en ce que** le réactif indicateur (8) est capable de se lier au réactif de capture (6) à un site qui interfère avec l'interaction de liaison spécifique entre l'analyte cible (10) et le réactif de capture (6).

50 5. Dispositif (1) selon la revendication 2, **caractérisé en ce que** l'analyte cible (10) est un antigène et le réactif de capture (6) est un anticorps monoclonal ou un anticorps polyclonal purifié d'affinité de l'antigène.

55 6. Dispositif (1) selon la revendication 1, **caractérisé en ce que** la zone de réaction (5) est composé d'une matière qui a une taille de pore permettant la séparation et la filtration des composants non liés de l'échantillon de test de liquide (9) et une épaisseur qui permet une quantité adéquate de réactif de capture (6) d'y être immobilisée.

7. Dispositif (1) selon la revendication 6, **caractérisé en ce que** la matière a une taille de pore allant de 0,1 à 12,0 microns.

8. Dispositif (1) selon la revendication 7, **caractérisé en ce que** la matière a une taille de pore allant de 0,2 à 0,8 microns.

## EP 1 417 489 B1

9. Dispositif (1) selon la revendication 6, **caractérisé en ce que** l'épaisseur de la matière se situe dans la plage de 0,05 à 3,0 mm.
- 5 10. Dispositif (1) selon la revendication 9, **caractérisé en ce que** l'épaisseur de la matière se situe dans la plage de 0,1 à 1,0 mm.
11. Dispositif (1) selon la revendication 6, où la matière est une membrane de nitrocellulose.
- 10 12. Dispositif (1) selon la revendication 1, **caractérisé en ce que** la zone de réaction (5) contient deux réactifs de capture différents ou plus (6) immobilisés dans cette dernière dans des zones discernables et séparées de manière à ce que des analytes cibles multiples (10) dans un même échantillon de test du liquide (9) puissent être analysés simultanément.
- 15 13. Dispositif (1) selon la revendication 1, **caractérisé en ce que** la zone de réaction (5) comprend en outre un réactif de contrôle immobilisé dans une zone discernable et séparée du réactif de capture (6).
- 20 14. Dispositif (1) selon la revendication 1, **caractérisé en ce que** la zone absorbante (4) est séparée de la zone de réaction (5) par une couche d'espacement intervenante (25) ayant un ou plusieurs ouvertures définies en son sein pour permettre la communication de liquide entre la zone de réaction (5) et la zone absorbante (4).
- 25 15. Dispositif (1) selon la revendication 14, **caractérisé en ce que** la couche d'espacement (25) est une matière résistante aux liquides rigide ou semi-rigide.
- 30 16. Dispositif (1) selon la revendication 1, **caractérisé en ce que** la zone absorbante (4) comprend une ou plusieurs couches d'une matière qui est capable de soutirer du liquide par action capillaire et d'absorber un volume considérable de liquide.
- 35 17. Dispositif (1) selon la revendication 16, **caractérisé en ce que** deux couches ou plus comportent des matières identiques ou différentes.
- 40 18. Dispositif (1) selon la revendication 16, **caractérisé en ce que** la matière est de l'acétate de cellulose.
- 45 19. Dispositif (1) selon la revendication 1, **caractérisé en ce que** la zone affectée à l'étiquette (7) comprend une matière de filtrage ayant une taille de pore capable de laisser le réactif indicateur séché (8) d'être efficacement résolubilisé par le réactif de tamponnage et transféré à la zone de réaction (5) par écoulement de liquide laminaire.
- 50 20. Dispositif (1) selon la revendication 19, **caractérisé en ce que** la matière de filtrage est une matière en fibre de verre.
- 55 21. Dispositif (1) selon la revendication 1, **caractérisé en ce que** le réactif indicateur (8) comprend une étiquette directe.
22. Dispositif (1) selon la revendication 21, **caractérisé en ce que** l'étiquette directe est un or colloïdal.
23. Dispositif (1) selon la revendication 1, **caractérisé en ce que** ladite unité de test (2) et ladite unité de post-filtrage (3) sont contenus dans un boîtier adéquat.
24. Dispositif (1) selon l'une quelconque des revendications 1 à 23, **caractérisé en ce que** ladite unité de test (2) est adaptée pour déterminer la présence ou l'absence d'un analyte cible (10) dans un échantillon d'analyse de sang (9N) et qui comprend en outre une zone de séparation du sang à écoulement latéral (100) en communication latérale avec la zone de réaction (5) où la zone de séparation du sang (100) a une première extrémité (101) définissant une région de réception d'un échantillon d'analyse de sang entier (9N) et une deuxième extrémité (102) en communication directe avec la zone de réaction (5).
25. Dispositif (1) selon la revendication 24, **caractérisé en ce que** la zone de séparation du sang (100) comprend une matière capable de retenir sélectivement une quantité effective de globules rouges (GR) de l'échantillon d'analyse de sang entier (9N) pour générer une partie liquide sensiblement exempte de globules rouges qui peut s'écouler en un flux sans obstacle depuis la première extrémité (101) de la zone de séparation du sang (100) à la zone de réaction (5).

## EP 1 417 489 B1

26. Dispositif (1) selon la revendication 25, **caractérisé en ce que** la matière est une matrice de fibre de verre.
27. Dispositif (1) selon la revendication 25, **caractérisé en ce que** la matière comprend un porteur hydrophobe capable de diminuer l'infiltration de l'échantillon d'analyse de sang (9N) et la partie de liquide exempte de globules rouges à mesure qu'elle migre le long de la zone de séparation du sang (100).
28. Dispositif (1) selon la revendication 24, **caractérisé en ce que** l'unité de test (2) et l'unité de post-filtrage (3) sont logées dans un récipient adéquat.
29. Dispositif (1) selon l'une quelconque des revendications 1 à 28, **caractérisé en ce que** ledit réactif de tamponnage (12) est un tampon multifonctionnel comprenant ; un tampon biologique pour maintenir le pH à entre 7,0 à 10,0 ; au moins un surfactant pour diminuer la liaison non spécifique des réactifs de dosage tout en évitant simultanément l'inhibition d'une interaction de liaison spécifique ; un polymère de poids moléculaire élevé à titre de réactif de dispersion et de suspension ayant un poids moléculaire se situant dans la plage de  $2 \times 10^2$  à  $2 \times 10^6$  D ; un stabilisateur du pH pour maintenir le pH du tampon multifonctionnel sur une plage de pH de 7,0 à 10,0 ; un sel ionique pour diminuer la liaison non spécifique des anticorps ; au moins un agent conservateur pour diminuer la croissance bactérienne et microbienne ; et un chélateur calcique pour empêcher un échantillon d'analyse de sang entier de se coaguler ; selon lequel le tampon biologique, le surfactant, le polymère de poids moléculaire élevé, le stabilisateur du pH, le sel ionique, l'agent de conservation et le chélateur calcique sont tous à des concentrations efficaces.
30. Dispositif (1) selon la revendication 29, **caractérisé en ce que** la concentration du tampon biologique se situe à hauteur de 5 à 100 mM.
31. Dispositif (1) selon la revendication 30, **caractérisé en ce que** la concentration du tampon biologique se situe dans la plage de 5 à 30 mM.
32. Dispositif (1) selon la revendication 31, **caractérisé en ce que** la concentration du tampon biologique est de 5 mM.
33. Dispositif (1) selon l'une quelconque des revendications 29 à 32, **caractérisé en ce que** le tampon biologique est un tampon de phosphate.
34. Dispositif (1) selon la revendication 29, **caractérisé en ce que** la concentration du surfactant se situe dans la plage de 0,01 à 0,50% (p/v).
35. Dispositif (1) selon la revendication 34, **caractérisé en ce que** la concentration du surfactant se situe dans la plage de 0,05 à 0,10% (p/v).
36. Dispositif (1) selon la revendication 35, **caractérisé en ce que** la concentration du surfactant est de 0,07% (p/v).
37. Dispositif (1) selon l'une quelconque des revendications 29 et 34 à 36, **caractérisé en ce que** le surfactant est du Triton<sup>7</sup>X-100.
38. Dispositif (1) selon la revendication 29, **caractérisé en ce que** la concentration du sel ionique est de 0 à 300 mM.
39. Dispositif (1) selon la revendication 38, **caractérisé en ce que** la concentration du sel ionique est entre 50 à 200 mM.
40. Dispositif (1) selon l'une quelconque des revendications 29, 38 et 39, **caractérisé en ce que** le sel ionique est un chlorure de sodium.
41. Dispositif (1) selon la revendication 29, **caractérisé en ce que** le polymère est du polyvinylpyrrolidone ayant une plage de poids moléculaire de 10 kD à environ 1500 kD.
42. Dispositif (1) selon la revendication 41, **caractérisé en ce que** la concentration du polymère de polyvinylpyrrolidone est de 0,1 à 0,5% (p/v).
43. Dispositif (1) selon la revendication 42, **caractérisé en ce que** la concentration du polymère de polyvinylpyrrolidone est de 0,5 à 2,5% (p/v).

## EP 1 417 489 B1

44. Dispositif (1) selon la revendication 43, **caractérisé en ce que** la concentration de polymère de polyvinylpyrrolidone est de 1,4% (p/v).

45. Dispositif (1) selon la revendication 29, **caractérisé en ce que** le chélateur calcique est de l'EDTA.

46. Dispositif (1) selon la revendication 45, **caractérisé en ce que** la concentration de l'EDTA est de 5,0 à 100,0 mM.

47. Dispositif (1) selon la revendication 46, **caractérisé en ce que** la concentration de l'EDTA est d'environ 10,0 à 50,0 mM.

48. Dispositif (1) selon la revendication 47, **caractérisé en ce que** la concentration de l'EDTA est de 20,0 mM.

49. Dispositif (1) selon la revendication 29, **caractérisé en ce que** le stabilisateur du pH est un tampon tris.

50. Dispositif (1) selon la revendication 49, **caractérisé en ce que** la concentration du stabilisateur de pH est de 20 à 30 mM.

51. Une méthode de détermination de la présence ou de l'absence d'un analyte cible (10) dans un échantillon de test de liquide (9) comprenant les étapes de:

- déposition de l'échantillon de test de liquide (9) sur la zone de réaction (5) de l'unité de test (2) du dispositif de test à écoulement descendant ou vertical (1) défini dans l'une quelconque des revendications 1 à 23 ;
- laisser l'échantillon de test de liquide (9) s'écouler à travers la zone de réaction (5) dans la zone absorbante (4) ;
- mise en place de l'unité de post-filtrage (3) sur l'unité de test (2) de manière à ce que la zone affectée à l'étiquette (7) de l'unité de post-filtrage (3) et la zone de réaction (5) de l'unité de test (2) soient disposées proximale de manière à favoriser un écoulement de liquide descendant ou vertical depuis la zone affectée à l'étiquette (7) à la zone de réaction (5) ;
- application d'un réactif de tamponnage (12) à l'unité de post-filtrage (3) pour reconstituer le réactif indicateur séché (8) ;
- laisser le réacteur indicateur reconstitué s'écouler à travers la zone de réaction (5) et dans la zone absorbante (4) avec l'un quelconque des réactants non liés chassé de la zone de réaction (5) dans la zone absorbante (4) ;
- retrait de l'unité de post-filtrage (3) pour observer un résultat de test décrit par la présence ou l'absence d'un signal visuellement détectable sur la zone de réaction (5).

52. La méthode selon la revendication 51, **caractérisée en ce que** le réactif de tamponnage (12) est un tampon multifonctionnel comprenant : un tampon biologique pour maintenir le pH à entre 7,0 à 10,0 ; au moins un surfactant pour diminuer la liaison non spécifique des réactifs de dosage tout en évitant simultanément l'inhibition d'une interaction de liaison spécifique ; un polymère de poids moléculaire élevé à titre de réactif de dispersion et de suspension ayant un poids moléculaire dans la plage de  $2 \times 10^2$  à  $2 \times 10^6$  D ; un stabilisateur du pH pour maintenir le pH du tampon multifonctionnel dans une plage de pH de 7,0 à 10,0 ; un sel ionique pour diminuer la liaison non spécifique des anticorps ; au moins un agent de conservation pour diminuer la croissance bactérienne et microbienne ; et un chélateur calcique pour empêcher un échantillon d'analyse du sang entier de se coaguler ; selon laquelle le tampon biologique, le surfactant, le polymère de poids moléculaire élevé, le stabilisateur du pH, le sel ionique, l'agent de conservation et le chélateur calcique sont tous présents à des concentrations efficaces.

53. Une méthode de détermination de la présence ou de l'absence d'un analyte cible (10) dans un échantillon d'analyse du sang entier (9N) comprenant les étapes de:

- déposition de l'échantillon d'analyse du sang entier (9N) sur la première extrémité (101) de la zone de séparation du sang (100) du dispositif (1) défini dans l'une quelconque des revendications 24 à 28 ;
- laisser l'échantillon d'analyse de sang entier (9') s'écouler latéralement le long de la zone de séparation du sang (100) avec l'échantillon exempt de globules rouges atteignant la zone de réaction (5) ;
- laisser l'échantillon exempt de globules rouges s'écouler verticalement ou dans le sens descendant à travers la zone de réaction (5) dans la zone absorbante (4) ;
- mise en place de l'unité de post-filtrage (3) sur l'unité de test (2) de sorte que la zone affectée à l'étiquette (7) de l'unité de post-filtrage (3) et la zone de réaction (5) de l'unité de test (2) soient disposées proximale de manière à laisser un écoulement de liquide directement descendant ou vertical depuis la zone affectée à l'étiquette (7) jusqu'à la zone de réaction (5) ;

## EP 1 417 489 B1

- application du réactif de tamponnage (12) à l'unité de post-filtrage (3) pour reconstituer le réactif indicateur séché (8) ;
- laisser le réactif indicateur reconstitué s'écouler à travers la zone de réaction (5) dans la zone absorbante (4), avec tous les réactifs non liés lessivés de la zone de réaction (5) dans la zone absorbante (4) ; et
- dépose de l'unité de post-filtrage (3) pour observer un résultat de test décrit par la présence ou l'absence d'un signal détectable visuellement sur la zone de réaction.

54. La méthode selon la revendication 53, **caractérisée en ce que** le réactif de tamponnage (12) est un tampon multifonctionnel comprenant : un tampon biologique pour maintenir le pH à entre 7,0 à 10,0 ; au moins un surfactant pour diminuer la liaison non spécifique des réactifs de dosage tout en évitant simultanément l'inhibition d'une interaction de liaison spécifique ; un polymère à poids moléculaire élevé à titre de réactif de dispersion et de suspension ayant un poids moléculaire dans la plage de  $2 \times 10^2$  à  $2 \times 10^6$  D ; un stabilisateur de pH pour maintenir le pH d'un tampon multifonctionnel dans une plage de pH de 7,0 à 10,0 ; un sel ionique pour diminuer la liaison non spécifique des anticorps ; au moins un agent de conservation pour diminuer la croissance bactérienne et microbactérienne ; et un chélateur calcique pour empêcher un échantillon d'analyse du sang entier de se coaguler ; selon laquelle le tampon biologique, le surfactant, le polymère de poids moléculaire élevé, le stabilisateur du pH, le sel ionique, l'agent de conservation et le chélateur calcique sont tous à des concentrations efficaces.

55. Un kit de test destiné pour une utilisation dans la détection d'un analyte cible (10) dans un échantillon de test du liquide (9) ou un échantillon d'analyse du sang entier (9N) suspecté de contenir l'analyte (10), **caractérisé en ce que**:

- un dispositif (1) tel que défini dans l'une quelconque des revendications 1 à 28 ; et
- un réactif de tamponnage (12) pour reconstituer le réactif indicateur séché (8) et pour laver tous réactifs non liés de la zone de réaction (5).

56. Le kit de test selon la revendication 55, **caractérisé en ce que** le réactif de tamponnage (12) est un tampon multifonctionnel comprenant ; un tampon biologique visant à maintenir le pH à entre 7,0 à 10,0 ; au moins un surfactant visant à diminuer la liaison non spécifique des réactifs de dosage tout en évitant simultanément l'inhibition d'une interaction de liaison spécifique ; un polymère de poids moléculaire élevé à titre de réactif de dispersion et de suspension ayant un poids moléculaire élevé se situant dans la plage de  $2 \times 10^2$  à  $2 \times 10^6$  D ; un stabilisateur de pH destiné à maintenir le pH du tampon multifonctionnel dans une plage de pH de 7,0 à 10,0 ; un sel ionique destiné à diminuer la liaison non spécifique d'anticorps ; au moins un agent de conservation destiné à diminuer la croissance bactérienne et microbienne ; et un chélateur calcique destiné à empêcher un échantillon d'analyse de sang entier (9N) de se coaguler ; où le tampon biologique, le surfactant, le polymère de poids moléculaire élevé, le stabilisateur de pH, le sel ionique, l'agent de conservation et le chélateur calcique sont tous présents à des concentrations efficaces.

57. Kit de test selon la revendication 55 comprenant en outre :

- des instructions pour la réalisation du dosage de diagnostic ; et
- une paire de pipettes pour l'application séparée de l'échantillon de test (9) et du réactif de tamponnage (12) à l'unité de test (2) et l'unité de post-filtrage (3), respectivement.

58. Les kit de test selon la revendication 55, **caractérisé en ce que** l'unité de test (2) et l'unité de post-filtrage (3) sont logées dans un récipient adéquat.




Fig. 1A




Fig. 1B




Fig. 2A




Fig. 2B




Fig. 2C




Fig. 2D




Fig. 3A

Fig. 3B






Fig. 3C

Fig. 3D







**Fig. 5**



**Fig. 6**



**Fig. 7A**



**Fig. 7B**

## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

## Patent documents cited in the description

- US 4517288 A [0008] [0064]
- US 4094647 A [0009]
- US 4235601 A [0009]
- US 4361537 A, Deutsch [0009]
- US 4960691 A, Gordon [0010]
- US 4168146 A, Grubb [0011]
- US 4632901 A, Valkirs [0012] [0064] [0083]
- US 4446232 A [0013]
- US 5879951 A [0017] [0019]
- US 5877028 A [0017]
- WO 0155723 A [0017]
- EP 0806666 A [0017]
- US 5185264 A [0019]
- US 4087567 A [0019]
- US 4515893 A, Kung [0044]
- US 3996345 A, Ullman [0048]
- US 4670381 A [0064]
- US 4666863 A [0064]
- US 4459361 A [0064]
- US 4552839 A [0064]
- US 4340479 A [0070]
- US 4066512 A [0070]
- US 4246339 A [0070]
- US 4186146 A [0075]
- US 4376110 A [0075]
- US 4452901 A [0075]
- US 5541059 A, Chu [0080]
- US 5185127 A [0083]
- US 5006464 A [0083] [0146]
- US 4818677 A [0083]
- US 3888629 A [0083]
- US 3768978 A, Grubb [0088]
- US 3902964 A, Greenspan [0088]
- US 4477575 A, Vogel [0088]
- US 4594372 A, Zuk [0088]
- US 4753776 A, Hillman [0088]
- US 4816224 A, Vogel [0088]
- US 4933092 A, Aunet [0088]
- US 5055195 A, Trasch [0088]
- US 5064541 A, Jeng [0088]
- US 5076925 A, Roesink [0088]
- US 5118428 A, Sand [0088]
- US 5118472 A, Tanaka [0088]
- US 5130258 A, Makino [0088]
- US 5135719 A, Hillman [0088]
- US 5209904 A, Forney [0088]
- US 5212060 A, Maddox [0088]
- US 5240862 A, Koenhen [0088]
- US 5262067 A, Wilk [0088]
- US 5306623 A, Kiser [0088]
- US 5364533 A, Ogura [0088]
- US 5397479 A, Kass [0088]
- US 4954452 A, Yost [0102]
- US 4373932 A, Gribnau [0102]
- WO 8808534 A, May [0102]
- EP 0280559 A [0102]
- EP 0281327 A [0102]
- US 4703017 A, Campbell [0102]
- US 4166105 A [0102]
- US 4313734 A [0102] [0103]
- DE 4132133 [0102]
- EP 158746 A, Moeremans [0102]
- US 4366241 A, Tom [0150]

## Non-patent literature cited in the description

- **WANDS, J. R. ; V. R. ZURAWSKI.** *Gastroenterology*, 1981, vol. 80, 225 [0044]
- **MARSHAK-ROTHSTEIN, A. et al.** *J. Immunol.*, 1979, vol. 122, 2491 [0044]
- Immunoglobulin Producing Hybrid. **OI, V. Y. ; L. A. HERZENBERG.** Selected Methods in Cellular Immunology. W.H. Freeman Publishing, 1979 [0044]
- **HERMANSON, G.T.** Bioconjugate Techniques. Academic Press, 1996 [0050]
- **POLSKY-CYNKIN, R. et al.** *Clin. Chem.*, 1985, vol. 31 (9), 1438 [0051]
- **IMAN ; HORNBY.** *Biochemical Journal*, vol. 129, 255 [0075]
- **CAMPBELL ; HORNBY ; MORRIS.** *Biochem. Biophys. Acta*, 1975, vol. 384, 307 [0075]
- **MATTISSON ; NILSSON.** *F.E.B.S. letters*, 1977, vol. 104, 78 [0075]
- **KOHLER ; MILSTEIN.** *Nature*, 1975, vol. 256, 495-497 [0079]
- **KENNET, R. et al.** Monoclonal Antibodies. Plenum Press, 1980, 365-367 [0079]
- **LEUVERING et al.** Sol Particle Immunoassay (SPIA). *Journal of Immunoassay*, 1980, vol. 1 (1), 77-91 [0102]
- **UDA et al.** *Anal. Biochem.*, 1994, vol. 218, 259-264 [0102]

## EP 1 417 489 B1

- **TANG et al.** *Nature*, 1992, vol. 356, 152-154 [0102]
- **EISENBRAUN et al.** *DNA and Cell Biology*, 1993, vol. 12, 791-797 [0102]
- **G. FRENS.** *Nature*, 1973, vol. 241, 20-22 [0104]
- **FRENS.** *Nature*, 1973, vol. 241, 20-23 [0108]
- **HORISBERGER.** Evaluation of Colloidal Gold as a Cytochromic Marker for Transmission and Scanning Electron Microscopy. *Biol. Cellulaire*, 1979, vol. 36, 253-258 [0111]
- **LEUVERING et al.** Sol Particle Immunoassay. *J. Immunoassay*, 1980, vol. 1 (1), 77-91 [0111]
- **FRENS.** Controlled Nucleation for the Regulation of the Particle Size in Monodisperse Gold Suspensions. *Nature, Physical Science*, 1973, vol. 241, 20-22 [0111]
- **SUREK et al.** *Biochem, and Biophys. Res. Comm.*, 1984, vol. 121, 284-289 [0111]
- Preparation of Colloidal Gold Probes. **HUGHES D.A ; J. E. BEESLEY.** *Methods in Molecular Biology.* Humana Press Inc, 1998, vol. 80 [0170]